<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03201419</url>
  </required_header>
  <id_info>
    <org_study_id>000233</org_study_id>
    <secondary_id>2016-003851-31</secondary_id>
    <nct_id>NCT03201419</nct_id>
  </id_info>
  <brief_title>A Trial to Investigate Efficacy, Safety and Tolerability of FE 201836 for Nocturia Due to Nocturnal Polyuria in Adults</brief_title>
  <official_title>A Randomised, Double-blind, Placebo-controlled, Response-adaptive Dose-finding Trial Investigating the Efficacy, Safety and Tolerability of Oral Doses of FE 201836, With Desmopressin Orally Disintegrating Tablet as a Benchmark, During 12 Weeks of Treatment for Nocturia Due to Nocturnal Polyuria in Adults</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ferring Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ferring Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this trial was to investigate the efficacy, safety and tolerability of&#xD;
      different oral doses of FE 201836, with desmopressin as a benchmark, during 12 weeks of&#xD;
      treatment for nocturia due to nocturnal polyuria in adults&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 27, 2017</start_date>
  <completion_date type="Actual">October 31, 2019</completion_date>
  <primary_completion_date type="Actual">October 31, 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>The trial consisted of a 2 week period of screening/lifestyle changes during which no treatment was given, a 2 week enrichment period (including a 1 week single blind active run-in period [FE 201836 500 µg] and a 1 week washout period) followed by a 12 week randomized treatment period for each subject. Prior to the first interim analysis, the first 129 subjects were randomized to daily treatment with FE 201836 500 µg, placebo, or desmopressin (25 µg for females and 50 µg for males) in a 2:2:1 ratio. After the first interim analysis, subjects were randomized to daily treatment with FE 201836 (50 µg, 100 µg, 150 µg, 250 µg, 350 µg, or 500 µg), placebo, or desmopressin (25 µg for females and 50 µg for males) using response adaptive allocation probabilities.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
    <masking_description>Each subject will receive 2 medications (an oral solution and an orally disintegrating tablet (ODT) formulation) throughout the trial, in order to keep the treatment blinded.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline in Aggregated Mean Number of Nocturnal Voids During 12 Weeks of Treatment</measure>
    <time_frame>Baseline, during 12 weeks of treatment</time_frame>
    <description>Nocturnal voids were defined as voids occuring from 5 minutes after bedtime until rising in the morning.&#xD;
The number of nocturnal voids at each visit was calculated as the average over the 3 consecutive 24 hour periods just prior to the respective visit. The visit-specific means were aggregated into a mean of current and preceding visits.&#xD;
Level estimated for baseline value of mean number of nocturnal voids equal to 2, and 95% credibility interval (2.5 and 97.5 percentiles of the posterior distribution) instead of confidence interval are presented in this endpoint.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Mean Number of Nocturnal Voids at Week 1</measure>
    <time_frame>Baseline, Week 1</time_frame>
    <description>Nocturnal voids were defined as voids occuring from 5 minutes after bedtime until rising in the morning.&#xD;
The number of nocturnal voids at each visit was calculated as the average over the 3 consecutive 24 hour periods just prior to the respective visit. Adjusted visit-specific mean changes from baseline in nocturnal voids are estimated using a baseline value of 2.&#xD;
MMRM=Mixed Model for Repeated Measurements.&#xD;
For all visit-specific results, the tables present the number of subjects with an observation of the endpoints in question at the specific visit. All secondary analyses are performed using the observed-case approach based on repeated measurements for all subjects in the ITT-RT population. That is, these secondary analyses are based on all subjects with at least one non-missing post-baseline observation (with a baseline value if relevant).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Mean Number of Nocturnal Voids at Week 4</measure>
    <time_frame>Baseline, Week 4</time_frame>
    <description>Nocturnal voids were defined as voids occuring from 5 minutes after bedtime until rising in the morning.&#xD;
The number of nocturnal voids at each visit was calculated as the average over the 3 consecutive 24 hour periods just prior to the respective visit. Adjusted visit-specific mean changes from baseline in nocturnal voids are estimated using a baseline value of 2.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Mean Number of Nocturnal Voids at Week 8</measure>
    <time_frame>Baseline, Week 8</time_frame>
    <description>Nocturnal voids were defined as voids occuring from 5 minutes after bedtime until rising in the morning.&#xD;
The number of nocturnal voids at each visit was calculated as the average over the 3 consecutive 24 hour periods just prior to the respective visit. Adjusted visit-specific mean changes from baseline in nocturnal voids are estimated using a baseline value of 2.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Mean Number of Nocturnal Voids at Week 12</measure>
    <time_frame>Baseline, Week 12</time_frame>
    <description>Nocturnal voids were defined as voids occuring from 5 minutes after bedtime until rising in the morning.&#xD;
The number of nocturnal voids at each visit was calculated as the average over the 3 consecutive 24 hour periods just prior to the respective visit. Adjusted visit-specific mean changes from baseline in nocturnal voids are estimated using a baseline value of 2.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Responder Rate in Nocturnal Voids at Week 1</measure>
    <time_frame>Week 1</time_frame>
    <description>Defined as 50% reduction in nocturnal voids from baseline.&#xD;
Adjusted visit-specific estimated odds of at least 50% in the reduction mean number of nocturnal voids are estimated using a baseline value of 2.&#xD;
The estimated odd equals the probability of response divided by the probability of non-response; these odds may vary between 0 and infinity. For example, if the probability of responding is 80%, the odd of responding is 4, as it is 4 times more likely to respond (80%) then it is not to respond (20%).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Responder Rate in Nocturnal Voids at Week 4</measure>
    <time_frame>Week 4</time_frame>
    <description>Defined as 50% reduction in nocturnal voids from baseline.&#xD;
Adjusted visit-specific estimated odds of at least 50% reduction in the mean number of nocturnal voids are estimated using a baseline value of 2.&#xD;
The estimated odd equals the probability of response divided by the probability of non-response; these odds may vary between 0 and infinity. For example, if the probability of responding is 80%, the odd of responding is 4, as it is 4 times more likely to respond (80%) then it is not to respond (20%).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Responder Rate in Nocturnal Voids at Week 8</measure>
    <time_frame>Week 8</time_frame>
    <description>Defined as 50% reduction in nocturnal voids from baseline.&#xD;
Adjusted visit-specific estimated odds of at least 50% reduction in the mean number of nocturnal voids are estimated using a baseline value of 2.&#xD;
The estimated odd equals the probability of response divided by the probability of non-response; these odds may vary between 0 and infinity. For example, if the probability of responding is 80%, the odd of responding is 4, as it is 4 times more likely to respond (80%) then it is not to respond (20%).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Responder Rate in Nocturnal Voids at Week 12</measure>
    <time_frame>Week 12</time_frame>
    <description>Defined as 50% reduction in nocturnal voids from baseline.&#xD;
Adjusted visit-specific estimated odds of at least 50% reduction in the mean number of nocturnal voids are estimated using a baseline value of 2.&#xD;
The estimated odd equals the probability of response divided by the probability of non-response; these odds may vary between 0 and infinity. For example, if the probability of responding is 80%, the odd of responding is 4, as it is 4 times more likely to respond (80%) then it is not to respond (20%).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Responder Rate in Nocturnal Voids During 12 Weeks of Treatment</measure>
    <time_frame>During 12 weeks of treatment</time_frame>
    <description>Defined as 50% reduction in nocturnal voids from baseline.&#xD;
Estimated odds of at least 50% reduction in the aggregated mean number of nocturnal voids for a subject with 2 nocturnal voids at baseline are presented in this endpoint.&#xD;
The 95% credibility interval (2.5 and 97.5 percentiles of the posterior distribution) instead of confidence interval is presented for this endpoint.&#xD;
The estimated odd equals the probability of response divided by the probability of non-response; these odds may vary between 0 and infinity. For example, if the probability of responding is 80%, the odd of responding is 4, as it is 4 times more likely to respond (80%) then it is not to respond (20%).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Mean NI Diary Total Score at Week 1</measure>
    <time_frame>Baseline, Week 1</time_frame>
    <description>The NI Diary is a 12-item questionnaire with 11 core items (Q1-Q11) and an overall quality of life (QoL) impact question (Q12). The NI Diary Total Scores are calculated by summing the 11 core items.Responses are scored from 0 to 4 (lowest t o highest impact). The NI Diary Total is standardized from 0 to 100 (lowest to highest impact).&#xD;
The score at each visit was calculated as the average over the three consecutive 24 hour periods just prior to the respective visit. Adjusted visit-specific mean changes from baseline in NI Diary Total Score are estimated using a baseline value of 40.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Mean NI Diary Total Score at Week 4</measure>
    <time_frame>Baseline, Week 4</time_frame>
    <description>The NI Diary is a 12-item questionnaire with 11 core items (Q1-Q11) and an overall QoL impact question (Q12). The NI Diary Total Scores are calculated by summing the 11 core items. Responses are scored from 0 to 4 (lowest to highest impact). The NI Diary Total is standardized from 0 to 100 (lowest to highest impact).&#xD;
The score at each visit was calculated as the average over the three consecutive 24 hour periods just prior to the respective visit. Adjusted visit-specific mean changes from baseline in NI Diary Total Score are estimated using a baseline value of 40.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Mean NI Diary Total Score at Week 8</measure>
    <time_frame>Baseline, Week 8</time_frame>
    <description>The NI Diary is a 12-item questionnaire with 11 core items (Q1-Q11) and an overall QoL impact question (Q12). The NI Diary Total Scores are calculated by summing the 11 core items. Responses are scored from 0 to 4 (lowest to highest impact). The NI Diary Total is standardized from 0 to 100 (lowest to highest impact).&#xD;
The score at each visit was calculated as the average over the three consecutive 24 hour periods just prior to the respective visit. Adjusted visit-specific mean changes from baseline in NI Diary Total Score are estimated using a baseline value of 40.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Mean NI Diary Total Score at Week 12</measure>
    <time_frame>Baseline, Week 12</time_frame>
    <description>The NI Diary is a 12-item questionnaire with 11 core items (Q1-Q11) and an overall QoL impact question (Q12). The NI Diary Total Scores are calculated by summing the 11 core items. Responses are scored from 0 to 4 (lowest to highest impact). The NI Diary Total is standardized from 0 to 100 (lowest to highest impact).&#xD;
The score at each visit was calculated as the average over the three consecutive 24 hour periods just prior to the respective visit. Adjusted visit-specific mean changes from baseline in NI Diary Total Score are estimated using a baseline value of 40.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Aggregated Mean NI Diary Total Score During 12 Weeks of Treatment</measure>
    <time_frame>Baseline, during 12 weeks of treatment</time_frame>
    <description>The NI Diary is a 12-item questionnaire with 11 core items (Q1-Q11) and an overall QoL impact question (Q12). The NI Diary Total Scores are calculated by summing the 11 core items. Responses are scored from 0 to 4 (lowest to highest impact). The NI Diary Total is standardized from 0 to 100 (lowest to highest impact).&#xD;
The score at each visit was calculated as the mean over the three consecutive 24 hour periods just prior to the respective visit. The visit-specific means were aggregated into a mean of current and preceding visits.&#xD;
Level estimated for baseline value of mean NI Diary Total Score equal to 40 is presented in this endpoint.&#xD;
The 95% credibility interval (2.5 and 97.5 percentiles of the posterior distribution) instead of confidence interval is presented for this endpoint.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Nights With at Most One Nocturnal Void During 12 Weeks of Treatment</measure>
    <time_frame>During 12 weeks of treatment</time_frame>
    <description>The percentages of nights during the treatment period with at most one nocturnal void are presented in this endpoint.&#xD;
Level estimated for baseline value of mean number of nocturnal voids equal to 2 is presented in this endpoint.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Nights With No Nocturnal Voids During 12 Weeks of Treatment</measure>
    <time_frame>During 12 weeks of treatment</time_frame>
    <description>The percentages of nights during the treatment period with complete response, i.e. no nocturnal voids are presented in this endpoint.&#xD;
Level estimated for baseline value of mean number of nocturnal voids equal to 2 is presented in this endpoint.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Mean NI Diary Overall Impact Score at Week 1</measure>
    <time_frame>Baseline, Week 1</time_frame>
    <description>The NI Diary is a 12-item questionnaire with 11 core items (Q1-Q11) and an overall QoL impact question (Q12). For the overall impact question (Q12), response options range from 0 (not at all) to 4 (a great deal). The NI Diary Overall Impact Scores are standardized from 0 to 100 (lowest to highest impact).&#xD;
The score at each visit was calculated as the average over the three consecutive 24 hour periods just prior to the respective visit. Adjusted visit-specific mean changes from baseline in NI Diary Overall Impact Score are estimated using a baseline value of 40.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Mean NI Diary Overall Impact Score at Week 4</measure>
    <time_frame>Baseline, Week 4</time_frame>
    <description>The NI Diary is a 12-item questionnaire with 11 core items (Q1-Q11) and an overall QoL impact question (Q12). For the overall impact question (Q12), response options range from 0 (not at all) to 4 (a great deal). The NI Diary Overall Impact Scores are standardized from 0 to 100 (lowest to highest impact).&#xD;
The score at each visit was calculated as the average over the three consecutive 24 hour periods just prior to the respective visit. Adjusted visit-specific mean changes from baseline in NI Diary Overall Impact Score are estimated using a baseline value of 40.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Mean NI Diary Overall Impact Score at Week 8</measure>
    <time_frame>Baseline, Week 8</time_frame>
    <description>The NI Diary is a 12-item questionnaire with 11 core items (Q1-Q11) and an overall QoL impact question (Q12). For the overall impact question (Q12), response options range from 0 (not at all) to 4 (a great deal). The NI Diary Overall Impact Scores are standardized from 0 to 100 (lowest to highest impact).&#xD;
The score at each visit was calculated as the average over the three consecutive 24 hour periods just prior to the respective visit. Adjusted visit-specific mean changes from baseline in NI Diary Overall Impact Score are estimated using a baseline value of 40.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Mean NI Diary Overall Impact Score at Week 12</measure>
    <time_frame>Baseline, Week 12</time_frame>
    <description>The NI Diary is a 12-item questionnaire with 11 core items (Q1-Q11) and an overall QoL impact question (Q12). For the overall impact question (Q12), response options range from 0 (not at all) to 4 (a great deal). The NI Diary Overall Impact Scores are standardized from 0 to 100 (lowest to highest impact).&#xD;
The score at each visit was calculated as the average over the three consecutive 24 hour periods just prior to the respective visit. Adjusted visit-specific mean changes from baseline in NI Diary Overall Impact Score are estimated using a baseline value of 40.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Aggregated Mean NI Diary Overall Impact Score During 12 Weeks of Treatment</measure>
    <time_frame>Baseline, during 12 weeks of treatment</time_frame>
    <description>The NI Diary is a 12-item questionnaire with 11 core items (Q1-Q11) and an overall QoL impact question (Q12). For the overall impact question (Q12), response options range from 0 (not at all) to 4 (a great deal). The NI Diary Overall Impact Scores are standardized from 0 to 100 (lowest to highest impact).&#xD;
The score at each visit was calculated as the average over the three consecutive 24 hour periods just prior to the respective visit. The visit-specific means were aggregated into a mean of current and preceding visits.&#xD;
Level estimated for baseline value of mean NI Diary Overall Impact Score equal to 40 is presented in this endpoint.&#xD;
The 95% credibility interval (2.5 and 97.5 percentiles of the posterior distribution) instead of confidence interval is presented for this endpoint.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Global Impression of Improvement (PGI-I) Urinary Symptoms Scores at Week 1</measure>
    <time_frame>Week 1</time_frame>
    <description>The PGI-I is a 1-item questionnaire designed to assess the patient's impression of changes in urinary symptoms. The PGI-I was scored from 1 (very much better) to 7 (very much worse).&#xD;
Visit-specific PGI-I in urinary symptoms is presented in this endpoint.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Global Impression of Improvement (PGI-I) Urinary Symptoms Scores at Week 4</measure>
    <time_frame>Week 4</time_frame>
    <description>The PGI-I is a 1-item questionnaire designed to assess the patient's impression of changes in urinary symptoms. The PGI-I was scored from 1 (very much better) to 7 (very much worse).&#xD;
Visit-specific PGI-I in urinary symptoms is presented in this endpoint.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Global Impression of Improvement (PGI-I) Urinary Symptoms Scores at Week 8</measure>
    <time_frame>Week 8</time_frame>
    <description>The PGI-I is a 1-item questionnaire designed to assess the patient's impression of changes in urinary symptoms. The PGI-I was scored from 1 (very much better) to 7 (very much worse).&#xD;
Visit-specific PGI-I in urinary symptoms is presented in this endpoint.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Global Impression of Improvement (PGI-I) Urinary Symptoms Scores at Week 12</measure>
    <time_frame>Week 12</time_frame>
    <description>The PGI-I is a 1-item questionnaire designed to assess the patient's impression of changes in urinary symptoms. The PGI-I was scored from 1 (very much better) to 7 (very much worse).&#xD;
Visit-specific PGI-I in urinary symptoms is presented in this endpoint.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Patient Global Impression of Severity (PGI-S) Scores at Week 1</measure>
    <time_frame>Baseline, Week 1</time_frame>
    <description>The PGI-S is a 1-item questionnaire designed to assess patient's impression of disease severity. The PGI-S was scored from 1 (none) to 4 (severe).&#xD;
Change from baseline in visit-specific PGI-S is presented in this endpoint.&#xD;
Level estimated for baseline value of PGI-S equal to 3 is presented in this endpoint.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in PGI-S Scores at Week 4</measure>
    <time_frame>Baseline, Week 4</time_frame>
    <description>The PGI-S is a 1-item questionnaire designed to assess patient's impression of disease severity. The PGI-S was scored from 1 (none) to 4 (severe).&#xD;
Change from baseline in visit-specific PGI-S is presented in this endpoint.&#xD;
Level estimated for baseline value of PGI-S equal to 3 is presented in this endpoint.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in PGI-S Scores at Week 8</measure>
    <time_frame>Baseline, Week 8</time_frame>
    <description>The PGI-S is a 1-item questionnaire designed to assess patient's impression of disease severity. The PGI-S was scored from 1 (none) to 4 (severe).&#xD;
Change from baseline in visit-specific PGI-S is presented in this endpoint.&#xD;
Level estimated for baseline value of PGI-S equal to 3 is presented in this endpoint.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in PGI-S Scores at Week 12</measure>
    <time_frame>Baseline, Week 12</time_frame>
    <description>The PGI-S is a 1-item questionnaire designed to assess patient's impression of disease severity. The PGI-S was scored from 1 (none) to 4 (severe).&#xD;
Change from baseline in visit-specific PGI-S is presented in this endpoint.&#xD;
Level estimated for baseline value of PGI-S equal to 3 is presented in this endpoint.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Hsu 5-point Likert Bother Scale at Week 1</measure>
    <time_frame>Baseline, Week 1</time_frame>
    <description>The Hsu 5-point Likert Bother scale is a questionnaire designed to assess the subjective bothersomeness and functional disruptiveness of nocturia. The Hsu 5 point Likert Bother Scale was scored from 0 (not at all) to 4 (extremely).&#xD;
Change from baseline in visit-specific Hsu Bother is presented in this endpoint.&#xD;
Level estimated for baseline value of Hsu Bother equal to 3 is presented in this endpoint.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Hsu 5-point Likert Bother Scale at Week 4</measure>
    <time_frame>Baseline, Week 4</time_frame>
    <description>The Hsu 5-point Likert Bother scale is a questionnaire designed to assess the subjective bothersomeness and functional disruptiveness of nocturia. The Hsu 5 point Likert Bother Scale was scored from 0 (not at all) to 4 (extremely).&#xD;
Change from baseline in visit-specific Hsu Bother is presented in this endpoint.&#xD;
Level estimated for baseline value of Hsu Bother equal to 3 is presented in this endpoint.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Hsu 5-point Likert Bother Scale at Week 8</measure>
    <time_frame>Baseline, Week 8</time_frame>
    <description>The Hsu 5-point Likert Bother scale is a questionnaire designed to assess the subjective bothersomeness and functional disruptiveness of nocturia. The Hsu 5 point Likert Bother Scale was scored from 0 (not at all) to 4 (extremely).&#xD;
Change from baseline in visit-specific Hsu Bother is presented in this endpoint.&#xD;
Level estimated for baseline value of Hsu Bother equal to 3 is presented in this endpoint.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Hsu 5-point Likert Bother Scale at Week 12</measure>
    <time_frame>Baseline, Week 12</time_frame>
    <description>The Hsu 5-point Likert Bother scale is a questionnaire designed to assess the subjective bothersomeness and functional disruptiveness of nocturia. The Hsu 5 point Likert Bother Scale was scored from 0 (not at all) to 4 (extremely).&#xD;
Change from baseline in visit-specific Hsu Bother is presented in this endpoint.&#xD;
Level estimated for baseline value of Hsu Bother equal to 3 is presented in this endpoint.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in ISI at Week 4</measure>
    <time_frame>Baseline, Week 4</time_frame>
    <description>The ISI is a 7-item questionnaire which comprises of four 'sleep-related' items and three 'wake-related' items. Each item is rated on a 0-4 scale and the total score ranges from 0 to 28 (higher score suggests more severe insomnia).&#xD;
Change from baseline in visit-specific ISI is presented in this endpoint.&#xD;
Level estimated for baseline value of ISI equal to 15 is presented in this endpoint.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in ISI at Week 8</measure>
    <time_frame>Baseline, Week 8</time_frame>
    <description>The ISI is a 7-item questionnaire which comprises of four 'sleep-related' items and three 'wake-related' items. Each item is rated on a 0-4 scale and the total score ranges from 0 to 28 (higher score suggests more severe insomnia).&#xD;
Change from baseline in visit-specific ISI is presented in this endpoint.&#xD;
Level estimated for baseline value of ISI equal to 15 is presented in this endpoint.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in ISI at Week 12</measure>
    <time_frame>Baseline, Week 12</time_frame>
    <description>The ISI is a 7-item questionnaire which comprises of four 'sleep-related' items and three 'wake-related' items. Each item is rated on a 0-4 scale and the total score ranges from 0 to 28 (higher score suggests more severe insomnia).&#xD;
Change from baseline in visit-specific ISI is presented in this endpoint.&#xD;
Level estimated for baseline value of ISI equal to 15 is presented in this endpoint.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Mean Duration of First Undisturbed Sleep Period (FUSP) at Week 1</measure>
    <time_frame>Baseline, Week 1</time_frame>
    <description>The FUSP is defined as the time in minutes from the time of going to bed to the time of first nocturnal void, or time of awakening if no void occured.&#xD;
The duration of FUSP at each visit was calculated as the average over the 3 consecutive 24-hour periods just prior to the respective visit. Adjusted visit-specific mean changes from baseline in FUSP are estimated using a baseline value of 180 (min).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Mean Duration of FUSP at Week 4</measure>
    <time_frame>Baseline, Week 4</time_frame>
    <description>The FUSP is defined as the time in minutes from the time of going to bed to the time of first nocturnal void, or time of awakening if no void occurred.&#xD;
The duration of FUSP at each visit was calculated as the average over the 3 consecutive 24-hour periods just prior to the respective visit. Adjusted visit-specific mean changes from baseline in FUSP are estimated using a baseline value of 180 (min).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Mean Duration of FUSP at Week 8</measure>
    <time_frame>Baseline, Week 8</time_frame>
    <description>The FUSP is defined as the time in minutes from the time of going to bed to the time of first nocturnal void, or time of awakening if no void occurred.&#xD;
The duration of FUSP at each visit was calculated as the average over the 3 consecutive 24-hour periods just prior to the respective visit. Adjusted visit-specific mean changes from baseline in FUSP are estimated using a baseline value of 180 (min).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Mean Duration of FUSP at Week 12</measure>
    <time_frame>Baseline, Week 12</time_frame>
    <description>The FUSP is defined as the time in minutes from the time of going to bed to the time of first nocturnal void, or time of awakening if no void occurred.&#xD;
The duration of FUSP at each visit was calculated as the average over the 3 consecutive 24-hour periods just prior to the respective visit. Adjusted visit-specific mean changes from baseline in FUSP are estimated using a baseline value of 180 (min).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Aggregated Mean Duration of FUSP During 12 Weeks of Treatment</measure>
    <time_frame>Baseline, During 12 Weeks of Treatment</time_frame>
    <description>The FUSP is defined as the time in minutes from the time of going to bed to the time of first nocturnal void, or time of awakening if no void occurred.&#xD;
The visit-specific means were aggregated into a mean of current and preceding visits.&#xD;
Level estimated for baseline value of mean duration of FUSP (minutes) equal to 180 is presented in this endpoint.&#xD;
The 95% credibility interval (2.5 and 97.5 percentiles of the posterior distribution) instead of confidence interval is presented for this endpoint.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Nocturnal Diuresis Rate Profiles at Week 1</measure>
    <time_frame>Baseline, Week 1</time_frame>
    <description>The nocturnal diuresis rate (mL/min) is calculated as the mean of the nocturnal diuresis for each of the three nights, with the single-night nocturnal diuresis calculated as the ratio of NUV to total time in bed.&#xD;
Change from baseline in visit-specific mean nocturnal diuresis (mL/min) is presented.&#xD;
Level estimated for baseline value of mean nocturnal diuresis (mL/min) equal to 1.3 is presented in this endpoint.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Nocturnal Diuresis Rate Profiles at Week 12</measure>
    <time_frame>Baseline, Week 12</time_frame>
    <description>The nocturnal diuresis rate (mL/min) is calculated as the mean of the nocturnal diuresis for each of the three nights, with the single-night nocturnal diuresis calculated as the ratio of NUV to total time in bed.&#xD;
Change from baseline in visit-specific mean nocturnal diuresis (mL/min) is presented.&#xD;
Level estimated for baseline value of mean nocturnal diuresis (mL/min) equal to 1.3 is presented in this endpoint.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Mean NUV in Week 1</measure>
    <time_frame>Baseline, Week 1</time_frame>
    <description>The NUV is defined as the total urine volume from 5 minutes after bedtime with the intention to sleep including the first void within 30 minutes of rising in the morning.&#xD;
The NUV at each visit was calculated as the average over the 3 consecutive 24-hour periods just prior to the respective visit. Adjusted visit-specific mean changes from baseline in NUV are estimated using a baseline value of 750 (mL).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Mean NUV at Week 12</measure>
    <time_frame>Baseline, Week 12</time_frame>
    <description>The NUV is defined as the total urine volume from 5 minutes after bedtime with the intention to sleep including the first void within 30 minutes of rising in the morning.&#xD;
The NUV at each visit was calculated as the average over the 3 consecutive 24-hour periods just prior to the respective visit. Adjusted visit-specific mean changes from baseline in NUV are estimated using a baseline value of 750 (mL).</description>
  </secondary_outcome>
  <number_of_arms>9</number_of_arms>
  <enrollment type="Actual">302</enrollment>
  <condition>Nocturia</condition>
  <arm_group>
    <arm_group_label>FE 201836 500 μg (Randomized Treatment Period)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>FE 201836 500 μg oral solution and placebo orally disintegrating tablet (ODT), administered once daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>FE 201836 350 μg (Randomized Treatment Period)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>FE 201836 350 μg oral solution and placebo ODT, administered once daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>FE 201836 250 μg (Randomized Treatment Period)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>FE 201836 250 μg oral solution and placebo ODT, administered once daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>FE 201836 150 μg (Randomized Treatment Period)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>FE 201836 150 μg oral solution and placebo ODT, administered once daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>FE 201836 100 μg (Randomized Treatment Period)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>FE 201836 100 μg oral solution and placebo ODT, administered once daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>FE 201836 50 μg (Randomized Treatment Period)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>FE 201836 50 μg oral solution and placebo ODT, administered once daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo (Randomized Treatment Period)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Placebo oral solution and placebo ODT, administered once daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Desmopressin 25 μg (Randomized Treatment Period)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Desmopressin 25 μg ODT and placebo oral solution, administered once daily (female subjects)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Desmopressin 50 μg (Randomized Treatment Period)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Desmopressin 50 μg ODT and placebo oral solution, administered once daily (male subjects)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>FE 201836</intervention_name>
    <description>Oral solution for daily intake</description>
    <arm_group_label>FE 201836 100 μg (Randomized Treatment Period)</arm_group_label>
    <arm_group_label>FE 201836 150 μg (Randomized Treatment Period)</arm_group_label>
    <arm_group_label>FE 201836 250 μg (Randomized Treatment Period)</arm_group_label>
    <arm_group_label>FE 201836 350 μg (Randomized Treatment Period)</arm_group_label>
    <arm_group_label>FE 201836 50 μg (Randomized Treatment Period)</arm_group_label>
    <arm_group_label>FE 201836 500 μg (Randomized Treatment Period)</arm_group_label>
    <other_name>Velmupressin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Desmopressin</intervention_name>
    <description>Desmopressin Orally Disintegrating Tablet (ODT)</description>
    <arm_group_label>Desmopressin 25 μg (Randomized Treatment Period)</arm_group_label>
    <arm_group_label>Desmopressin 50 μg (Randomized Treatment Period)</arm_group_label>
    <other_name>NOCDURNA</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo oral solution</intervention_name>
    <description>Manufactured to mimic experimental drug</description>
    <arm_group_label>Desmopressin 25 μg (Randomized Treatment Period)</arm_group_label>
    <arm_group_label>Desmopressin 50 μg (Randomized Treatment Period)</arm_group_label>
    <arm_group_label>Placebo (Randomized Treatment Period)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo ODT</intervention_name>
    <description>Manufactured to mimic experimental drug</description>
    <arm_group_label>FE 201836 100 μg (Randomized Treatment Period)</arm_group_label>
    <arm_group_label>FE 201836 150 μg (Randomized Treatment Period)</arm_group_label>
    <arm_group_label>FE 201836 250 μg (Randomized Treatment Period)</arm_group_label>
    <arm_group_label>FE 201836 350 μg (Randomized Treatment Period)</arm_group_label>
    <arm_group_label>FE 201836 50 μg (Randomized Treatment Period)</arm_group_label>
    <arm_group_label>FE 201836 500 μg (Randomized Treatment Period)</arm_group_label>
    <arm_group_label>Placebo (Randomized Treatment Period)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Adults ≥18 years of age (at the time of written consent)&#xD;
&#xD;
          -  Medical history of, or subject reported nocturia symptoms during the 6 months prior to&#xD;
             Visit 1&#xD;
&#xD;
          -  ≥2 nocturnal voids (an average over 3 days) as documented in the 3-day e-Diary prior&#xD;
             to Visit 2&#xD;
&#xD;
          -  The largest single voided volume must be ≥200 mL (at least 1 void ≥200 mL) as&#xD;
             documented in the 3-day e-Diary prior to Visit 2&#xD;
&#xD;
          -  Nocturnal polyuria, defined as Nocturnal Polyuria index &gt;33%, a ratio of Nocturnal&#xD;
             Urine Volume in excess of 33% of total daily (24-hour) urine volume as documented in&#xD;
             the 3-day e-Diary prior to Visit 2&#xD;
&#xD;
          -  ≥20% decrease in the nocturnal diuresis rate (mL/min) (that was recorded at Visit 2)&#xD;
             as documented in the 3-day e-Diary prior to Visit 3&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Current diagnosis of Obstructive Sleep Apnoea (OSA)&#xD;
&#xD;
          -  Restless Legs Syndrome (RLS)&#xD;
&#xD;
          -  Bladder Outlet Obstruction (BOO) or urine flow &lt;5 mL/s, as confirmed by uroflowmetry&#xD;
             upon suspicion during screening prior to Visit 2&#xD;
&#xD;
          -  Urinary incontinence defined as an average of &gt;1 episode/day in the 3-day e-Diary&#xD;
             prior to Visit 2 (occasional urge incontinence during daytime or at night on the way&#xD;
             to void is not necessarily exclusionary)&#xD;
&#xD;
          -  Any pelvic or lower urinary tract surgery and/or radio therapy or previous pelvic&#xD;
             irradiation within the past 6 months prior to Visit 1. Including e.g., transurethral&#xD;
             resection for Bladder Outlet Obstruction or Benign Prostatic Hyperplasia, hysterectomy&#xD;
             or female incontinence procedures&#xD;
&#xD;
          -  Genito-urinary tract pathology that can in the investigator's opinion be responsible&#xD;
             for urgency or urinary incontinence e.g., symptomatic or recurrent urinary tract&#xD;
             infections, interstitial cystitis, bladder-related pain, chronic pelvic pain syndrome,&#xD;
             or stone in the bladder or urethra causing symptoms&#xD;
&#xD;
          -  A history of cancer with the last date of disease activity/presence of malignancy&#xD;
             within the last 12 months prior to Visit 1, except for adequately treated basal cell&#xD;
             carcinoma of the skin&#xD;
&#xD;
          -  History of any neurological disease affecting bladder function or muscle strength&#xD;
             (e.g., Multiple Sclerosis, Parkinson's, spinal cord injury, spina bifida)&#xD;
&#xD;
          -  Habitual (fluid intake &gt;3L per day) or psychogenic polydipsia&#xD;
&#xD;
          -  Uncontrolled hypertension, as judged by the investigator&#xD;
&#xD;
          -  Uncontrolled diabetes mellitus, as judged by the investigator&#xD;
&#xD;
          -  Central or nephrogenic diabetes insipidus&#xD;
&#xD;
          -  Known history of Syndrome of Inappropriate Antidiuretic Hormone (SIADH) secretion&#xD;
&#xD;
          -  History of gastric retention&#xD;
&#xD;
          -  Suspicion or evidence of congestive heart failure, (New York Heart Association (NYHA)&#xD;
             class II, III, IV)&#xD;
&#xD;
          -  Hyponatraemia:&#xD;
&#xD;
               -  Serum sodium level &lt;135 mmol/L at Visit 1(re-tested, with results available&#xD;
                  within 7 days)&#xD;
&#xD;
               -  Serum sodium level &lt;130 mmol/L at Visit 3 (re-tested, with results available&#xD;
                  within 7 days)&#xD;
&#xD;
          -  Use of any prohibited therapy listed below:&#xD;
&#xD;
               -  Current or former (within 3 months prior to screening) treatment with any other&#xD;
                  investigational medicinal product (IMP)&#xD;
&#xD;
               -  Unstable electrostimulation or behavioural bladder training program less than 3&#xD;
                  months prior to screening (stable electrostimulation or behavioural bladder&#xD;
                  training program started at least 3 months before screening are acceptable)&#xD;
&#xD;
               -  Thiazide diuretics&#xD;
&#xD;
               -  Antiarrhythmic agents&#xD;
&#xD;
               -  V2-receptor antagonists/agonists (e.g., vaptans/desmopressin, vasopressin)&#xD;
&#xD;
               -  Loperamide&#xD;
&#xD;
               -  Botulinum toxin (cosmetic non-urological use is acceptable)&#xD;
&#xD;
               -  Valproate&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Global Clinical Compliance</last_name>
    <role>Study Director</role>
    <affiliation>Ferring Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Achieve Clinical Research, LLC</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35216</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Coastal Clinical Research, an AMR company</name>
      <address>
        <city>Mobile</city>
        <state>Alabama</state>
        <zip>36608</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Trials Research</name>
      <address>
        <city>Lincoln</city>
        <state>California</state>
        <zip>95648</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tri Valley Urology Medical Group</name>
      <address>
        <city>Murrieta</city>
        <state>California</state>
        <zip>92562</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>San Diego Clinical Trials</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92120</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Advanced Rx Clinical Research Group, Inc.</name>
      <address>
        <city>Westminster</city>
        <state>California</state>
        <zip>92683</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Downtown Women's Health Care</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80209</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Genitourinary Surgical Consultants, P.C.</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80220</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>South Florida Medical Research</name>
      <address>
        <city>Aventura</city>
        <state>Florida</state>
        <zip>33180</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Women's Medical Research Group, LLC</name>
      <address>
        <city>Clearwater</city>
        <state>Florida</state>
        <zip>33759</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tampa Bay Medical Research, Inc.</name>
      <address>
        <city>Clearwater</city>
        <state>Florida</state>
        <zip>33761</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research of South Florida</name>
      <address>
        <city>Coral Gables</city>
        <state>Florida</state>
        <zip>33134</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Avail Clinical Research, LLC</name>
      <address>
        <city>DeLand</city>
        <state>Florida</state>
        <zip>32720</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Finlay Medical Research Corp</name>
      <address>
        <city>Greenacres City</city>
        <state>Florida</state>
        <zip>33467</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pharmax Research Clinic</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33126</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Doctors Research Institute Corporation</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33145</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanitas Research</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33155</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bayside Clinical Research LLC</name>
      <address>
        <city>New Port Richey</city>
        <state>Florida</state>
        <zip>34655</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pines Care Research Center, Inc</name>
      <address>
        <city>Pembroke Pines</city>
        <state>Florida</state>
        <zip>33026</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Center of Florida</name>
      <address>
        <city>Pompano Beach</city>
        <state>Florida</state>
        <zip>33060</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Meridien Research, Inc.</name>
      <address>
        <city>Saint Petersburg</city>
        <state>Florida</state>
        <zip>33709</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>American Health Network of Indiana, LLC</name>
      <address>
        <city>Avon</city>
        <state>Indiana</state>
        <zip>46123</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>American Health Network of Indiana, LLC</name>
      <address>
        <city>Greenfield</city>
        <state>Indiana</state>
        <zip>46140</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bay State Clinical Trials, Inc.</name>
      <address>
        <city>Watertown</city>
        <state>Massachusetts</state>
        <zip>02472</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Beyer Research</name>
      <address>
        <city>Kalamazoo</city>
        <state>Michigan</state>
        <zip>49009</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Remedica LLC</name>
      <address>
        <city>Rochester</city>
        <state>Michigan</state>
        <zip>48307</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Quality Clinical Research Center, Inc.</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Consortium, an AMR company</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89119-5190</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mid Hudson Medical Research, PLLC</name>
      <address>
        <city>New Windsor</city>
        <state>New York</state>
        <zip>12553</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Premier Medical Group of the Hudson Valley, PC</name>
      <address>
        <city>Poughkeepsie</city>
        <state>New York</state>
        <zip>12601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>American Health Research, Inc.</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28207</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medication Management, LLC</name>
      <address>
        <city>Greensboro</city>
        <state>North Carolina</state>
        <zip>27408</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Peters Medical Research</name>
      <address>
        <city>High Point</city>
        <state>North Carolina</state>
        <zip>27262</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>PMG Research of Raleigh, LLC</name>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <zip>27609</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>PMG Research of Wilmington, LLC</name>
      <address>
        <city>Wilmington</city>
        <state>North Carolina</state>
        <zip>28401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>HWC Women's Research Center</name>
      <address>
        <city>Englewood</city>
        <state>Ohio</state>
        <zip>45322</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NECCR Primacare Research, LLC</name>
      <address>
        <city>Providence</city>
        <state>Rhode Island</state>
        <zip>02908</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Coastal Carolina Research Center, Inc</name>
      <address>
        <city>Mount Pleasant</city>
        <state>South Carolina</state>
        <zip>29464</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>PMG Research of Charleston, LLC</name>
      <address>
        <city>Mount Pleasant</city>
        <state>South Carolina</state>
        <zip>29464</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MCA Research - Partner</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77079</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ericksen Research &amp; Development, LLC</name>
      <address>
        <city>Clinton</city>
        <state>Utah</state>
        <zip>84015</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Advanced Research Institute</name>
      <address>
        <city>Ogden</city>
        <state>Utah</state>
        <zip>84405</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Associates of Tidewater, an AMR company</name>
      <address>
        <city>Norfolk</city>
        <state>Virginia</state>
        <zip>23507</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ULB Hopital Erasme</name>
      <address>
        <city>Bruxelles</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UZ Antwerpen</name>
      <address>
        <city>Edegem</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitair Ziekenhuis Gent</name>
      <address>
        <city>Gent</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AZ Groeninge - Campus Vercruysselaan</name>
      <address>
        <city>Kortrijk</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UZ Leuven</name>
      <address>
        <city>Leuven</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ultra-Med Inc.</name>
      <address>
        <city>Pointe-Claire</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Milestone Research</name>
      <address>
        <city>London</city>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SKDS Research Inc.</name>
      <address>
        <city>Newmarket</city>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>DIEX Recherche Quebec Inc.</name>
      <address>
        <city>Quebec</city>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinique Médicale St-Louis (Recherche) inc d/b/a/ Centre de Recherche Saint-Louis</name>
      <address>
        <city>Québec</city>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bluewater Health-Norman Site</name>
      <address>
        <city>Sarnia</city>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHUS - Hôpital Fleurimont</name>
      <address>
        <city>Sherbrooke</city>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>DIEX Recherche Sherbrooke Inc.</name>
      <address>
        <city>Sherbrooke</city>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ferring Investigational Site</name>
      <address>
        <city>Toronto</city>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>DIEX Recherche Victoriaville Inc.</name>
      <address>
        <city>Victoriaville</city>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Urologie Benešov - Afimed s.r.o.</name>
      <address>
        <city>Benešov</city>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fakultni nemocnice Brno, Dept of Klinika nemoci plicnich a tuberkulozy</name>
      <address>
        <city>Brno</city>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Krajska nemocnice Liberec, a.s.</name>
      <address>
        <city>Liberec</city>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Urocentrum Plzen</name>
      <address>
        <city>Plzen</city>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Thomayerova nemocnice, PARENT</name>
      <address>
        <city>Praha</city>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gemeinschaftspraxis fuer Urologie und Andrologie</name>
      <address>
        <city>Duisburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Urologische Gemeinschaftspraxis</name>
      <address>
        <city>Emmendingen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Weiden, Klinik f. Urologie, Andrologie und Kinderurologie</name>
      <address>
        <city>Weiden</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jahn Ferenc Del-pesti Korhaz es Rendelointezet</name>
      <address>
        <city>Budapest</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Synexus Magyarorszag Kft.</name>
      <address>
        <city>Budapest</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bagoly Egeszseghaz</name>
      <address>
        <city>Kecskemet</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SzSzB Megyei Korhazak es Egyetemi Oktatokorhaz, Josa Andras Oktatokorhaz Urologia</name>
      <address>
        <city>Nyiregyhaza</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jasz-Nagykun-Szolnok Megyei Hetenyi Geza Korhaz-Rendelointezet</name>
      <address>
        <city>Szolnok</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nasz Lekarz Osrodek Badan Klinicznych</name>
      <address>
        <city>Bydgoszcz</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Canada</country>
    <country>Czechia</country>
    <country>Germany</country>
    <country>Hungary</country>
    <country>Poland</country>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>June 26, 2017</study_first_submitted>
  <study_first_submitted_qc>June 26, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">June 28, 2017</study_first_posted>
  <results_first_submitted>October 28, 2020</results_first_submitted>
  <results_first_submitted_qc>November 26, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">December 23, 2020</results_first_posted>
  <last_update_submitted>October 27, 2021</last_update_submitted>
  <last_update_submitted_qc>October 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 3, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Polyuria</mesh_term>
    <mesh_term>Nocturia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Deamino Arginine Vasopressin</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>July 5, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/19/NCT03201419/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>December 12, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/19/NCT03201419/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>A total of 71 sites were authorized to recruit subjects for the trial between July 2017 and July 2019. The trial sites that screened subjects to the trial were: 5 in Belgium, 10 in Canada, 5 in Czech Republic, 2 in Germany, 5 in Hungary, 1 in Poland and 43 in the Unites States of America (USA).</recruitment_details>
      <pre_assignment_details>A total of 1721 subjects were screened, wherein, 531 met the eligibility criteria and entered the enrichment period. Of these, 302 subjects met the eligibility criteria at Visit (V) 4 (randomization), and were randomized to treatment with FE 201836 (different doses), placebo, or desmopressin. A total of 278 subjects completed the trial.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>FE 201836 500 µg (Randomized Treatment Period)</title>
          <description>FE 201836 500 µg oral solution and placebo orally disintegrating tablet (ODT), administered once daily</description>
        </group>
        <group group_id="P2">
          <title>FE 201836 350 µg (Randomized Treatment Period)</title>
          <description>FE 201836 350 µg oral solution and placebo ODT, administered once daily</description>
        </group>
        <group group_id="P3">
          <title>FE 201836 250 µg (Randomized Treatment Period)</title>
          <description>FE 201836 250 µg oral solution and placebo ODT, administered once daily</description>
        </group>
        <group group_id="P4">
          <title>FE 201836 150 µg (Randomized Treatment Period)</title>
          <description>FE 201836 150 µg oral solution and placebo ODT, administered once daily</description>
        </group>
        <group group_id="P5">
          <title>FE 201836 100 µg (Randomized Treatment Period)</title>
          <description>FE 201836 100 µg oral solution and placebo ODT, administered once daily</description>
        </group>
        <group group_id="P6">
          <title>FE 201836 50 µg (Randomized Treatment Period)</title>
          <description>FE 201836 50 µg oral solution and placebo ODT, administered once daily</description>
        </group>
        <group group_id="P7">
          <title>Placebo (Randomized Treatment Period)</title>
          <description>Placebo oral solution and placebo ODT, administered once daily</description>
        </group>
        <group group_id="P8">
          <title>Desmopressin 25 µg (Randomized Treatment Period)</title>
          <description>Desmopressin 25 µg ODT and placebo oral solution, administered once daily (female subjects)</description>
        </group>
        <group group_id="P9">
          <title>Desmopressin 50 µg (Randomized Treatment Period)</title>
          <description>Desmopressin 50 µg ODT and placebo oral solution, administered once daily (male subjects)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="60"/>
                <participants group_id="P2" count="27"/>
                <participants group_id="P3" count="24"/>
                <participants group_id="P4" count="14"/>
                <participants group_id="P5" count="13"/>
                <participants group_id="P6" count="34"/>
                <participants group_id="P7" count="87"/>
                <participants group_id="P8" count="26"/>
                <participants group_id="P9" count="17"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="52"/>
                <participants group_id="P2" count="24"/>
                <participants group_id="P3" count="22"/>
                <participants group_id="P4" count="14"/>
                <participants group_id="P5" count="12"/>
                <participants group_id="P6" count="33"/>
                <participants group_id="P7" count="81"/>
                <participants group_id="P8" count="25"/>
                <participants group_id="P9" count="15"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="1"/>
                <participants group_id="P7" count="6"/>
                <participants group_id="P8" count="1"/>
                <participants group_id="P9" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="1"/>
                <participants group_id="P7" count="5"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Deviation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="1"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="1"/>
                <participants group_id="P9" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>FE 201836 500 µg (Randomized Treatment Period)</title>
          <description>FE 201836 500 µg oral solution and placebo ODT, administered once daily</description>
        </group>
        <group group_id="B2">
          <title>FE 201836 350 µg (Randomized Treatment Period)</title>
          <description>FE 201836 350 µg oral solution and placebo ODT, administered once daily</description>
        </group>
        <group group_id="B3">
          <title>FE 201836 250 µg (Randomized Treatment Period)</title>
          <description>FE 201836 250 µg oral solution and placebo ODT, administered once daily</description>
        </group>
        <group group_id="B4">
          <title>FE 201836 150 µg (Randomized Treatment Period)</title>
          <description>FE 201836 150 µg oral solution and placebo ODT, administered once daily</description>
        </group>
        <group group_id="B5">
          <title>FE 201836 100 µg (Randomized Treatment Period)</title>
          <description>FE 201836 100 µg oral solution and placebo ODT, administered once daily</description>
        </group>
        <group group_id="B6">
          <title>FE 201836 50 µg (Randomized Treatment Period)</title>
          <description>FE 201836 50 µg oral solution and placebo ODT, administered once daily</description>
        </group>
        <group group_id="B7">
          <title>Placebo (Randomized Treatment Period)</title>
          <description>Placebo oral solution and placebo ODT, administered once daily</description>
        </group>
        <group group_id="B8">
          <title>Desmopressin 25µg (Randomized Treatment Period)</title>
          <description>Desmopressin 25 µg ODT and placebo oral solution, administered once daily (female subjects)</description>
        </group>
        <group group_id="B9">
          <title>Desmopressin 50 µg (Randomized Treatment Period)</title>
          <description>Desmopressin 50 µg ODT and placebo oral solution, administered once daily (male subjects)</description>
        </group>
        <group group_id="B10">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="60"/>
            <count group_id="B2" value="27"/>
            <count group_id="B3" value="24"/>
            <count group_id="B4" value="14"/>
            <count group_id="B5" value="13"/>
            <count group_id="B6" value="34"/>
            <count group_id="B7" value="87"/>
            <count group_id="B8" value="26"/>
            <count group_id="B9" value="17"/>
            <count group_id="B10" value="302"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="60"/>
                    <count group_id="B2" value="27"/>
                    <count group_id="B3" value="24"/>
                    <count group_id="B4" value="14"/>
                    <count group_id="B5" value="13"/>
                    <count group_id="B6" value="34"/>
                    <count group_id="B7" value="87"/>
                    <count group_id="B8" value="26"/>
                    <count group_id="B9" value="17"/>
                    <count group_id="B10" value="302"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="59.0" spread="14.1"/>
                    <measurement group_id="B2" value="58.0" spread="14.3"/>
                    <measurement group_id="B3" value="60.8" spread="13.0"/>
                    <measurement group_id="B4" value="63.9" spread="7.5"/>
                    <measurement group_id="B5" value="61.5" spread="9.2"/>
                    <measurement group_id="B6" value="59.1" spread="10.4"/>
                    <measurement group_id="B7" value="58.9" spread="13.9"/>
                    <measurement group_id="B8" value="51.1" spread="11.1"/>
                    <measurement group_id="B9" value="60.9" spread="9.5"/>
                    <measurement group_id="B10" value="58.8" spread="12.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age, Customized</title>
          <units>years</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;65 years old</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="60"/>
                    <count group_id="B2" value="27"/>
                    <count group_id="B3" value="24"/>
                    <count group_id="B4" value="14"/>
                    <count group_id="B5" value="13"/>
                    <count group_id="B6" value="34"/>
                    <count group_id="B7" value="87"/>
                    <count group_id="B8" value="26"/>
                    <count group_id="B9" value="17"/>
                    <count group_id="B10" value="302"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="35"/>
                    <measurement group_id="B2" value="19"/>
                    <measurement group_id="B3" value="14"/>
                    <measurement group_id="B4" value="6"/>
                    <measurement group_id="B5" value="6"/>
                    <measurement group_id="B6" value="21"/>
                    <measurement group_id="B7" value="52"/>
                    <measurement group_id="B8" value="24"/>
                    <measurement group_id="B9" value="11"/>
                    <measurement group_id="B10" value="188"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years old</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="60"/>
                    <count group_id="B2" value="27"/>
                    <count group_id="B3" value="24"/>
                    <count group_id="B4" value="14"/>
                    <count group_id="B5" value="13"/>
                    <count group_id="B6" value="34"/>
                    <count group_id="B7" value="87"/>
                    <count group_id="B8" value="26"/>
                    <count group_id="B9" value="17"/>
                    <count group_id="B10" value="302"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="10"/>
                    <measurement group_id="B4" value="8"/>
                    <measurement group_id="B5" value="7"/>
                    <measurement group_id="B6" value="13"/>
                    <measurement group_id="B7" value="35"/>
                    <measurement group_id="B8" value="2"/>
                    <measurement group_id="B9" value="6"/>
                    <measurement group_id="B10" value="114"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="60"/>
                    <count group_id="B2" value="27"/>
                    <count group_id="B3" value="24"/>
                    <count group_id="B4" value="14"/>
                    <count group_id="B5" value="13"/>
                    <count group_id="B6" value="34"/>
                    <count group_id="B7" value="87"/>
                    <count group_id="B8" value="26"/>
                    <count group_id="B9" value="17"/>
                    <count group_id="B10" value="302"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="40"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="16"/>
                    <measurement group_id="B4" value="5"/>
                    <measurement group_id="B5" value="8"/>
                    <measurement group_id="B6" value="16"/>
                    <measurement group_id="B7" value="51"/>
                    <measurement group_id="B8" value="26"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="180"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="9"/>
                    <measurement group_id="B5" value="5"/>
                    <measurement group_id="B6" value="18"/>
                    <measurement group_id="B7" value="36"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="17"/>
                    <measurement group_id="B10" value="122"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <population>Number analyzed differs from the overall population as baseline ethnicity was not reported for some of the subjects.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="59"/>
                    <count group_id="B2" value="27"/>
                    <count group_id="B3" value="24"/>
                    <count group_id="B4" value="14"/>
                    <count group_id="B5" value="13"/>
                    <count group_id="B6" value="34"/>
                    <count group_id="B7" value="86"/>
                    <count group_id="B8" value="26"/>
                    <count group_id="B9" value="17"/>
                    <count group_id="B10" value="300"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="7"/>
                    <measurement group_id="B6" value="12"/>
                    <measurement group_id="B7" value="35"/>
                    <measurement group_id="B8" value="12"/>
                    <measurement group_id="B9" value="4"/>
                    <measurement group_id="B10" value="105"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="42"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="18"/>
                    <measurement group_id="B4" value="11"/>
                    <measurement group_id="B5" value="6"/>
                    <measurement group_id="B6" value="22"/>
                    <measurement group_id="B7" value="51"/>
                    <measurement group_id="B8" value="14"/>
                    <measurement group_id="B9" value="13"/>
                    <measurement group_id="B10" value="195"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <population>Number analyzed differs from the overall population as baseline race was not reported for some of the subjects.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="60"/>
                    <count group_id="B2" value="27"/>
                    <count group_id="B3" value="24"/>
                    <count group_id="B4" value="14"/>
                    <count group_id="B5" value="13"/>
                    <count group_id="B6" value="33"/>
                    <count group_id="B7" value="86"/>
                    <count group_id="B8" value="26"/>
                    <count group_id="B9" value="17"/>
                    <count group_id="B10" value="300"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="1"/>
                    <measurement group_id="B6" value="1"/>
                    <measurement group_id="B7" value="1"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="2"/>
                    <measurement group_id="B8" value="1"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="1"/>
                    <measurement group_id="B6" value="1"/>
                    <measurement group_id="B7" value="5"/>
                    <measurement group_id="B8" value="6"/>
                    <measurement group_id="B9" value="4"/>
                    <measurement group_id="B10" value="28"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="52"/>
                    <measurement group_id="B2" value="24"/>
                    <measurement group_id="B3" value="22"/>
                    <measurement group_id="B4" value="14"/>
                    <measurement group_id="B5" value="11"/>
                    <measurement group_id="B6" value="31"/>
                    <measurement group_id="B7" value="78"/>
                    <measurement group_id="B8" value="19"/>
                    <measurement group_id="B9" value="13"/>
                    <measurement group_id="B10" value="264"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Baseline body mass index (BMI)</title>
          <units>kg/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="60"/>
                    <count group_id="B2" value="27"/>
                    <count group_id="B3" value="24"/>
                    <count group_id="B4" value="14"/>
                    <count group_id="B5" value="13"/>
                    <count group_id="B6" value="34"/>
                    <count group_id="B7" value="87"/>
                    <count group_id="B8" value="26"/>
                    <count group_id="B9" value="17"/>
                    <count group_id="B10" value="302"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30.66" spread="6.05"/>
                    <measurement group_id="B2" value="29.91" spread="4.64"/>
                    <measurement group_id="B3" value="29.56" spread="6.50"/>
                    <measurement group_id="B4" value="32.03" spread="8.26"/>
                    <measurement group_id="B5" value="31.52" spread="4.60"/>
                    <measurement group_id="B6" value="30.93" spread="6.16"/>
                    <measurement group_id="B7" value="29.54" spread="5.14"/>
                    <measurement group_id="B8" value="31.89" spread="7.99"/>
                    <measurement group_id="B9" value="31.05" spread="6.49"/>
                    <measurement group_id="B10" value="30.44" spread="6.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Mean Number of Nocturnal Voids</title>
          <population>Number analyzed differs from the overall population as baseline mean number of nocturnal voids was not calculated for some of the subjects.</population>
          <units>nocturnal voids</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="59"/>
                    <count group_id="B2" value="27"/>
                    <count group_id="B3" value="24"/>
                    <count group_id="B4" value="14"/>
                    <count group_id="B5" value="13"/>
                    <count group_id="B6" value="34"/>
                    <count group_id="B7" value="86"/>
                    <count group_id="B8" value="25"/>
                    <count group_id="B9" value="17"/>
                    <count group_id="B10" value="299"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2.88" spread="0.84"/>
                    <measurement group_id="B2" value="3.01" spread="0.72"/>
                    <measurement group_id="B3" value="3.10" spread="1.11"/>
                    <measurement group_id="B4" value="2.98" spread="0.84"/>
                    <measurement group_id="B5" value="3.33" spread="0.82"/>
                    <measurement group_id="B6" value="3.24" spread="1.18"/>
                    <measurement group_id="B7" value="3.09" spread="0.83"/>
                    <measurement group_id="B8" value="3.38" spread="1.45"/>
                    <measurement group_id="B9" value="3.16" spread="1.22"/>
                    <measurement group_id="B10" value="3.09" spread="0.98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Mean Nocturnal Urine Volume (NUV)</title>
          <population>Number analyzed differs from the overall population as baseline mean NUV was not calculated for some of the subjects.</population>
          <units>mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="58"/>
                    <count group_id="B2" value="26"/>
                    <count group_id="B3" value="24"/>
                    <count group_id="B4" value="14"/>
                    <count group_id="B5" value="13"/>
                    <count group_id="B6" value="34"/>
                    <count group_id="B7" value="86"/>
                    <count group_id="B8" value="25"/>
                    <count group_id="B9" value="17"/>
                    <count group_id="B10" value="297"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="804.6" spread="313.8"/>
                    <measurement group_id="B2" value="766.0" spread="242.1"/>
                    <measurement group_id="B3" value="897.3" spread="373.6"/>
                    <measurement group_id="B4" value="803.1" spread="304.7"/>
                    <measurement group_id="B5" value="892.4" spread="206.7"/>
                    <measurement group_id="B6" value="879.9" spread="354.1"/>
                    <measurement group_id="B7" value="752.3" spread="269.5"/>
                    <measurement group_id="B8" value="839.3" spread="286.4"/>
                    <measurement group_id="B9" value="803.5" spread="425.8"/>
                    <measurement group_id="B10" value="808.8" spread="307.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Mean Nocturnal Polyuria Index</title>
          <description>Nocturnal polyuria index (NPi) is calculated by dividing the nocturnal urine volume (NUV) by the 24-hour urine volume. In this clinical trial the NPi definition &gt;33% is used for all ages to define presence of nocturnal polyuria (NP).</description>
          <population>Number analyzed differs from the overall population as baseline mean nocturnal polyuria index was not calculated for some of the subjects.</population>
          <units>percentage</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="55"/>
                    <count group_id="B2" value="25"/>
                    <count group_id="B3" value="22"/>
                    <count group_id="B4" value="14"/>
                    <count group_id="B5" value="12"/>
                    <count group_id="B6" value="31"/>
                    <count group_id="B7" value="76"/>
                    <count group_id="B8" value="23"/>
                    <count group_id="B9" value="16"/>
                    <count group_id="B10" value="274"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="48.87" spread="12.04"/>
                    <measurement group_id="B2" value="46.76" spread="10.08"/>
                    <measurement group_id="B3" value="49.75" spread="15.96"/>
                    <measurement group_id="B4" value="50.99" spread="12.93"/>
                    <measurement group_id="B5" value="44.59" spread="6.58"/>
                    <measurement group_id="B6" value="47.01" spread="9.86"/>
                    <measurement group_id="B7" value="47.91" spread="14.29"/>
                    <measurement group_id="B8" value="49.21" spread="13.93"/>
                    <measurement group_id="B9" value="49.10" spread="17.93"/>
                    <measurement group_id="B10" value="48.24" spread="12.99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Mean Nocturia Impact (NI) Diary Total Score</title>
          <population>Number analyzed differs from the overall population as mean NI Diary Total Score was not calculated for some of the subjects.</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="60"/>
                    <count group_id="B2" value="26"/>
                    <count group_id="B3" value="24"/>
                    <count group_id="B4" value="14"/>
                    <count group_id="B5" value="13"/>
                    <count group_id="B6" value="32"/>
                    <count group_id="B7" value="86"/>
                    <count group_id="B8" value="25"/>
                    <count group_id="B9" value="17"/>
                    <count group_id="B10" value="297"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="47.20" spread="18.39"/>
                    <measurement group_id="B2" value="47.03" spread="28.44"/>
                    <measurement group_id="B3" value="38.76" spread="19.09"/>
                    <measurement group_id="B4" value="36.28" spread="22.10"/>
                    <measurement group_id="B5" value="51.63" spread="17.73"/>
                    <measurement group_id="B6" value="42.46" spread="23.28"/>
                    <measurement group_id="B7" value="47.66" spread="21.25"/>
                    <measurement group_id="B8" value="58.06" spread="20.78"/>
                    <measurement group_id="B9" value="39.88" spread="23.08"/>
                    <measurement group_id="B10" value="46.30" spread="21.81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Mean NI Diary Overall Impact Score</title>
          <description>The Nocturia Impact (NI) Diary is a 12-item questionnaire with 11 core items (Q1-Q11) and an overall Quality-of-Life (QoL) impact question (Q12). For the overall impact question (Q12), response options range from 0 (not at all) to 4 (a great deal). The NI Diary Overall Impact Score is standardized from 0 to 100 (lowest to highest impact). The score at each visit was calculated as the average over the three consecutive 24-hour periods just prior to the respective visit.</description>
          <population>Number analyzed differs from the overall population as mean NI Diary Overall Impact Score was not calculated for some of the subjects.</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="60"/>
                    <count group_id="B2" value="26"/>
                    <count group_id="B3" value="24"/>
                    <count group_id="B4" value="14"/>
                    <count group_id="B5" value="13"/>
                    <count group_id="B6" value="32"/>
                    <count group_id="B7" value="86"/>
                    <count group_id="B8" value="25"/>
                    <count group_id="B9" value="17"/>
                    <count group_id="B10" value="297"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="59.2" spread="25.4"/>
                    <measurement group_id="B2" value="62.3" spread="29.8"/>
                    <measurement group_id="B3" value="55.9" spread="21.6"/>
                    <measurement group_id="B4" value="53.0" spread="30.6"/>
                    <measurement group_id="B5" value="68.6" spread="20.7"/>
                    <measurement group_id="B6" value="59.9" spread="26.8"/>
                    <measurement group_id="B7" value="62.7" spread="26.8"/>
                    <measurement group_id="B8" value="71.5" spread="23.8"/>
                    <measurement group_id="B9" value="54.2" spread="28.0"/>
                    <measurement group_id="B10" value="61.2" spread="26.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Insomnia Severity Index (ISI)</title>
          <description>The Insomnia Severity Index (ISI) is a 7-item questionnaire which comprises of four 'sleep-related' items and three 'wake-related' items. Each item is rated on a 0-4 scale and the total score ranges from 0 to 28 (higher score suggests more severe insomnia).</description>
          <population>Number analyzed differs from the overall population as mean ISI was not calculated for some of the subjects.</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="55"/>
                    <count group_id="B2" value="26"/>
                    <count group_id="B3" value="24"/>
                    <count group_id="B4" value="14"/>
                    <count group_id="B5" value="9"/>
                    <count group_id="B6" value="31"/>
                    <count group_id="B7" value="77"/>
                    <count group_id="B8" value="26"/>
                    <count group_id="B9" value="17"/>
                    <count group_id="B10" value="279"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15.8" spread="5.4"/>
                    <measurement group_id="B2" value="15.7" spread="6.1"/>
                    <measurement group_id="B3" value="14.3" spread="5.1"/>
                    <measurement group_id="B4" value="13.0" spread="6.7"/>
                    <measurement group_id="B5" value="16.4" spread="5.6"/>
                    <measurement group_id="B6" value="14.7" spread="4.8"/>
                    <measurement group_id="B7" value="15.6" spread="5.8"/>
                    <measurement group_id="B8" value="18.2" spread="4.7"/>
                    <measurement group_id="B9" value="15.5" spread="6.8"/>
                    <measurement group_id="B10" value="15.6" spread="5.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Aggregated Mean Number of Nocturnal Voids During 12 Weeks of Treatment</title>
        <description>Nocturnal voids were defined as voids occuring from 5 minutes after bedtime until rising in the morning.&#xD;
The number of nocturnal voids at each visit was calculated as the average over the 3 consecutive 24 hour periods just prior to the respective visit. The visit-specific means were aggregated into a mean of current and preceding visits.&#xD;
Level estimated for baseline value of mean number of nocturnal voids equal to 2, and 95% credibility interval (2.5 and 97.5 percentiles of the posterior distribution) instead of confidence interval are presented in this endpoint.</description>
        <time_frame>Baseline, during 12 weeks of treatment</time_frame>
        <population>The intention-to-treat analysis set for the randomized treatment period (ITT-RT) comprised of all the subjects randomized at Visit 4.</population>
        <group_list>
          <group group_id="O1">
            <title>FE 201836 500 ug (Randomized Treatment Period)</title>
            <description>FE 201836 500 µg oral solution and placebo ODT, administered once daily</description>
          </group>
          <group group_id="O2">
            <title>FE 201836 350 ug (Randomized Treatment Period)</title>
            <description>FE 201836 350 µg oral solution and placebo ODT, administered once daily</description>
          </group>
          <group group_id="O3">
            <title>FE 201836 250 ug (Randomized Treatment Period)</title>
            <description>FE 201836 250 µg oral solution and placebo ODT, administered once daily</description>
          </group>
          <group group_id="O4">
            <title>FE 201836 150 ug (Randomized Treatment Period)</title>
            <description>FE 201836 150 µg oral solution and placebo ODT, administered once daily</description>
          </group>
          <group group_id="O5">
            <title>FE 201836 100 ug (Randomized Treatment Period)</title>
            <description>FE 201836 100 µg oral solution and placebo ODT, administered once daily</description>
          </group>
          <group group_id="O6">
            <title>FE 201836 50 ug (Randomized Treatment Period)</title>
            <description>FE 201836 50 µg oral solution and placebo ODT, administered once daily</description>
          </group>
          <group group_id="O7">
            <title>Placebo (Randomized Treatment Period)</title>
            <description>Placebo oral solution and placebo ODT, administered once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Aggregated Mean Number of Nocturnal Voids During 12 Weeks of Treatment</title>
          <description>Nocturnal voids were defined as voids occuring from 5 minutes after bedtime until rising in the morning.&#xD;
The number of nocturnal voids at each visit was calculated as the average over the 3 consecutive 24 hour periods just prior to the respective visit. The visit-specific means were aggregated into a mean of current and preceding visits.&#xD;
Level estimated for baseline value of mean number of nocturnal voids equal to 2, and 95% credibility interval (2.5 and 97.5 percentiles of the posterior distribution) instead of confidence interval are presented in this endpoint.</description>
          <population>The intention-to-treat analysis set for the randomized treatment period (ITT-RT) comprised of all the subjects randomized at Visit 4.</population>
          <units>nocturnal voids</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="60"/>
                <count group_id="O2" value="27"/>
                <count group_id="O3" value="24"/>
                <count group_id="O4" value="14"/>
                <count group_id="O5" value="13"/>
                <count group_id="O6" value="34"/>
                <count group_id="O7" value="87"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.06" lower_limit="-1.28" upper_limit="-0.86"/>
                    <measurement group_id="O2" value="-0.99" lower_limit="-1.20" upper_limit="-0.78"/>
                    <measurement group_id="O3" value="-0.89" lower_limit="-1.12" upper_limit="-0.69"/>
                    <measurement group_id="O4" value="-0.80" lower_limit="-1.00" upper_limit="-0.62"/>
                    <measurement group_id="O5" value="-0.77" lower_limit="-0.97" upper_limit="-0.59"/>
                    <measurement group_id="O6" value="-0.76" lower_limit="-0.95" upper_limit="-0.58"/>
                    <measurement group_id="O7" value="-0.76" lower_limit="-0.95" upper_limit="-0.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <groups_desc>Based on a Bayesian analysis of a sigmoidal dose-response relationship.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Mean Difference</param_type>
            <param_value>-0.30</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.54</ci_lower_limit>
            <ci_upper_limit>-0.07</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <groups_desc>Based on a Bayesian analysis of a sigmoidal dose-response relationship.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Mean Difference</param_type>
            <param_value>-0.23</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.46</ci_lower_limit>
            <ci_upper_limit>-0.02</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <groups_desc>Based on a Bayesian analysis of a sigmoidal dose-response relationship.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Mean Difference</param_type>
            <param_value>-0.14</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.36</ci_lower_limit>
            <ci_upper_limit>-0.00</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <groups_desc>Based on a Bayesian analysis of a sigmoidal dose-response relationship.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Mean Difference</param_type>
            <param_value>-0.040</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.23</ci_lower_limit>
            <ci_upper_limit>-0.00</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <groups_desc>Based on a Bayesian analysis of a sigmoidal dose-response relationship.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Mean Difference</param_type>
            <param_value>-0.02</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.14</ci_lower_limit>
            <ci_upper_limit>-0.00</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O6</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <groups_desc>Based on a Bayesian analysis of a sigmoidal dose-response relationship.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Mean Difference</param_type>
            <param_value>-0.01</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.07</ci_lower_limit>
            <ci_upper_limit>-0.00</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Mean Number of Nocturnal Voids at Week 1</title>
        <description>Nocturnal voids were defined as voids occuring from 5 minutes after bedtime until rising in the morning.&#xD;
The number of nocturnal voids at each visit was calculated as the average over the 3 consecutive 24 hour periods just prior to the respective visit. Adjusted visit-specific mean changes from baseline in nocturnal voids are estimated using a baseline value of 2.&#xD;
MMRM=Mixed Model for Repeated Measurements.&#xD;
For all visit-specific results, the tables present the number of subjects with an observation of the endpoints in question at the specific visit. All secondary analyses are performed using the observed-case approach based on repeated measurements for all subjects in the ITT-RT population. That is, these secondary analyses are based on all subjects with at least one non-missing post-baseline observation (with a baseline value if relevant).</description>
        <time_frame>Baseline, Week 1</time_frame>
        <population>The ITT-RT comprised of all the subjects randomized at Visit 4.</population>
        <group_list>
          <group group_id="O1">
            <title>FE 201836 500 ug (Randomized Treatment Period)</title>
            <description>FE 201836 500 µg oral solution and placebo ODT, administered once daily</description>
          </group>
          <group group_id="O2">
            <title>FE 201836 350 ug (Randomized Treatment Period)</title>
            <description>FE 201836 350 µg oral solution and placebo ODT, administered once daily</description>
          </group>
          <group group_id="O3">
            <title>FE 201836 250 ug (Randomized Treatment Period)</title>
            <description>FE 201836 250 µg oral solution and placebo ODT, administered once daily</description>
          </group>
          <group group_id="O4">
            <title>FE 201836 150 ug (Randomized Treatment Period)</title>
            <description>FE 201836 150 µg oral solution and placebo ODT, administered once daily</description>
          </group>
          <group group_id="O5">
            <title>FE 201836 100 ug (Randomized Treatment Period)</title>
            <description>FE 201836 100 µg oral solution and placebo ODT, administered once daily</description>
          </group>
          <group group_id="O6">
            <title>FE 201836 50 ug (Randomized Treatment Period)</title>
            <description>FE 201836 50 µg oral solution and placebo ODT, administered once daily</description>
          </group>
          <group group_id="O7">
            <title>Placebo (Randomized Treatment Period)</title>
            <description>Placebo oral solution and placebo ODT, administered once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Mean Number of Nocturnal Voids at Week 1</title>
          <description>Nocturnal voids were defined as voids occuring from 5 minutes after bedtime until rising in the morning.&#xD;
The number of nocturnal voids at each visit was calculated as the average over the 3 consecutive 24 hour periods just prior to the respective visit. Adjusted visit-specific mean changes from baseline in nocturnal voids are estimated using a baseline value of 2.&#xD;
MMRM=Mixed Model for Repeated Measurements.&#xD;
For all visit-specific results, the tables present the number of subjects with an observation of the endpoints in question at the specific visit. All secondary analyses are performed using the observed-case approach based on repeated measurements for all subjects in the ITT-RT population. That is, these secondary analyses are based on all subjects with at least one non-missing post-baseline observation (with a baseline value if relevant).</description>
          <population>The ITT-RT comprised of all the subjects randomized at Visit 4.</population>
          <units>nocturnal voids</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="54"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="24"/>
                <count group_id="O4" value="14"/>
                <count group_id="O5" value="11"/>
                <count group_id="O6" value="33"/>
                <count group_id="O7" value="80"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.714" lower_limit="-1.005" upper_limit="-0.424"/>
                    <measurement group_id="O2" value="-1.162" lower_limit="-1.577" upper_limit="-0.747"/>
                    <measurement group_id="O3" value="-0.722" lower_limit="-1.149" upper_limit="-0.296"/>
                    <measurement group_id="O4" value="-0.520" lower_limit="-1.058" upper_limit="0.017"/>
                    <measurement group_id="O5" value="-0.722" lower_limit="-1.318" upper_limit="-0.126"/>
                    <measurement group_id="O6" value="-0.325" lower_limit="-0.709" upper_limit="0.059"/>
                    <measurement group_id="O7" value="-0.575" lower_limit="-0.842" upper_limit="-0.308"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.4214</p_value>
            <p_value_desc>Threshold for significance at 0.05 level.</p_value_desc>
            <method>MMRM</method>
            <param_type>Mean Difference</param_type>
            <param_value>-0.139</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.480</ci_lower_limit>
            <ci_upper_limit>0.201</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0101</p_value>
            <p_value_desc>Threshold for significance at 0.05 level.</p_value_desc>
            <method>MMRM</method>
            <param_type>Mean Difference</param_type>
            <param_value>-0.587</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.034</ci_lower_limit>
            <ci_upper_limit>-0.141</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.5203</p_value>
            <p_value_desc>Threshold for significance at 0.05 level.</p_value_desc>
            <method>MMRM</method>
            <param_type>Mean Difference</param_type>
            <param_value>-0.148</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.599</ci_lower_limit>
            <ci_upper_limit>0.304</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.8483</p_value>
            <p_value_desc>Threshold for significance at 0.05 level.</p_value_desc>
            <method>MMRM</method>
            <param_type>Mean Difference</param_type>
            <param_value>0.055</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.508</ci_lower_limit>
            <ci_upper_limit>0.617</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.6357</p_value>
            <p_value_desc>Threshold for significance at 0.05 level.</p_value_desc>
            <method>MMRM</method>
            <param_type>Mean Difference</param_type>
            <param_value>-0.147</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.759</ci_lower_limit>
            <ci_upper_limit>0.464</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O6</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.2222</p_value>
            <p_value_desc>Threshold for significance at 0.05 level.</p_value_desc>
            <method>MMRM</method>
            <param_type>Mean Difference</param_type>
            <param_value>0.250</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.152</ci_lower_limit>
            <ci_upper_limit>0.652</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Mean Number of Nocturnal Voids at Week 4</title>
        <description>Nocturnal voids were defined as voids occuring from 5 minutes after bedtime until rising in the morning.&#xD;
The number of nocturnal voids at each visit was calculated as the average over the 3 consecutive 24 hour periods just prior to the respective visit. Adjusted visit-specific mean changes from baseline in nocturnal voids are estimated using a baseline value of 2.</description>
        <time_frame>Baseline, Week 4</time_frame>
        <population>The ITT-RT comprised of all the subjects randomized at Visit 4.</population>
        <group_list>
          <group group_id="O1">
            <title>FE 201836 500 ug (Randomized Treatment Period)</title>
            <description>FE 201836 500 µg oral solution and placebo ODT, administered once daily</description>
          </group>
          <group group_id="O2">
            <title>FE 201836 350 ug (Randomized Treatment Period)</title>
            <description>FE 201836 350 µg oral solution and placebo ODT, administered once daily</description>
          </group>
          <group group_id="O3">
            <title>FE 201836 250 ug (Randomized Treatment Period)</title>
            <description>FE 201836 250 µg oral solution and placebo ODT, administered once daily</description>
          </group>
          <group group_id="O4">
            <title>FE 201836 150 ug (Randomized Treatment Period)</title>
            <description>FE 201836 150 µg oral solution and placebo ODT, administered once daily</description>
          </group>
          <group group_id="O5">
            <title>FE 201836 100 ug (Randomized Treatment Period)</title>
            <description>FE 201836 100 µg oral solution and placebo ODT, administered once daily</description>
          </group>
          <group group_id="O6">
            <title>FE 201836 50 ug (Randomized Treatment Period)</title>
            <description>FE 201836 50 µg oral solution and placebo ODT, administered once daily</description>
          </group>
          <group group_id="O7">
            <title>Placebo (Randomized Treatment Period)</title>
            <description>Placebo oral solution and placebo ODT, administered once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Mean Number of Nocturnal Voids at Week 4</title>
          <description>Nocturnal voids were defined as voids occuring from 5 minutes after bedtime until rising in the morning.&#xD;
The number of nocturnal voids at each visit was calculated as the average over the 3 consecutive 24 hour periods just prior to the respective visit. Adjusted visit-specific mean changes from baseline in nocturnal voids are estimated using a baseline value of 2.</description>
          <population>The ITT-RT comprised of all the subjects randomized at Visit 4.</population>
          <units>nocturnal voids</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
                <count group_id="O2" value="22"/>
                <count group_id="O3" value="21"/>
                <count group_id="O4" value="12"/>
                <count group_id="O5" value="12"/>
                <count group_id="O6" value="31"/>
                <count group_id="O7" value="76"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.078" lower_limit="-1.345" upper_limit="-0.811"/>
                    <measurement group_id="O2" value="-1.330" lower_limit="-1.708" upper_limit="-0.952"/>
                    <measurement group_id="O3" value="-0.784" lower_limit="-1.181" upper_limit="-0.386"/>
                    <measurement group_id="O4" value="-0.471" lower_limit="-0.969" upper_limit="0.028"/>
                    <measurement group_id="O5" value="-0.952" lower_limit="-1.469" upper_limit="-0.435"/>
                    <measurement group_id="O6" value="-0.518" lower_limit="-0.866" upper_limit="-0.171"/>
                    <measurement group_id="O7" value="-0.912" lower_limit="-1.152" upper_limit="-0.673"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.2909</p_value>
            <p_value_desc>Threshold for significance at 0.05 level.</p_value_desc>
            <method>MMRM</method>
            <param_type>Mean Difference</param_type>
            <param_value>-0.166</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.474</ci_lower_limit>
            <ci_upper_limit>0.143</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0440</p_value>
            <p_value_desc>Threshold for significance at 0.05 level.</p_value_desc>
            <method>MMRM</method>
            <param_type>Mean Difference</param_type>
            <param_value>-0.418</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.824</ci_lower_limit>
            <ci_upper_limit>-0.011</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.5438</p_value>
            <p_value_desc>Threshold for significance at 0.05 level.</p_value_desc>
            <method>MMRM</method>
            <param_type>Mean Difference</param_type>
            <param_value>0.128</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.288</ci_lower_limit>
            <ci_upper_limit>0.545</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0960</p_value>
            <p_value_desc>Threshold for significance at 0.05 level.</p_value_desc>
            <method>MMRM</method>
            <param_type>Mean Difference</param_type>
            <param_value>0.441</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.079</ci_lower_limit>
            <ci_upper_limit>0.962</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.8826</p_value>
            <p_value_desc>Threshold for significance at 0.05 level.</p_value_desc>
            <method>MMRM</method>
            <param_type>Mean Difference</param_type>
            <param_value>-0.040</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.568</ci_lower_limit>
            <ci_upper_limit>0.488</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O6</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0344</p_value>
            <p_value_desc>Threshold for significance at 0.05 level.</p_value_desc>
            <method>MMRM</method>
            <param_type>Mean Difference</param_type>
            <param_value>0.394</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.029</ci_lower_limit>
            <ci_upper_limit>0.759</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Mean Number of Nocturnal Voids at Week 8</title>
        <description>Nocturnal voids were defined as voids occuring from 5 minutes after bedtime until rising in the morning.&#xD;
The number of nocturnal voids at each visit was calculated as the average over the 3 consecutive 24 hour periods just prior to the respective visit. Adjusted visit-specific mean changes from baseline in nocturnal voids are estimated using a baseline value of 2.</description>
        <time_frame>Baseline, Week 8</time_frame>
        <population>The ITT-RT comprised of all the subjects randomized at Visit 4.</population>
        <group_list>
          <group group_id="O1">
            <title>FE 201836 500 ug (Randomized Treatment Period)</title>
            <description>FE 201836 500 µg oral solution and placebo ODT, administered once daily</description>
          </group>
          <group group_id="O2">
            <title>FE 201836 350 ug (Randomized Treatment Period)</title>
            <description>FE 201836 350 µg oral solution and placebo ODT, administered once daily</description>
          </group>
          <group group_id="O3">
            <title>FE 201836 250 ug (Randomized Treatment Period)</title>
            <description>FE 201836 250 µg oral solution and placebo ODT, administered once daily</description>
          </group>
          <group group_id="O4">
            <title>FE 201836 150 ug (Randomized Treatment Period)</title>
            <description>FE 201836 150 µg oral solution and placebo ODT, administered once daily</description>
          </group>
          <group group_id="O5">
            <title>FE 201836 100 ug (Randomized Treatment Period)</title>
            <description>FE 201836 100 µg oral solution and placebo ODT, administered once daily</description>
          </group>
          <group group_id="O6">
            <title>FE 201836 50 ug (Randomized Treatment Period)</title>
            <description>FE 201836 50 µg oral solution and placebo ODT, administered once daily</description>
          </group>
          <group group_id="O7">
            <title>Placebo (Randomized Treatment Period)</title>
            <description>Placebo oral solution and placebo ODT, administered once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Mean Number of Nocturnal Voids at Week 8</title>
          <description>Nocturnal voids were defined as voids occuring from 5 minutes after bedtime until rising in the morning.&#xD;
The number of nocturnal voids at each visit was calculated as the average over the 3 consecutive 24 hour periods just prior to the respective visit. Adjusted visit-specific mean changes from baseline in nocturnal voids are estimated using a baseline value of 2.</description>
          <population>The ITT-RT comprised of all the subjects randomized at Visit 4.</population>
          <units>nocturnal voids</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="44"/>
                <count group_id="O2" value="23"/>
                <count group_id="O3" value="21"/>
                <count group_id="O4" value="14"/>
                <count group_id="O5" value="12"/>
                <count group_id="O6" value="30"/>
                <count group_id="O7" value="70"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.085" lower_limit="-1.394" upper_limit="-0.776"/>
                    <measurement group_id="O2" value="-1.177" lower_limit="-1.603" upper_limit="-0.751"/>
                    <measurement group_id="O3" value="-0.965" lower_limit="-1.414" upper_limit="-0.516"/>
                    <measurement group_id="O4" value="-0.490" lower_limit="-1.037" upper_limit="0.058"/>
                    <measurement group_id="O5" value="-1.077" lower_limit="-1.671" upper_limit="-0.484"/>
                    <measurement group_id="O6" value="-0.786" lower_limit="-1.187" upper_limit="-0.386"/>
                    <measurement group_id="O7" value="-0.953" lower_limit="-1.233" upper_limit="-0.672"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.4732</p_value>
            <p_value_desc>Threshold for significance at 0.05 level.</p_value_desc>
            <method>MMRM</method>
            <param_type>Mean Difference</param_type>
            <param_value>-0.132</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.496</ci_lower_limit>
            <ci_upper_limit>0.231</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.3394</p_value>
            <p_value_desc>Threshold for significance at 0.05 level.</p_value_desc>
            <method>MMRM</method>
            <param_type>Mean Difference</param_type>
            <param_value>-0.224</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.685</ci_lower_limit>
            <ci_upper_limit>0.237</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.9600</p_value>
            <p_value_desc>Threshold for significance at 0.05 level.</p_value_desc>
            <method>MMRM</method>
            <param_type>Mean Difference</param_type>
            <param_value>-0.012</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.488</ci_lower_limit>
            <ci_upper_limit>0.463</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.1131</p_value>
            <p_value_desc>Threshold for significance at 0.05 level.</p_value_desc>
            <method>MMRM</method>
            <param_type>Mean Difference</param_type>
            <param_value>0.463</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.111</ci_lower_limit>
            <ci_upper_limit>1.037</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.6853</p_value>
            <p_value_desc>Threshold for significance at 0.05 level.</p_value_desc>
            <method>MMRM</method>
            <param_type>Mean Difference</param_type>
            <param_value>-0.124</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.729</ci_lower_limit>
            <ci_upper_limit>0.480</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O6</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.4364</p_value>
            <p_value_desc>Threshold for significance at 0.05 level.</p_value_desc>
            <method>MMRM</method>
            <param_type>Mean Difference</param_type>
            <param_value>0.166</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.254</ci_lower_limit>
            <ci_upper_limit>0.587</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Mean Number of Nocturnal Voids at Week 12</title>
        <description>Nocturnal voids were defined as voids occuring from 5 minutes after bedtime until rising in the morning.&#xD;
The number of nocturnal voids at each visit was calculated as the average over the 3 consecutive 24 hour periods just prior to the respective visit. Adjusted visit-specific mean changes from baseline in nocturnal voids are estimated using a baseline value of 2.</description>
        <time_frame>Baseline, Week 12</time_frame>
        <population>The ITT-RT comprised of all the subjects randomized at Visit 4.</population>
        <group_list>
          <group group_id="O1">
            <title>FE 201836 500 ug (Randomized Treatment Period)</title>
            <description>FE 201836 500 µg oral solution and placebo ODT, administered once daily</description>
          </group>
          <group group_id="O2">
            <title>FE 201836 350 ug (Randomized Treatment Period)</title>
            <description>FE 201836 350 µg oral solution and placebo ODT, administered once daily</description>
          </group>
          <group group_id="O3">
            <title>FE 201836 250 ug (Randomized Treatment Period)</title>
            <description>FE 201836 250 µg oral solution and placebo ODT, administered once daily</description>
          </group>
          <group group_id="O4">
            <title>FE 201836 150 ug (Randomized Treatment Period)</title>
            <description>FE 201836 150 µg oral solution and placebo ODT, administered once daily</description>
          </group>
          <group group_id="O5">
            <title>FE 201836 100 ug (Randomized Treatment Period)</title>
            <description>FE 201836 100 µg oral solution and placebo ODT, administered once daily</description>
          </group>
          <group group_id="O6">
            <title>FE 201836 50 ug (Randomized Treatment Period)</title>
            <description>FE 201836 50 µg oral solution and placebo ODT, administered once daily</description>
          </group>
          <group group_id="O7">
            <title>Placebo (Randomized Treatment Period)</title>
            <description>Placebo oral solution and placebo ODT, administered once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Mean Number of Nocturnal Voids at Week 12</title>
          <description>Nocturnal voids were defined as voids occuring from 5 minutes after bedtime until rising in the morning.&#xD;
The number of nocturnal voids at each visit was calculated as the average over the 3 consecutive 24 hour periods just prior to the respective visit. Adjusted visit-specific mean changes from baseline in nocturnal voids are estimated using a baseline value of 2.</description>
          <population>The ITT-RT comprised of all the subjects randomized at Visit 4.</population>
          <units>nocturnal voids</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="19"/>
                <count group_id="O3" value="19"/>
                <count group_id="O4" value="14"/>
                <count group_id="O5" value="11"/>
                <count group_id="O6" value="29"/>
                <count group_id="O7" value="69"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.256" lower_limit="-1.568" upper_limit="-0.944"/>
                    <measurement group_id="O2" value="-1.120" lower_limit="-1.558" upper_limit="-0.683"/>
                    <measurement group_id="O3" value="-0.850" lower_limit="-1.301" upper_limit="-0.400"/>
                    <measurement group_id="O4" value="-0.674" lower_limit="-1.206" upper_limit="-0.142"/>
                    <measurement group_id="O5" value="-1.053" lower_limit="-1.650" upper_limit="-0.456"/>
                    <measurement group_id="O6" value="-0.921" lower_limit="-1.317" upper_limit="-0.524"/>
                    <measurement group_id="O7" value="-0.957" lower_limit="-1.237" upper_limit="-0.677"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.1106</p_value>
            <p_value_desc>Threshold for significance at 0.05 level.</p_value_desc>
            <method>MMRM</method>
            <param_type>Mean Difference</param_type>
            <param_value>-0.299</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.667</ci_lower_limit>
            <ci_upper_limit>0.069</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.5005</p_value>
            <p_value_desc>Threshold for significance at 0.05 level.</p_value_desc>
            <method>MMRM</method>
            <param_type>Mean Difference</param_type>
            <param_value>-0.163</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.639</ci_lower_limit>
            <ci_upper_limit>0.313</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.6604</p_value>
            <p_value_desc>Threshold for significance at 0.05 level.</p_value_desc>
            <method>MMRM</method>
            <param_type>Mean Difference</param_type>
            <param_value>0.107</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.372</ci_lower_limit>
            <ci_upper_limit>0.586</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.3178</p_value>
            <p_value_desc>Threshold for significance at 0.05 level.</p_value_desc>
            <method>MMRM</method>
            <param_type>Mean Difference</param_type>
            <param_value>0.283</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.275</ci_lower_limit>
            <ci_upper_limit>0.842</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.7561</p_value>
            <p_value_desc>Threshold for significance at 0.05 level.</p_value_desc>
            <method>MMRM</method>
            <param_type>Mean Difference</param_type>
            <param_value>-0.096</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.701</ci_lower_limit>
            <ci_upper_limit>0.510</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O6</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.8614</p_value>
            <p_value_desc>Threshold for significance at 0.05 level.</p_value_desc>
            <method>MMRM</method>
            <param_type>Mean Difference</param_type>
            <param_value>0.037</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.378</ci_lower_limit>
            <ci_upper_limit>0.452</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Responder Rate in Nocturnal Voids at Week 1</title>
        <description>Defined as 50% reduction in nocturnal voids from baseline.&#xD;
Adjusted visit-specific estimated odds of at least 50% in the reduction mean number of nocturnal voids are estimated using a baseline value of 2.&#xD;
The estimated odd equals the probability of response divided by the probability of non-response; these odds may vary between 0 and infinity. For example, if the probability of responding is 80%, the odd of responding is 4, as it is 4 times more likely to respond (80%) then it is not to respond (20%).</description>
        <time_frame>Week 1</time_frame>
        <population>The ITT-RT comprised of all the subjects randomized at Visit 4.</population>
        <group_list>
          <group group_id="O1">
            <title>FE 201836 500 ug (Randomized Treatment Period)</title>
            <description>FE 201836 500 µg oral solution and placebo ODT, administered once daily</description>
          </group>
          <group group_id="O2">
            <title>FE 201836 350 ug (Randomized Treatment Period)</title>
            <description>FE 201836 350 µg oral solution and placebo ODT, administered once daily</description>
          </group>
          <group group_id="O3">
            <title>FE 201836 250 ug (Randomized Treatment Period)</title>
            <description>FE 201836 250 µg oral solution and placebo ODT, administered once daily</description>
          </group>
          <group group_id="O4">
            <title>FE 201836 150 ug (Randomized Treatment Period)</title>
            <description>FE 201836 150 µg oral solution and placebo ODT, administered once daily</description>
          </group>
          <group group_id="O5">
            <title>FE 201836 100 ug (Randomized Treatment Period)</title>
            <description>FE 201836 100 µg oral solution and placebo ODT, administered once daily</description>
          </group>
          <group group_id="O6">
            <title>FE 201836 50 ug (Randomized Treatment Period)</title>
            <description>FE 201836 50 µg oral solution and placebo ODT, administered once daily</description>
          </group>
          <group group_id="O7">
            <title>Placebo (Randomized Treatment Period)</title>
            <description>Placebo oral solution and placebo ODT, administered once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Responder Rate in Nocturnal Voids at Week 1</title>
          <description>Defined as 50% reduction in nocturnal voids from baseline.&#xD;
Adjusted visit-specific estimated odds of at least 50% in the reduction mean number of nocturnal voids are estimated using a baseline value of 2.&#xD;
The estimated odd equals the probability of response divided by the probability of non-response; these odds may vary between 0 and infinity. For example, if the probability of responding is 80%, the odd of responding is 4, as it is 4 times more likely to respond (80%) then it is not to respond (20%).</description>
          <population>The ITT-RT comprised of all the subjects randomized at Visit 4.</population>
          <units>odd of response</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="54"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="24"/>
                <count group_id="O4" value="14"/>
                <count group_id="O5" value="11"/>
                <count group_id="O6" value="33"/>
                <count group_id="O7" value="80"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.844" lower_limit="0.457" upper_limit="1.558"/>
                    <measurement group_id="O2" value="1.202" lower_limit="0.510" upper_limit="2.833"/>
                    <measurement group_id="O3" value="0.682" lower_limit="0.280" upper_limit="1.662"/>
                    <measurement group_id="O4" value="0.818" lower_limit="0.269" upper_limit="2.490"/>
                    <measurement group_id="O5" value="0.810" lower_limit="0.240" upper_limit="2.738"/>
                    <measurement group_id="O6" value="0.513" lower_limit="0.227" upper_limit="1.157"/>
                    <measurement group_id="O7" value="0.480" lower_limit="0.272" upper_limit="0.848"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.117</p_value>
            <p_value_desc>Threshold for significance at 0.05 level.</p_value_desc>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.759</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.869</ci_lower_limit>
            <ci_upper_limit>3.560</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.048</p_value>
            <p_value_desc>Threshold for significance at 0.05 level.</p_value_desc>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>2.505</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.010</ci_lower_limit>
            <ci_upper_limit>6.214</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.460</p_value>
            <p_value_desc>Threshold for significance at 0.05 level.</p_value_desc>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.420</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.560</ci_lower_limit>
            <ci_upper_limit>3.602</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.367</p_value>
            <p_value_desc>Threshold for significance at 0.05 level.</p_value_desc>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.704</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.535</ci_lower_limit>
            <ci_upper_limit>5.427</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.407</p_value>
            <p_value_desc>Threshold for significance at 0.05 level.</p_value_desc>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.689</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.489</ci_lower_limit>
            <ci_upper_limit>5.825</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O6</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.876</p_value>
            <p_value_desc>Threshold for significance at 0.05 level.</p_value_desc>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.069</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.462</ci_lower_limit>
            <ci_upper_limit>2.473</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Responder Rate in Nocturnal Voids at Week 4</title>
        <description>Defined as 50% reduction in nocturnal voids from baseline.&#xD;
Adjusted visit-specific estimated odds of at least 50% reduction in the mean number of nocturnal voids are estimated using a baseline value of 2.&#xD;
The estimated odd equals the probability of response divided by the probability of non-response; these odds may vary between 0 and infinity. For example, if the probability of responding is 80%, the odd of responding is 4, as it is 4 times more likely to respond (80%) then it is not to respond (20%).</description>
        <time_frame>Week 4</time_frame>
        <population>The ITT-RT comprised of all the subjects randomized at Visit 4.</population>
        <group_list>
          <group group_id="O1">
            <title>FE 201836 500 ug (Randomized Treatment Period)</title>
            <description>FE 201836 500 µg oral solution and placebo ODT, administered once daily</description>
          </group>
          <group group_id="O2">
            <title>FE 201836 350 ug (Randomized Treatment Period)</title>
            <description>FE 201836 350 µg oral solution and placebo ODT, administered once daily</description>
          </group>
          <group group_id="O3">
            <title>FE 201836 250 ug (Randomized Treatment Period)</title>
            <description>FE 201836 250 µg oral solution and placebo ODT, administered once daily</description>
          </group>
          <group group_id="O4">
            <title>FE 201836 150 ug (Randomized Treatment Period)</title>
            <description>FE 201836 150 µg oral solution and placebo ODT, administered once daily</description>
          </group>
          <group group_id="O5">
            <title>FE 201836 100 ug (Randomized Treatment Period)</title>
            <description>FE 201836 100 µg oral solution and placebo ODT, administered once daily</description>
          </group>
          <group group_id="O6">
            <title>FE 201836 50 ug (Randomized Treatment Period)</title>
            <description>FE 201836 50 µg oral solution and placebo ODT, administered once daily</description>
          </group>
          <group group_id="O7">
            <title>Placebo (Randomized Treatment Period)</title>
            <description>Placebo oral solution and placebo ODT, administered once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Responder Rate in Nocturnal Voids at Week 4</title>
          <description>Defined as 50% reduction in nocturnal voids from baseline.&#xD;
Adjusted visit-specific estimated odds of at least 50% reduction in the mean number of nocturnal voids are estimated using a baseline value of 2.&#xD;
The estimated odd equals the probability of response divided by the probability of non-response; these odds may vary between 0 and infinity. For example, if the probability of responding is 80%, the odd of responding is 4, as it is 4 times more likely to respond (80%) then it is not to respond (20%).</description>
          <population>The ITT-RT comprised of all the subjects randomized at Visit 4.</population>
          <units>odd of response</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
                <count group_id="O2" value="22"/>
                <count group_id="O3" value="21"/>
                <count group_id="O4" value="12"/>
                <count group_id="O5" value="12"/>
                <count group_id="O6" value="31"/>
                <count group_id="O7" value="76"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.199" lower_limit="0.633" upper_limit="2.270"/>
                    <measurement group_id="O2" value="5.851" lower_limit="1.511" upper_limit="22.650"/>
                    <measurement group_id="O3" value="0.634" lower_limit="0.255" upper_limit="1.575"/>
                    <measurement group_id="O4" value="0.534" lower_limit="0.165" upper_limit="1.731"/>
                    <measurement group_id="O5" value="1.760" lower_limit="0.470" upper_limit="6.596"/>
                    <measurement group_id="O6" value="0.683" lower_limit="0.301" upper_limit="1.550"/>
                    <measurement group_id="O7" value="1.235" lower_limit="0.686" upper_limit="2.224"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.937</p_value>
            <p_value_desc>Threshold for significance at 0.05 level.</p_value_desc>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.971</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.470</ci_lower_limit>
            <ci_upper_limit>2.005</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.028</p_value>
            <p_value_desc>Threshold for significance at 0.05 level.</p_value_desc>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>4.738</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.183</ci_lower_limit>
            <ci_upper_limit>18.968</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.166</p_value>
            <p_value_desc>Threshold for significance at 0.05 level.</p_value_desc>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.513</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.200</ci_lower_limit>
            <ci_upper_limit>1.318</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.174</p_value>
            <p_value_desc>Threshold for significance at 0.05 level.</p_value_desc>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.433</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.129</ci_lower_limit>
            <ci_upper_limit>1.447</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.608</p_value>
            <p_value_desc>Threshold for significance at 0.05 level.</p_value_desc>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.425</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.369</ci_lower_limit>
            <ci_upper_limit>5.512</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O6</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.171</p_value>
            <p_value_desc>Threshold for significance at 0.05 level.</p_value_desc>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.553</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.237</ci_lower_limit>
            <ci_upper_limit>1.292</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Responder Rate in Nocturnal Voids at Week 8</title>
        <description>Defined as 50% reduction in nocturnal voids from baseline.&#xD;
Adjusted visit-specific estimated odds of at least 50% reduction in the mean number of nocturnal voids are estimated using a baseline value of 2.&#xD;
The estimated odd equals the probability of response divided by the probability of non-response; these odds may vary between 0 and infinity. For example, if the probability of responding is 80%, the odd of responding is 4, as it is 4 times more likely to respond (80%) then it is not to respond (20%).</description>
        <time_frame>Week 8</time_frame>
        <population>The ITT-RT comprised of all the subjects randomized at Visit 4.</population>
        <group_list>
          <group group_id="O1">
            <title>FE 201836 500 ug (Randomized Treatment Period)</title>
            <description>FE 201836 500 µg oral solution and placebo ODT, administered once daily</description>
          </group>
          <group group_id="O2">
            <title>FE 201836 350 ug (Randomized Treatment Period)</title>
            <description>FE 201836 350 µg oral solution and placebo ODT, administered once daily</description>
          </group>
          <group group_id="O3">
            <title>FE 201836 250 ug (Randomized Treatment Period)</title>
            <description>FE 201836 250 µg oral solution and placebo ODT, administered once daily</description>
          </group>
          <group group_id="O4">
            <title>FE 201836 150 ug (Randomized Treatment Period)</title>
            <description>FE 201836 150 µg oral solution and placebo ODT, administered once daily</description>
          </group>
          <group group_id="O5">
            <title>FE 201836 100 ug (Randomized Treatment Period)</title>
            <description>FE 201836 100 µg oral solution and placebo ODT, administered once daily</description>
          </group>
          <group group_id="O6">
            <title>FE 201836 50 ug (Randomized Treatment Period)</title>
            <description>FE 201836 50 µg oral solution and placebo ODT, administered once daily</description>
          </group>
          <group group_id="O7">
            <title>Placebo (Randomized Treatment Period)</title>
            <description>Placebo oral solution and placebo ODT, administered once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Responder Rate in Nocturnal Voids at Week 8</title>
          <description>Defined as 50% reduction in nocturnal voids from baseline.&#xD;
Adjusted visit-specific estimated odds of at least 50% reduction in the mean number of nocturnal voids are estimated using a baseline value of 2.&#xD;
The estimated odd equals the probability of response divided by the probability of non-response; these odds may vary between 0 and infinity. For example, if the probability of responding is 80%, the odd of responding is 4, as it is 4 times more likely to respond (80%) then it is not to respond (20%).</description>
          <population>The ITT-RT comprised of all the subjects randomized at Visit 4.</population>
          <units>odd of response</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="44"/>
                <count group_id="O2" value="23"/>
                <count group_id="O3" value="21"/>
                <count group_id="O4" value="14"/>
                <count group_id="O5" value="12"/>
                <count group_id="O6" value="30"/>
                <count group_id="O7" value="70"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.395" lower_limit="0.717" upper_limit="2.715"/>
                    <measurement group_id="O2" value="3.398" lower_limit="1.150" upper_limit="10.043"/>
                    <measurement group_id="O3" value="1.928" lower_limit="0.721" upper_limit="5.155"/>
                    <measurement group_id="O4" value="0.877" lower_limit="0.286" upper_limit="2.688"/>
                    <measurement group_id="O5" value="1.039" lower_limit="0.302" upper_limit="3.569"/>
                    <measurement group_id="O6" value="1.489" lower_limit="0.638" upper_limit="3.474"/>
                    <measurement group_id="O7" value="1.503" lower_limit="0.806" upper_limit="2.803"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.850</p_value>
            <p_value_desc>Threshold for significance at 0.05 level.</p_value_desc>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.928</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.430</ci_lower_limit>
            <ci_upper_limit>2.003</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.150</p_value>
            <p_value_desc>Threshold for significance at 0.05 level.</p_value_desc>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>2.261</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.745</ci_lower_limit>
            <ci_upper_limit>6.862</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.632</p_value>
            <p_value_desc>Threshold for significance at 0.05 level.</p_value_desc>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.283</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.462</ci_lower_limit>
            <ci_upper_limit>3.566</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.363</p_value>
            <p_value_desc>Threshold for significance at 0.05 level.</p_value_desc>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.583</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.183</ci_lower_limit>
            <ci_upper_limit>1.863</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.555</p_value>
            <p_value_desc>Threshold for significance at 0.05 level.</p_value_desc>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.691</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.203</ci_lower_limit>
            <ci_upper_limit>2.359</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O6</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.984</p_value>
            <p_value_desc>Threshold for significance at 0.05 level.</p_value_desc>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.991</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.408</ci_lower_limit>
            <ci_upper_limit>2.405</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Responder Rate in Nocturnal Voids at Week 12</title>
        <description>Defined as 50% reduction in nocturnal voids from baseline.&#xD;
Adjusted visit-specific estimated odds of at least 50% reduction in the mean number of nocturnal voids are estimated using a baseline value of 2.&#xD;
The estimated odd equals the probability of response divided by the probability of non-response; these odds may vary between 0 and infinity. For example, if the probability of responding is 80%, the odd of responding is 4, as it is 4 times more likely to respond (80%) then it is not to respond (20%).</description>
        <time_frame>Week 12</time_frame>
        <population>The ITT-RT comprised of all the subjects randomized at Visit 4.</population>
        <group_list>
          <group group_id="O1">
            <title>FE 201836 500 ug (Randomized Treatment Period)</title>
            <description>FE 201836 500 µg oral solution and placebo ODT, administered once daily</description>
          </group>
          <group group_id="O2">
            <title>FE 201836 350 ug (Randomized Treatment Period)</title>
            <description>FE 201836 350 µg oral solution and placebo ODT, administered once daily</description>
          </group>
          <group group_id="O3">
            <title>FE 201836 250 ug (Randomized Treatment Period)</title>
            <description>FE 201836 250 µg oral solution and placebo ODT, administered once daily</description>
          </group>
          <group group_id="O4">
            <title>FE 201836 150 ug (Randomized Treatment Period)</title>
            <description>FE 201836 150 µg oral solution and placebo ODT, administered once daily</description>
          </group>
          <group group_id="O5">
            <title>FE 201836 100 ug (Randomized Treatment Period)</title>
            <description>FE 201836 100 µg oral solution and placebo ODT, administered once daily</description>
          </group>
          <group group_id="O6">
            <title>FE 201836 50 ug (Randomized Treatment Period)</title>
            <description>FE 201836 50 µg oral solution and placebo ODT, administered once daily</description>
          </group>
          <group group_id="O7">
            <title>Placebo (Randomized Treatment Period)</title>
            <description>Placebo oral solution and placebo ODT, administered once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Responder Rate in Nocturnal Voids at Week 12</title>
          <description>Defined as 50% reduction in nocturnal voids from baseline.&#xD;
Adjusted visit-specific estimated odds of at least 50% reduction in the mean number of nocturnal voids are estimated using a baseline value of 2.&#xD;
The estimated odd equals the probability of response divided by the probability of non-response; these odds may vary between 0 and infinity. For example, if the probability of responding is 80%, the odd of responding is 4, as it is 4 times more likely to respond (80%) then it is not to respond (20%).</description>
          <population>The ITT-RT comprised of all the subjects randomized at Visit 4.</population>
          <units>odd of response</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="19"/>
                <count group_id="O3" value="19"/>
                <count group_id="O4" value="14"/>
                <count group_id="O5" value="11"/>
                <count group_id="O6" value="29"/>
                <count group_id="O7" value="69"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.914" lower_limit="1.830" upper_limit="8.370"/>
                    <measurement group_id="O2" value="1.891" lower_limit="0.693" upper_limit="5.163"/>
                    <measurement group_id="O3" value="1.824" lower_limit="0.694" upper_limit="4.795"/>
                    <measurement group_id="O4" value="0.854" lower_limit="0.279" upper_limit="2.611"/>
                    <measurement group_id="O5" value="1.400" lower_limit="0.401" upper_limit="4.893"/>
                    <measurement group_id="O6" value="1.395" lower_limit="0.611" upper_limit="3.181"/>
                    <measurement group_id="O7" value="1.590" lower_limit="0.844" upper_limit="2.993"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.046</p_value>
            <p_value_desc>Threshold for significance at 0.05 level.</p_value_desc>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>2.462</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.017</ci_lower_limit>
            <ci_upper_limit>5.961</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.745</p_value>
            <p_value_desc>Threshold for significance at 0.05 level.</p_value_desc>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.190</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.418</ci_lower_limit>
            <ci_upper_limit>3.386</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.790</p_value>
            <p_value_desc>Threshold for significance at 0.05 level.</p_value_desc>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.147</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.417</ci_lower_limit>
            <ci_upper_limit>3.155</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.293</p_value>
            <p_value_desc>Threshold for significance at 0.05 level.</p_value_desc>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.537</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.169</ci_lower_limit>
            <ci_upper_limit>1.710</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.843</p_value>
            <p_value_desc>Threshold for significance at 0.05 level.</p_value_desc>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.881</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.252</ci_lower_limit>
            <ci_upper_limit>3.076</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O6</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.763</p_value>
            <p_value_desc>Threshold for significance at 0.05 level.</p_value_desc>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.877</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.375</ci_lower_limit>
            <ci_upper_limit>2.053</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Responder Rate in Nocturnal Voids During 12 Weeks of Treatment</title>
        <description>Defined as 50% reduction in nocturnal voids from baseline.&#xD;
Estimated odds of at least 50% reduction in the aggregated mean number of nocturnal voids for a subject with 2 nocturnal voids at baseline are presented in this endpoint.&#xD;
The 95% credibility interval (2.5 and 97.5 percentiles of the posterior distribution) instead of confidence interval is presented for this endpoint.&#xD;
The estimated odd equals the probability of response divided by the probability of non-response; these odds may vary between 0 and infinity. For example, if the probability of responding is 80%, the odd of responding is 4, as it is 4 times more likely to respond (80%) then it is not to respond (20%).</description>
        <time_frame>During 12 weeks of treatment</time_frame>
        <population>The ITT-RT comprised of all the subjects randomized at Visit 4.</population>
        <group_list>
          <group group_id="O1">
            <title>FE 201836 500 ug (Randomized Treatment Period)</title>
            <description>FE 201836 500 µg oral solution and placebo ODT, administered once daily</description>
          </group>
          <group group_id="O2">
            <title>FE 201836 350 ug (Randomized Treatment Period)</title>
            <description>FE 201836 350 µg oral solution and placebo ODT, administered once daily</description>
          </group>
          <group group_id="O3">
            <title>FE 201836 250 ug (Randomized Treatment Period)</title>
            <description>FE 201836 250 µg oral solution and placebo ODT, administered once daily</description>
          </group>
          <group group_id="O4">
            <title>FE 201836 150 ug (Randomized Treatment Period)</title>
            <description>FE 201836 150 µg oral solution and placebo ODT, administered once daily</description>
          </group>
          <group group_id="O5">
            <title>FE 201836 100 ug (Randomized Treatment Period)</title>
            <description>FE 201836 100 µg oral solution and placebo ODT, administered once daily</description>
          </group>
          <group group_id="O6">
            <title>FE 201836 50 ug (Randomized Treatment Period)</title>
            <description>FE 201836 50 µg oral solution and placebo ODT, administered once daily</description>
          </group>
          <group group_id="O7">
            <title>Placebo (Randomized Treatment Period)</title>
            <description>Placebo oral solution and placebo ODT, administered once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Responder Rate in Nocturnal Voids During 12 Weeks of Treatment</title>
          <description>Defined as 50% reduction in nocturnal voids from baseline.&#xD;
Estimated odds of at least 50% reduction in the aggregated mean number of nocturnal voids for a subject with 2 nocturnal voids at baseline are presented in this endpoint.&#xD;
The 95% credibility interval (2.5 and 97.5 percentiles of the posterior distribution) instead of confidence interval is presented for this endpoint.&#xD;
The estimated odd equals the probability of response divided by the probability of non-response; these odds may vary between 0 and infinity. For example, if the probability of responding is 80%, the odd of responding is 4, as it is 4 times more likely to respond (80%) then it is not to respond (20%).</description>
          <population>The ITT-RT comprised of all the subjects randomized at Visit 4.</population>
          <units>odd of response</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="60"/>
                <count group_id="O2" value="27"/>
                <count group_id="O3" value="24"/>
                <count group_id="O4" value="14"/>
                <count group_id="O5" value="13"/>
                <count group_id="O6" value="34"/>
                <count group_id="O7" value="87"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.129" lower_limit="0.808" upper_limit="1.753"/>
                    <measurement group_id="O2" value="1.095" lower_limit="0.772" upper_limit="1.661"/>
                    <measurement group_id="O3" value="1.032" lower_limit="0.711" upper_limit="1.543"/>
                    <measurement group_id="O4" value="0.934" lower_limit="0.597" upper_limit="1.378"/>
                    <measurement group_id="O5" value="0.887" lower_limit="0.555" upper_limit="1.253"/>
                    <measurement group_id="O6" value="0.849" lower_limit="0.534" upper_limit="1.187"/>
                    <measurement group_id="O7" value="0.834" lower_limit="0.514" upper_limit="1.180"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <groups_desc>Based on a Bayesian analysis of a sigmoidal dose-response relationship.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.422</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.868</ci_lower_limit>
            <ci_upper_limit>2.597</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <groups_desc>Based on a Bayesian analysis of a sigmoidal dose-response relationship.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.373</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.905</ci_lower_limit>
            <ci_upper_limit>2.450</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <groups_desc>Based on a Bayesian analysis of a sigmoidal dose-response relationship.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.284</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.927</ci_lower_limit>
            <ci_upper_limit>2.264</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <groups_desc>Based on a Bayesian analysis of a sigmoidal dose-response relationship.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.145</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.957</ci_lower_limit>
            <ci_upper_limit>1.896</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <groups_desc>Based on a Bayesian analysis of a sigmoidal dose-response relationship.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.079</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.972</ci_lower_limit>
            <ci_upper_limit>1.638</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O6</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <groups_desc>Based on a Bayesian analysis of a sigmoidal dose-response relationship.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.023</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.991</ci_lower_limit>
            <ci_upper_limit>1.313</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Mean NI Diary Total Score at Week 1</title>
        <description>The NI Diary is a 12-item questionnaire with 11 core items (Q1-Q11) and an overall quality of life (QoL) impact question (Q12). The NI Diary Total Scores are calculated by summing the 11 core items.Responses are scored from 0 to 4 (lowest t o highest impact). The NI Diary Total is standardized from 0 to 100 (lowest to highest impact).&#xD;
The score at each visit was calculated as the average over the three consecutive 24 hour periods just prior to the respective visit. Adjusted visit-specific mean changes from baseline in NI Diary Total Score are estimated using a baseline value of 40.</description>
        <time_frame>Baseline, Week 1</time_frame>
        <population>The ITT-RT comprised of all the subjects randomized at Visit 4.</population>
        <group_list>
          <group group_id="O1">
            <title>FE 201836 500 ug (Randomized Treatment Period)</title>
            <description>FE 201836 500 µg oral solution and placebo ODT, administered once daily</description>
          </group>
          <group group_id="O2">
            <title>FE 201836 350 ug (Randomized Treatment Period)</title>
            <description>FE 201836 350 µg oral solution and placebo ODT, administered once daily</description>
          </group>
          <group group_id="O3">
            <title>FE 201836 250 ug (Randomized Treatment Period)</title>
            <description>FE 201836 250 µg oral solution and placebo ODT, administered once daily</description>
          </group>
          <group group_id="O4">
            <title>FE 201836 150 ug (Randomized Treatment Period)</title>
            <description>FE 201836 150 µg oral solution and placebo ODT, administered once daily</description>
          </group>
          <group group_id="O5">
            <title>FE 201836 100 ug (Randomized Treatment Period)</title>
            <description>FE 201836 100 µg oral solution and placebo ODT, administered once daily</description>
          </group>
          <group group_id="O6">
            <title>FE 201836 50 ug (Randomized Treatment Period)</title>
            <description>FE 201836 50 µg oral solution and placebo ODT, administered once daily</description>
          </group>
          <group group_id="O7">
            <title>Placebo (Randomized Treatment Period)</title>
            <description>Placebo oral solution and placebo ODT, administered once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Mean NI Diary Total Score at Week 1</title>
          <description>The NI Diary is a 12-item questionnaire with 11 core items (Q1-Q11) and an overall quality of life (QoL) impact question (Q12). The NI Diary Total Scores are calculated by summing the 11 core items.Responses are scored from 0 to 4 (lowest t o highest impact). The NI Diary Total is standardized from 0 to 100 (lowest to highest impact).&#xD;
The score at each visit was calculated as the average over the three consecutive 24 hour periods just prior to the respective visit. Adjusted visit-specific mean changes from baseline in NI Diary Total Score are estimated using a baseline value of 40.</description>
          <population>The ITT-RT comprised of all the subjects randomized at Visit 4.</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="55"/>
                <count group_id="O2" value="23"/>
                <count group_id="O3" value="24"/>
                <count group_id="O4" value="14"/>
                <count group_id="O5" value="12"/>
                <count group_id="O6" value="31"/>
                <count group_id="O7" value="83"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.55" lower_limit="-11.67" upper_limit="-3.43"/>
                    <measurement group_id="O2" value="-21.91" lower_limit="-28.15" upper_limit="-15.68"/>
                    <measurement group_id="O3" value="-10.90" lower_limit="-17.17" upper_limit="-4.63"/>
                    <measurement group_id="O4" value="-8.93" lower_limit="-17.15" upper_limit="-0.72"/>
                    <measurement group_id="O5" value="-9.68" lower_limit="-18.41" upper_limit="-0.94"/>
                    <measurement group_id="O6" value="-8.75" lower_limit="-14.27" upper_limit="-3.23"/>
                    <measurement group_id="O7" value="-8.07" lower_limit="-11.48" upper_limit="-4.65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.8463</p_value>
            <p_value_desc>Threshold for significance at 0.05 level.</p_value_desc>
            <method>MMRM</method>
            <param_type>Mean Difference</param_type>
            <param_value>0.52</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.75</ci_lower_limit>
            <ci_upper_limit>5.78</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0001</p_value>
            <p_value_desc>Threshold for significance at 0.05 level.</p_value_desc>
            <method>MMRM</method>
            <param_type>Mean Difference</param_type>
            <param_value>-13.85</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-20.89</ci_lower_limit>
            <ci_upper_limit>-6.81</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.4355</p_value>
            <p_value_desc>Threshold for significance at 0.05 level.</p_value_desc>
            <method>MMRM</method>
            <param_type>Mean Difference</param_type>
            <param_value>-2.84</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-9.99</ci_lower_limit>
            <ci_upper_limit>4.32</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.8483</p_value>
            <p_value_desc>Threshold for significance at 0.05 level.</p_value_desc>
            <method>MMRM</method>
            <param_type>Mean Difference</param_type>
            <param_value>-0.87</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-9.79</ci_lower_limit>
            <ci_upper_limit>8.06</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.7336</p_value>
            <p_value_desc>Threshold for significance at 0.05 level.</p_value_desc>
            <method>MMRM</method>
            <param_type>Mean Difference</param_type>
            <param_value>-1.61</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-10.91</ci_lower_limit>
            <ci_upper_limit>7.69</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O6</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.8347</p_value>
            <p_value_desc>Threshold for significance at 0.05 level.</p_value_desc>
            <method>MMRM</method>
            <param_type>Mean Difference</param_type>
            <param_value>-0.69</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-7.15</ci_lower_limit>
            <ci_upper_limit>5.78</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Mean NI Diary Total Score at Week 4</title>
        <description>The NI Diary is a 12-item questionnaire with 11 core items (Q1-Q11) and an overall QoL impact question (Q12). The NI Diary Total Scores are calculated by summing the 11 core items. Responses are scored from 0 to 4 (lowest to highest impact). The NI Diary Total is standardized from 0 to 100 (lowest to highest impact).&#xD;
The score at each visit was calculated as the average over the three consecutive 24 hour periods just prior to the respective visit. Adjusted visit-specific mean changes from baseline in NI Diary Total Score are estimated using a baseline value of 40.</description>
        <time_frame>Baseline, Week 4</time_frame>
        <population>The ITT-RT comprised of all the subjects randomized at Visit 4.</population>
        <group_list>
          <group group_id="O1">
            <title>FE 201836 500 ug (Randomized Treatment Period)</title>
            <description>FE 201836 500 µg oral solution and placebo ODT, administered once daily</description>
          </group>
          <group group_id="O2">
            <title>FE 201836 350 ug (Randomized Treatment Period)</title>
            <description>FE 201836 350 µg oral solution and placebo ODT, administered once daily</description>
          </group>
          <group group_id="O3">
            <title>FE 201836 250 ug (Randomized Treatment Period)</title>
            <description>FE 201836 250 µg oral solution and placebo ODT, administered once daily</description>
          </group>
          <group group_id="O4">
            <title>FE 201836 150 ug (Randomized Treatment Period)</title>
            <description>FE 201836 150 µg oral solution and placebo ODT, administered once daily</description>
          </group>
          <group group_id="O5">
            <title>FE 201836 100 ug (Randomized Treatment Period)</title>
            <description>FE 201836 100 µg oral solution and placebo ODT, administered once daily</description>
          </group>
          <group group_id="O6">
            <title>FE 201836 50 ug (Randomized Treatment Period)</title>
            <description>FE 201836 50 µg oral solution and placebo ODT, administered once daily</description>
          </group>
          <group group_id="O7">
            <title>Placebo (Randomized Treatment Period)</title>
            <description>Placebo oral solution and placebo ODT, administered once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Mean NI Diary Total Score at Week 4</title>
          <description>The NI Diary is a 12-item questionnaire with 11 core items (Q1-Q11) and an overall QoL impact question (Q12). The NI Diary Total Scores are calculated by summing the 11 core items. Responses are scored from 0 to 4 (lowest to highest impact). The NI Diary Total is standardized from 0 to 100 (lowest to highest impact).&#xD;
The score at each visit was calculated as the average over the three consecutive 24 hour periods just prior to the respective visit. Adjusted visit-specific mean changes from baseline in NI Diary Total Score are estimated using a baseline value of 40.</description>
          <population>The ITT-RT comprised of all the subjects randomized at Visit 4.</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="53"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="22"/>
                <count group_id="O4" value="13"/>
                <count group_id="O5" value="13"/>
                <count group_id="O6" value="31"/>
                <count group_id="O7" value="78"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-12.62" lower_limit="-16.89" upper_limit="-8.35"/>
                    <measurement group_id="O2" value="-17.44" lower_limit="-23.80" upper_limit="-11.08"/>
                    <measurement group_id="O3" value="-14.37" lower_limit="-20.96" upper_limit="-7.78"/>
                    <measurement group_id="O4" value="-11.23" lower_limit="-19.82" upper_limit="-2.65"/>
                    <measurement group_id="O5" value="-22.23" lower_limit="-31.11" upper_limit="-13.35"/>
                    <measurement group_id="O6" value="-13.29" lower_limit="-19.00" upper_limit="-7.58"/>
                    <measurement group_id="O7" value="-14.20" lower_limit="-17.77" upper_limit="-10.64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.5695</p_value>
            <p_value_desc>Threshold for significance at 0.05 level.</p_value_desc>
            <method>MMRM</method>
            <param_type>Mean Difference</param_type>
            <param_value>1.59</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.90</ci_lower_limit>
            <ci_upper_limit>7.07</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.3784</p_value>
            <p_value_desc>Threshold for significance at 0.05 level.</p_value_desc>
            <method>MMRM</method>
            <param_type>Mean Difference</param_type>
            <param_value>-3.23</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-10.46</ci_lower_limit>
            <ci_upper_limit>3.99</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.9653</p_value>
            <p_value_desc>Threshold for significance at 0.05 level.</p_value_desc>
            <method>MMRM</method>
            <param_type>Mean Difference</param_type>
            <param_value>-0.17</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-7.67</ci_lower_limit>
            <ci_upper_limit>7.34</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.5304</p_value>
            <p_value_desc>Threshold for significance at 0.05 level.</p_value_desc>
            <method>MMRM</method>
            <param_type>Mean Difference</param_type>
            <param_value>2.97</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-6.35</ci_lower_limit>
            <ci_upper_limit>12.29</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0968</p_value>
            <p_value_desc>Threshold for significance at 0.05 level.</p_value_desc>
            <method>MMRM</method>
            <param_type>Mean Difference</param_type>
            <param_value>-8.02</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-17.51</ci_lower_limit>
            <ci_upper_limit>1.46</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O6</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.7885</p_value>
            <p_value_desc>Threshold for significance at 0.05 level.</p_value_desc>
            <method>MMRM</method>
            <param_type>Mean Difference</param_type>
            <param_value>0.91</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-5.79</ci_lower_limit>
            <ci_upper_limit>7.62</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Mean NI Diary Total Score at Week 8</title>
        <description>The NI Diary is a 12-item questionnaire with 11 core items (Q1-Q11) and an overall QoL impact question (Q12). The NI Diary Total Scores are calculated by summing the 11 core items. Responses are scored from 0 to 4 (lowest to highest impact). The NI Diary Total is standardized from 0 to 100 (lowest to highest impact).&#xD;
The score at each visit was calculated as the average over the three consecutive 24 hour periods just prior to the respective visit. Adjusted visit-specific mean changes from baseline in NI Diary Total Score are estimated using a baseline value of 40.</description>
        <time_frame>Baseline, Week 8</time_frame>
        <population>The ITT-RT comprised of all the subjects randomized at Visit 4.</population>
        <group_list>
          <group group_id="O1">
            <title>FE 201836 500 ug (Randomized Treatment Period)</title>
            <description>FE 201836 500 µg oral solution and placebo ODT, administered once daily</description>
          </group>
          <group group_id="O2">
            <title>FE 201836 350 ug (Randomized Treatment Period)</title>
            <description>FE 201836 350 µg oral solution and placebo ODT, administered once daily</description>
          </group>
          <group group_id="O3">
            <title>FE 201836 250 ug (Randomized Treatment Period)</title>
            <description>FE 201836 250 µg oral solution and placebo ODT, administered once daily</description>
          </group>
          <group group_id="O4">
            <title>FE 201836 150 ug (Randomized Treatment Period)</title>
            <description>FE 201836 150 µg oral solution and placebo ODT, administered once daily</description>
          </group>
          <group group_id="O5">
            <title>FE 201836 100 ug (Randomized Treatment Period)</title>
            <description>FE 201836 100 µg oral solution and placebo ODT, administered once daily</description>
          </group>
          <group group_id="O6">
            <title>FE 201836 50 ug (Randomized Treatment Period)</title>
            <description>FE 201836 50 µg oral solution and placebo ODT, administered once daily</description>
          </group>
          <group group_id="O7">
            <title>Placebo (Randomized Treatment Period)</title>
            <description>Placebo oral solution and placebo ODT, administered once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Mean NI Diary Total Score at Week 8</title>
          <description>The NI Diary is a 12-item questionnaire with 11 core items (Q1-Q11) and an overall QoL impact question (Q12). The NI Diary Total Scores are calculated by summing the 11 core items. Responses are scored from 0 to 4 (lowest to highest impact). The NI Diary Total is standardized from 0 to 100 (lowest to highest impact).&#xD;
The score at each visit was calculated as the average over the three consecutive 24 hour periods just prior to the respective visit. Adjusted visit-specific mean changes from baseline in NI Diary Total Score are estimated using a baseline value of 40.</description>
          <population>The ITT-RT comprised of all the subjects randomized at Visit 4.</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="23"/>
                <count group_id="O4" value="14"/>
                <count group_id="O5" value="11"/>
                <count group_id="O6" value="30"/>
                <count group_id="O7" value="79"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-16.03" lower_limit="-20.49" upper_limit="-11.57"/>
                    <measurement group_id="O2" value="-23.22" lower_limit="-29.79" upper_limit="-16.64"/>
                    <measurement group_id="O3" value="-15.10" lower_limit="-21.85" upper_limit="-8.35"/>
                    <measurement group_id="O4" value="-12.04" lower_limit="-20.77" upper_limit="-3.32"/>
                    <measurement group_id="O5" value="-19.23" lower_limit="-28.62" upper_limit="-9.83"/>
                    <measurement group_id="O6" value="-14.11" lower_limit="-20.00" upper_limit="-8.22"/>
                    <measurement group_id="O7" value="-14.83" lower_limit="-18.50" upper_limit="-11.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.6792</p_value>
            <p_value_desc>Threshold for significance at 0.05 level.</p_value_desc>
            <method>MMRM</method>
            <param_type>Mean Difference</param_type>
            <param_value>-1.20</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-6.89</ci_lower_limit>
            <ci_upper_limit>4.50</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0276</p_value>
            <p_value_desc>Threshold for significance at 0.05 level.</p_value_desc>
            <method>MMRM</method>
            <param_type>Mean Difference</param_type>
            <param_value>-8.39</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-15.84</ci_lower_limit>
            <ci_upper_limit>-0.93</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.9445</p_value>
            <p_value_desc>Threshold for significance at 0.05 level.</p_value_desc>
            <method>MMRM</method>
            <param_type>Mean Difference</param_type>
            <param_value>-0.27</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-7.97</ci_lower_limit>
            <ci_upper_limit>7.42</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.5637</p_value>
            <p_value_desc>Threshold for significance at 0.05 level.</p_value_desc>
            <method>MMRM</method>
            <param_type>Mean Difference</param_type>
            <param_value>2.79</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-6.71</ci_lower_limit>
            <ci_upper_limit>12.28</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.3870</p_value>
            <p_value_desc>Threshold for significance at 0.05 level.</p_value_desc>
            <method>MMRM</method>
            <param_type>Mean Difference</param_type>
            <param_value>-4.40</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-14.39</ci_lower_limit>
            <ci_upper_limit>5.60</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O6</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.8373</p_value>
            <p_value_desc>Threshold for significance at 0.05 level.</p_value_desc>
            <method>MMRM</method>
            <param_type>Mean Difference</param_type>
            <param_value>0.72</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-6.19</ci_lower_limit>
            <ci_upper_limit>7.63</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Mean NI Diary Total Score at Week 12</title>
        <description>The NI Diary is a 12-item questionnaire with 11 core items (Q1-Q11) and an overall QoL impact question (Q12). The NI Diary Total Scores are calculated by summing the 11 core items. Responses are scored from 0 to 4 (lowest to highest impact). The NI Diary Total is standardized from 0 to 100 (lowest to highest impact).&#xD;
The score at each visit was calculated as the average over the three consecutive 24 hour periods just prior to the respective visit. Adjusted visit-specific mean changes from baseline in NI Diary Total Score are estimated using a baseline value of 40.</description>
        <time_frame>Baseline, Week 12</time_frame>
        <population>The ITT-RT comprised of all the subjects randomized at Visit 4.</population>
        <group_list>
          <group group_id="O1">
            <title>FE 201836 500 ug (Randomized Treatment Period)</title>
            <description>FE 201836 500 µg oral solution and placebo ODT, administered once daily</description>
          </group>
          <group group_id="O2">
            <title>FE 201836 350 ug (Randomized Treatment Period)</title>
            <description>FE 201836 350 µg oral solution and placebo ODT, administered once daily</description>
          </group>
          <group group_id="O3">
            <title>FE 201836 250 ug (Randomized Treatment Period)</title>
            <description>FE 201836 250 µg oral solution and placebo ODT, administered once daily</description>
          </group>
          <group group_id="O4">
            <title>FE 201836 150 ug (Randomized Treatment Period)</title>
            <description>FE 201836 150 µg oral solution and placebo ODT, administered once daily</description>
          </group>
          <group group_id="O5">
            <title>FE 201836 100 ug (Randomized Treatment Period)</title>
            <description>FE 201836 100 µg oral solution and placebo ODT, administered once daily</description>
          </group>
          <group group_id="O6">
            <title>FE 201836 50 ug (Randomized Treatment Period)</title>
            <description>FE 201836 50 µg oral solution and placebo ODT, administered once daily</description>
          </group>
          <group group_id="O7">
            <title>Placebo (Randomized Treatment Period)</title>
            <description>Placebo oral solution and placebo ODT, administered once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Mean NI Diary Total Score at Week 12</title>
          <description>The NI Diary is a 12-item questionnaire with 11 core items (Q1-Q11) and an overall QoL impact question (Q12). The NI Diary Total Scores are calculated by summing the 11 core items. Responses are scored from 0 to 4 (lowest to highest impact). The NI Diary Total is standardized from 0 to 100 (lowest to highest impact).&#xD;
The score at each visit was calculated as the average over the three consecutive 24 hour periods just prior to the respective visit. Adjusted visit-specific mean changes from baseline in NI Diary Total Score are estimated using a baseline value of 40.</description>
          <population>The ITT-RT comprised of all the subjects randomized at Visit 4.</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
                <count group_id="O2" value="22"/>
                <count group_id="O3" value="21"/>
                <count group_id="O4" value="14"/>
                <count group_id="O5" value="12"/>
                <count group_id="O6" value="31"/>
                <count group_id="O7" value="77"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-16.92" lower_limit="-21.66" upper_limit="-12.18"/>
                    <measurement group_id="O2" value="-24.44" lower_limit="-31.52" upper_limit="-17.35"/>
                    <measurement group_id="O3" value="-14.68" lower_limit="-21.94" upper_limit="-7.42"/>
                    <measurement group_id="O4" value="-10.13" lower_limit="-19.37" upper_limit="-0.88"/>
                    <measurement group_id="O5" value="-22.59" lower_limit="-32.46" upper_limit="-12.71"/>
                    <measurement group_id="O6" value="-17.18" lower_limit="-23.39" upper_limit="-10.96"/>
                    <measurement group_id="O7" value="-17.45" lower_limit="-21.36" upper_limit="-13.53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.8646</p_value>
            <p_value_desc>Threshold for significance at 0.05 level.</p_value_desc>
            <method>MMRM</method>
            <param_type>Mean Difference</param_type>
            <param_value>0.53</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-5.54</ci_lower_limit>
            <ci_upper_limit>6.59</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0870</p_value>
            <p_value_desc>Threshold for significance at 0.05 level.</p_value_desc>
            <method>MMRM</method>
            <param_type>Mean Difference</param_type>
            <param_value>-6.99</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-15.00</ci_lower_limit>
            <ci_upper_limit>1.02</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.5100</p_value>
            <p_value_desc>Threshold for significance at 0.05 level.</p_value_desc>
            <method>MMRM</method>
            <param_type>Mean Difference</param_type>
            <param_value>2.77</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-5.50</ci_lower_limit>
            <ci_upper_limit>11.04</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.1535</p_value>
            <p_value_desc>Threshold for significance at 0.05 level.</p_value_desc>
            <method>MMRM</method>
            <param_type>Mean Difference</param_type>
            <param_value>7.32</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.75</ci_lower_limit>
            <ci_upper_limit>17.39</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.3369</p_value>
            <p_value_desc>Threshold for significance at 0.05 level.</p_value_desc>
            <method>MMRM</method>
            <param_type>Mean Difference</param_type>
            <param_value>-5.14</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-15.66</ci_lower_limit>
            <ci_upper_limit>5.38</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O6</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.9417</p_value>
            <p_value_desc>Threshold for significance at 0.05 level.</p_value_desc>
            <method>MMRM</method>
            <param_type>Mean Difference</param_type>
            <param_value>0.27</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-7.05</ci_lower_limit>
            <ci_upper_limit>7.59</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Aggregated Mean NI Diary Total Score During 12 Weeks of Treatment</title>
        <description>The NI Diary is a 12-item questionnaire with 11 core items (Q1-Q11) and an overall QoL impact question (Q12). The NI Diary Total Scores are calculated by summing the 11 core items. Responses are scored from 0 to 4 (lowest to highest impact). The NI Diary Total is standardized from 0 to 100 (lowest to highest impact).&#xD;
The score at each visit was calculated as the mean over the three consecutive 24 hour periods just prior to the respective visit. The visit-specific means were aggregated into a mean of current and preceding visits.&#xD;
Level estimated for baseline value of mean NI Diary Total Score equal to 40 is presented in this endpoint.&#xD;
The 95% credibility interval (2.5 and 97.5 percentiles of the posterior distribution) instead of confidence interval is presented for this endpoint.</description>
        <time_frame>Baseline, during 12 weeks of treatment</time_frame>
        <population>The ITT-RT comprised of all the subjects randomized at Visit 4.</population>
        <group_list>
          <group group_id="O1">
            <title>FE 201836 500 ug (Randomized Treatment Period)</title>
            <description>FE 201836 500 µg oral solution and placebo ODT, administered once daily</description>
          </group>
          <group group_id="O2">
            <title>FE 201836 350 ug (Randomized Treatment Period)</title>
            <description>FE 201836 350 µg oral solution and placebo ODT, administered once daily</description>
          </group>
          <group group_id="O3">
            <title>FE 201836 250 ug (Randomized Treatment Period)</title>
            <description>FE 201836 250 µg oral solution and placebo ODT, administered once daily</description>
          </group>
          <group group_id="O4">
            <title>FE 201836 150 ug (Randomized Treatment Period)</title>
            <description>FE 201836 150 µg oral solution and placebo ODT, administered once daily</description>
          </group>
          <group group_id="O5">
            <title>FE 201836 100 ug (Randomized Treatment Period)</title>
            <description>FE 201836 100 µg oral solution and placebo ODT, administered once daily</description>
          </group>
          <group group_id="O6">
            <title>FE 201836 50 ug (Randomized Treatment Period)</title>
            <description>FE 201836 50 µg oral solution and placebo ODT, administered once daily</description>
          </group>
          <group group_id="O7">
            <title>Placebo (Randomized Treatment Period)</title>
            <description>Placebo oral solution and placebo ODT, administered once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Aggregated Mean NI Diary Total Score During 12 Weeks of Treatment</title>
          <description>The NI Diary is a 12-item questionnaire with 11 core items (Q1-Q11) and an overall QoL impact question (Q12). The NI Diary Total Scores are calculated by summing the 11 core items. Responses are scored from 0 to 4 (lowest to highest impact). The NI Diary Total is standardized from 0 to 100 (lowest to highest impact).&#xD;
The score at each visit was calculated as the mean over the three consecutive 24 hour periods just prior to the respective visit. The visit-specific means were aggregated into a mean of current and preceding visits.&#xD;
Level estimated for baseline value of mean NI Diary Total Score equal to 40 is presented in this endpoint.&#xD;
The 95% credibility interval (2.5 and 97.5 percentiles of the posterior distribution) instead of confidence interval is presented for this endpoint.</description>
          <population>The ITT-RT comprised of all the subjects randomized at Visit 4.</population>
          <units>score on a scale</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="60"/>
                <count group_id="O2" value="27"/>
                <count group_id="O3" value="24"/>
                <count group_id="O4" value="14"/>
                <count group_id="O5" value="13"/>
                <count group_id="O6" value="34"/>
                <count group_id="O7" value="87"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-12.40" lower_limit="-14.71" upper_limit="-8.59"/>
                    <measurement group_id="O2" value="-12.69" lower_limit="-15.07" upper_limit="-10.53"/>
                    <measurement group_id="O3" value="-12.75" lower_limit="-15.16" upper_limit="-10.57"/>
                    <measurement group_id="O4" value="-12.77" lower_limit="-15.21" upper_limit="-10.59"/>
                    <measurement group_id="O5" value="-12.77" lower_limit="-15.23" upper_limit="-10.54"/>
                    <measurement group_id="O6" value="-12.78" lower_limit="-15.18" upper_limit="-10.50"/>
                    <measurement group_id="O7" value="-12.77" lower_limit="-15.18" upper_limit="-10.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <groups_desc>Based on a Bayesian analysis of a sigmoidal dose-response relationship.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Median difference</param_type>
            <param_value>0.00</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.41</ci_lower_limit>
            <ci_upper_limit>5.47</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <groups_desc>Based on a Bayesian analysis of a sigmoidal dose-response relationship.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Median difference</param_type>
            <param_value>0.00</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.43</ci_lower_limit>
            <ci_upper_limit>1.19</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <groups_desc>Based on a Bayesian analysis of a sigmoidal dose-response relationship.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Median difference</param_type>
            <param_value>0.00</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.16</ci_lower_limit>
            <ci_upper_limit>0.50</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <groups_desc>Based on a Bayesian analysis of a sigmoidal dose-response relationship.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Median difference</param_type>
            <param_value>0.00</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.03</ci_lower_limit>
            <ci_upper_limit>0.15</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <groups_desc>Based on a Bayesian analysis of a sigmoidal dose-response relationship.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Median difference</param_type>
            <param_value>0.00</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.01</ci_lower_limit>
            <ci_upper_limit>0.05</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O6</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <groups_desc>Based on a Bayesian analysis of a sigmoidal dose-response relationship.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Median difference</param_type>
            <param_value>0.00</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.00</ci_lower_limit>
            <ci_upper_limit>0.01</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Nights With at Most One Nocturnal Void During 12 Weeks of Treatment</title>
        <description>The percentages of nights during the treatment period with at most one nocturnal void are presented in this endpoint.&#xD;
Level estimated for baseline value of mean number of nocturnal voids equal to 2 is presented in this endpoint.</description>
        <time_frame>During 12 weeks of treatment</time_frame>
        <population>The ITT-RT comprised of all the subjects randomized at Visit 4.</population>
        <group_list>
          <group group_id="O1">
            <title>FE 201836 500 ug (Randomized Treatment Period)</title>
            <description>FE 201836 500 µg oral solution and placebo ODT, administered once daily</description>
          </group>
          <group group_id="O2">
            <title>FE 201836 350 ug (Randomized Treatment Period)</title>
            <description>FE 201836 350 µg oral solution and placebo ODT, administered once daily</description>
          </group>
          <group group_id="O3">
            <title>FE 201836 250 ug (Randomized Treatment Period)</title>
            <description>FE 201836 250 µg oral solution and placebo ODT, administered once daily</description>
          </group>
          <group group_id="O4">
            <title>FE 201836 150 ug (Randomized Treatment Period)</title>
            <description>FE 201836 150 µg oral solution and placebo ODT, administered once daily</description>
          </group>
          <group group_id="O5">
            <title>FE 201836 100 ug (Randomized Treatment Period)</title>
            <description>FE 201836 100 µg oral solution and placebo ODT, administered once daily</description>
          </group>
          <group group_id="O6">
            <title>FE 201836 50 ug (Randomized Treatment Period)</title>
            <description>FE 201836 50 µg oral solution and placebo ODT, administered once daily</description>
          </group>
          <group group_id="O7">
            <title>Placebo (Randomized Treatment Period)</title>
            <description>Placebo oral solution and placebo ODT, administered once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Nights With at Most One Nocturnal Void During 12 Weeks of Treatment</title>
          <description>The percentages of nights during the treatment period with at most one nocturnal void are presented in this endpoint.&#xD;
Level estimated for baseline value of mean number of nocturnal voids equal to 2 is presented in this endpoint.</description>
          <population>The ITT-RT comprised of all the subjects randomized at Visit 4.</population>
          <units>percentage of nights</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="58"/>
                <count group_id="O2" value="27"/>
                <count group_id="O3" value="24"/>
                <count group_id="O4" value="14"/>
                <count group_id="O5" value="13"/>
                <count group_id="O6" value="33"/>
                <count group_id="O7" value="84"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="67.2" lower_limit="58.2" upper_limit="76.2"/>
                    <measurement group_id="O2" value="77.5" lower_limit="64.9" upper_limit="90.2"/>
                    <measurement group_id="O3" value="64.5" lower_limit="51.0" upper_limit="78.0"/>
                    <measurement group_id="O4" value="55.3" lower_limit="38.3" upper_limit="72.3"/>
                    <measurement group_id="O5" value="73.2" lower_limit="55.1" upper_limit="91.2"/>
                    <measurement group_id="O6" value="61.4" lower_limit="49.3" upper_limit="73.5"/>
                    <measurement group_id="O7" value="62.0" lower_limit="53.8" upper_limit="70.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.3328</p_value>
            <p_value_desc>Threshold for significance at 0.05 level.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Mean Difference</param_type>
            <param_value>5.2</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-5.3</ci_lower_limit>
            <ci_upper_limit>15.7</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0255</p_value>
            <p_value_desc>Threshold for significance at 0.05 level.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Mean Difference</param_type>
            <param_value>15.5</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.9</ci_lower_limit>
            <ci_upper_limit>29.2</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.7296</p_value>
            <p_value_desc>Threshold for significance at 0.05 level.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Mean Difference</param_type>
            <param_value>2.5</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-11.7</ci_lower_limit>
            <ci_upper_limit>16.7</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.4586</p_value>
            <p_value_desc>Threshold for significance at 0.05 level.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Mean Difference</param_type>
            <param_value>-6.7</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-24.5</ci_lower_limit>
            <ci_upper_limit>11.1</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.2327</p_value>
            <p_value_desc>Threshold for significance at 0.05 level.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Mean Difference</param_type>
            <param_value>11.2</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-7.2</ci_lower_limit>
            <ci_upper_limit>29.5</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O6</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.9240</p_value>
            <p_value_desc>Threshold for significance at 0.05 level.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Mean Difference</param_type>
            <param_value>-0.6</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-13.3</ci_lower_limit>
            <ci_upper_limit>12.1</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Nights With No Nocturnal Voids During 12 Weeks of Treatment</title>
        <description>The percentages of nights during the treatment period with complete response, i.e. no nocturnal voids are presented in this endpoint.&#xD;
Level estimated for baseline value of mean number of nocturnal voids equal to 2 is presented in this endpoint.</description>
        <time_frame>During 12 weeks of treatment</time_frame>
        <population>The ITT-RT comprised of all the subjects randomized at Visit 4.</population>
        <group_list>
          <group group_id="O1">
            <title>FE 201836 500 ug (Randomized Treatment Period)</title>
            <description>FE 201836 500 µg oral solution and placebo ODT, administered once daily</description>
          </group>
          <group group_id="O2">
            <title>FE 201836 350 ug (Randomized Treatment Period)</title>
            <description>FE 201836 350 µg oral solution and placebo ODT, administered once daily</description>
          </group>
          <group group_id="O3">
            <title>FE 201836 250 ug (Randomized Treatment Period)</title>
            <description>FE 201836 250 µg oral solution and placebo ODT, administered once daily</description>
          </group>
          <group group_id="O4">
            <title>FE 201836 150 ug (Randomized Treatment Period)</title>
            <description>FE 201836 150 µg oral solution and placebo ODT, administered once daily</description>
          </group>
          <group group_id="O5">
            <title>FE 201836 100 ug (Randomized Treatment Period)</title>
            <description>FE 201836 100 µg oral solution and placebo ODT, administered once daily</description>
          </group>
          <group group_id="O6">
            <title>FE 201836 50 ug (Randomized Treatment Period)</title>
            <description>FE 201836 50 µg oral solution and placebo ODT, administered once daily</description>
          </group>
          <group group_id="O7">
            <title>Placebo (Randomized Treatment Period)</title>
            <description>Placebo oral solution and placebo ODT, administered once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Nights With No Nocturnal Voids During 12 Weeks of Treatment</title>
          <description>The percentages of nights during the treatment period with complete response, i.e. no nocturnal voids are presented in this endpoint.&#xD;
Level estimated for baseline value of mean number of nocturnal voids equal to 2 is presented in this endpoint.</description>
          <population>The ITT-RT comprised of all the subjects randomized at Visit 4.</population>
          <units>percentage of nights</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="58"/>
                <count group_id="O2" value="27"/>
                <count group_id="O3" value="24"/>
                <count group_id="O4" value="14"/>
                <count group_id="O5" value="13"/>
                <count group_id="O6" value="33"/>
                <count group_id="O7" value="84"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.3" lower_limit="16.3" upper_limit="30.3"/>
                    <measurement group_id="O2" value="28.8" lower_limit="19.0" upper_limit="38.6"/>
                    <measurement group_id="O3" value="17.3" lower_limit="6.8" upper_limit="27.8"/>
                    <measurement group_id="O4" value="12.9" lower_limit="-0.3" upper_limit="26.1"/>
                    <measurement group_id="O5" value="14.8" lower_limit="0.8" upper_limit="28.8"/>
                    <measurement group_id="O6" value="21.5" lower_limit="12.1" upper_limit="30.9"/>
                    <measurement group_id="O7" value="23.0" lower_limit="16.6" upper_limit="29.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.9499</p_value>
            <p_value_desc>Threshold for significance at 0.05 level.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Mean Difference</param_type>
            <param_value>0.3</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-7.9</ci_lower_limit>
            <ci_upper_limit>8.5</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.2842</p_value>
            <p_value_desc>Threshold for significance at 0.05 level.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Mean Difference</param_type>
            <param_value>5.8</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.8</ci_lower_limit>
            <ci_upper_limit>16.4</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.3100</p_value>
            <p_value_desc>Threshold for significance at 0.05 level.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Mean Difference</param_type>
            <param_value>-5.7</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-16.8</ci_lower_limit>
            <ci_upper_limit>5.4</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.1499</p_value>
            <p_value_desc>Threshold for significance at 0.05 level.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Mean Difference</param_type>
            <param_value>-10.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-23.9</ci_lower_limit>
            <ci_upper_limit>3.7</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.2571</p_value>
            <p_value_desc>Threshold for significance at 0.05 level.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Mean Difference</param_type>
            <param_value>-8.2</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-22.5</ci_lower_limit>
            <ci_upper_limit>6.0</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O6</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.7629</p_value>
            <p_value_desc>Threshold for significance at 0.05 level.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Mean Difference</param_type>
            <param_value>-1.5</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-11.4</ci_lower_limit>
            <ci_upper_limit>8.3</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Mean NI Diary Overall Impact Score at Week 1</title>
        <description>The NI Diary is a 12-item questionnaire with 11 core items (Q1-Q11) and an overall QoL impact question (Q12). For the overall impact question (Q12), response options range from 0 (not at all) to 4 (a great deal). The NI Diary Overall Impact Scores are standardized from 0 to 100 (lowest to highest impact).&#xD;
The score at each visit was calculated as the average over the three consecutive 24 hour periods just prior to the respective visit. Adjusted visit-specific mean changes from baseline in NI Diary Overall Impact Score are estimated using a baseline value of 40.</description>
        <time_frame>Baseline, Week 1</time_frame>
        <population>The ITT-RT comprised of all the subjects randomized at Visit 4.</population>
        <group_list>
          <group group_id="O1">
            <title>FE 201836 500 ug (Randomized Treatment Period)</title>
            <description>FE 201836 500 µg oral solution and placebo ODT, administered once daily</description>
          </group>
          <group group_id="O2">
            <title>FE 201836 350 ug (Randomized Treatment Period)</title>
            <description>FE 201836 350 µg oral solution and placebo ODT, administered once daily</description>
          </group>
          <group group_id="O3">
            <title>FE 201836 250 ug (Randomized Treatment Period)</title>
            <description>FE 201836 250 µg oral solution and placebo ODT, administered once daily</description>
          </group>
          <group group_id="O4">
            <title>FE 201836 150 ug (Randomized Treatment Period)</title>
            <description>FE 201836 150 µg oral solution and placebo ODT, administered once daily</description>
          </group>
          <group group_id="O5">
            <title>FE 201836 100 ug (Randomized Treatment Period)</title>
            <description>FE 201836 100 µg oral solution and placebo ODT, administered once daily</description>
          </group>
          <group group_id="O6">
            <title>FE 201836 50 ug (Randomized Treatment Period)</title>
            <description>FE 201836 50 µg oral solution and placebo ODT, administered once daily</description>
          </group>
          <group group_id="O7">
            <title>Placebo (Randomized Treatment Period)</title>
            <description>Placebo oral solution and placebo ODT, administered once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Mean NI Diary Overall Impact Score at Week 1</title>
          <description>The NI Diary is a 12-item questionnaire with 11 core items (Q1-Q11) and an overall QoL impact question (Q12). For the overall impact question (Q12), response options range from 0 (not at all) to 4 (a great deal). The NI Diary Overall Impact Scores are standardized from 0 to 100 (lowest to highest impact).&#xD;
The score at each visit was calculated as the average over the three consecutive 24 hour periods just prior to the respective visit. Adjusted visit-specific mean changes from baseline in NI Diary Overall Impact Score are estimated using a baseline value of 40.</description>
          <population>The ITT-RT comprised of all the subjects randomized at Visit 4.</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="55"/>
                <count group_id="O2" value="23"/>
                <count group_id="O3" value="24"/>
                <count group_id="O4" value="14"/>
                <count group_id="O5" value="12"/>
                <count group_id="O6" value="31"/>
                <count group_id="O7" value="83"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-10.98" lower_limit="-16.40" upper_limit="-5.56"/>
                    <measurement group_id="O2" value="-30.39" lower_limit="-38.62" upper_limit="-22.17"/>
                    <measurement group_id="O3" value="-15.51" lower_limit="-23.85" upper_limit="-7.17"/>
                    <measurement group_id="O4" value="-11.77" lower_limit="-22.69" upper_limit="-0.85"/>
                    <measurement group_id="O5" value="-2.79" lower_limit="-14.29" upper_limit="8.70"/>
                    <measurement group_id="O6" value="-12.26" lower_limit="-19.57" upper_limit="-4.95"/>
                    <measurement group_id="O7" value="-13.46" lower_limit="-17.89" upper_limit="-9.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.4846</p_value>
            <p_value_desc>Threshold for significance at 0.05 level.</p_value_desc>
            <method>MMRM</method>
            <param_type>Mean Difference</param_type>
            <param_value>2.48</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.50</ci_lower_limit>
            <ci_upper_limit>9.46</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0004</p_value>
            <p_value_desc>Threshold for significance at 0.05 level.</p_value_desc>
            <method>MMRM</method>
            <param_type>Mean Difference</param_type>
            <param_value>-16.93</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-26.26</ci_lower_limit>
            <ci_upper_limit>-7.60</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.6685</p_value>
            <p_value_desc>Threshold for significance at 0.05 level.</p_value_desc>
            <method>MMRM</method>
            <param_type>Mean Difference</param_type>
            <param_value>-2.05</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-11.47</ci_lower_limit>
            <ci_upper_limit>7.37</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.7772</p_value>
            <p_value_desc>Threshold for significance at 0.05 level.</p_value_desc>
            <method>MMRM</method>
            <param_type>Mean Difference</param_type>
            <param_value>1.69</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-10.07</ci_lower_limit>
            <ci_upper_limit>13.46</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0895</p_value>
            <p_value_desc>Threshold for significance at 0.05 level.</p_value_desc>
            <method>MMRM</method>
            <param_type>Mean Difference</param_type>
            <param_value>10.67</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.66</ci_lower_limit>
            <ci_upper_limit>23.00</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O6</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.7820</p_value>
            <method>MMRM</method>
            <param_type>Mean Difference</param_type>
            <param_value>1.20</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-7.34</ci_lower_limit>
            <ci_upper_limit>9.74</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Mean NI Diary Overall Impact Score at Week 4</title>
        <description>The NI Diary is a 12-item questionnaire with 11 core items (Q1-Q11) and an overall QoL impact question (Q12). For the overall impact question (Q12), response options range from 0 (not at all) to 4 (a great deal). The NI Diary Overall Impact Scores are standardized from 0 to 100 (lowest to highest impact).&#xD;
The score at each visit was calculated as the average over the three consecutive 24 hour periods just prior to the respective visit. Adjusted visit-specific mean changes from baseline in NI Diary Overall Impact Score are estimated using a baseline value of 40.</description>
        <time_frame>Baseline, Week 4</time_frame>
        <population>The ITT-RT comprised of all the subjects randomized at Visit 4.</population>
        <group_list>
          <group group_id="O1">
            <title>FE 201836 500 ug (Randomized Treatment Period)</title>
            <description>FE 201836 500 µg oral solution and placebo ODT, administered once daily</description>
          </group>
          <group group_id="O2">
            <title>FE 201836 350 ug (Randomized Treatment Period)</title>
            <description>FE 201836 350 µg oral solution and placebo ODT, administered once daily</description>
          </group>
          <group group_id="O3">
            <title>FE 201836 250 ug (Randomized Treatment Period)</title>
            <description>FE 201836 250 µg oral solution and placebo ODT, administered once daily</description>
          </group>
          <group group_id="O4">
            <title>FE 201836 150 ug (Randomized Treatment Period)</title>
            <description>FE 201836 150 µg oral solution and placebo ODT, administered once daily</description>
          </group>
          <group group_id="O5">
            <title>FE 201836 100 ug (Randomized Treatment Period)</title>
            <description>FE 201836 100 µg oral solution and placebo ODT, administered once daily</description>
          </group>
          <group group_id="O6">
            <title>FE 201836 50 ug (Randomized Treatment Period)</title>
            <description>FE 201836 50 µg oral solution and placebo ODT, administered once daily</description>
          </group>
          <group group_id="O7">
            <title>Placebo (Randomized Treatment Period)</title>
            <description>Placebo oral solution and placebo ODT, administered once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Mean NI Diary Overall Impact Score at Week 4</title>
          <description>The NI Diary is a 12-item questionnaire with 11 core items (Q1-Q11) and an overall QoL impact question (Q12). For the overall impact question (Q12), response options range from 0 (not at all) to 4 (a great deal). The NI Diary Overall Impact Scores are standardized from 0 to 100 (lowest to highest impact).&#xD;
The score at each visit was calculated as the average over the three consecutive 24 hour periods just prior to the respective visit. Adjusted visit-specific mean changes from baseline in NI Diary Overall Impact Score are estimated using a baseline value of 40.</description>
          <population>The ITT-RT comprised of all the subjects randomized at Visit 4.</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="53"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="22"/>
                <count group_id="O4" value="13"/>
                <count group_id="O5" value="13"/>
                <count group_id="O6" value="31"/>
                <count group_id="O7" value="78"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-22.17" lower_limit="-28.25" upper_limit="-16.09"/>
                    <measurement group_id="O2" value="-26.07" lower_limit="-35.09" upper_limit="-17.05"/>
                    <measurement group_id="O3" value="-19.35" lower_limit="-28.80" upper_limit="-9.90"/>
                    <measurement group_id="O4" value="-18.36" lower_limit="-30.66" upper_limit="-6.07"/>
                    <measurement group_id="O5" value="-17.95" lower_limit="-30.50" upper_limit="-5.41"/>
                    <measurement group_id="O6" value="-21.40" lower_limit="-29.54" upper_limit="-13.26"/>
                    <measurement group_id="O7" value="-21.75" lower_limit="-26.74" upper_limit="-16.77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.9175</p_value>
            <p_value_desc>Threshold for significance at 0.05 level.</p_value_desc>
            <method>MMRM</method>
            <param_type>Mean Difference</param_type>
            <param_value>-0.41</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-8.25</ci_lower_limit>
            <ci_upper_limit>7.42</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.4098</p_value>
            <p_value_desc>Threshold for significance at 0.05 level.</p_value_desc>
            <method>MMRM</method>
            <param_type>Mean Difference</param_type>
            <param_value>-4.32</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-14.62</ci_lower_limit>
            <ci_upper_limit>5.98</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.6566</p_value>
            <p_value_desc>Threshold for significance at 0.05 level.</p_value_desc>
            <method>MMRM</method>
            <param_type>Mean Difference</param_type>
            <param_value>2.41</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-8.25</ci_lower_limit>
            <ci_upper_limit>13.06</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.6144</p_value>
            <p_value_desc>Threshold for significance at 0.05 level.</p_value_desc>
            <method>MMRM</method>
            <param_type>Mean Difference</param_type>
            <param_value>3.39</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-9.85</ci_lower_limit>
            <ci_upper_limit>16.63</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.5798</p_value>
            <p_value_desc>Threshold for significance at 0.05 level.</p_value_desc>
            <method>MMRM</method>
            <param_type>Mean Difference</param_type>
            <param_value>3.80</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-9.71</ci_lower_limit>
            <ci_upper_limit>17.31</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O6</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.9417</p_value>
            <p_value_desc>Threshold for significance at 0.05 level.</p_value_desc>
            <method>MMRM</method>
            <param_type>Mean Difference</param_type>
            <param_value>0.35</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-9.17</ci_lower_limit>
            <ci_upper_limit>9.88</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Mean NI Diary Overall Impact Score at Week 8</title>
        <description>The NI Diary is a 12-item questionnaire with 11 core items (Q1-Q11) and an overall QoL impact question (Q12). For the overall impact question (Q12), response options range from 0 (not at all) to 4 (a great deal). The NI Diary Overall Impact Scores are standardized from 0 to 100 (lowest to highest impact).&#xD;
The score at each visit was calculated as the average over the three consecutive 24 hour periods just prior to the respective visit. Adjusted visit-specific mean changes from baseline in NI Diary Overall Impact Score are estimated using a baseline value of 40.</description>
        <time_frame>Baseline, Week 8</time_frame>
        <population>The ITT-RT comprised of all the subjects randomized at Visit 4.</population>
        <group_list>
          <group group_id="O1">
            <title>FE 201836 500 ug (Randomized Treatment Period)</title>
            <description>FE 201836 500 µg oral solution and placebo ODT, administered once daily</description>
          </group>
          <group group_id="O2">
            <title>FE 201836 350 ug (Randomized Treatment Period)</title>
            <description>FE 201836 350 µg oral solution and placebo ODT, administered once daily</description>
          </group>
          <group group_id="O3">
            <title>FE 201836 250 ug (Randomized Treatment Period)</title>
            <description>FE 201836 250 µg oral solution and placebo ODT, administered once daily</description>
          </group>
          <group group_id="O4">
            <title>FE 201836 150 ug (Randomized Treatment Period)</title>
            <description>FE 201836 150 µg oral solution and placebo ODT, administered once daily</description>
          </group>
          <group group_id="O5">
            <title>FE 201836 100 ug (Randomized Treatment Period)</title>
            <description>FE 201836 100 µg oral solution and placebo ODT, administered once daily</description>
          </group>
          <group group_id="O6">
            <title>FE 201836 50 ug (Randomized Treatment Period)</title>
            <description>FE 201836 50 µg oral solution and placebo ODT, administered once daily</description>
          </group>
          <group group_id="O7">
            <title>Placebo (Randomized Treatment Period)</title>
            <description>Placebo oral solution and placebo ODT, administered once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Mean NI Diary Overall Impact Score at Week 8</title>
          <description>The NI Diary is a 12-item questionnaire with 11 core items (Q1-Q11) and an overall QoL impact question (Q12). For the overall impact question (Q12), response options range from 0 (not at all) to 4 (a great deal). The NI Diary Overall Impact Scores are standardized from 0 to 100 (lowest to highest impact).&#xD;
The score at each visit was calculated as the average over the three consecutive 24 hour periods just prior to the respective visit. Adjusted visit-specific mean changes from baseline in NI Diary Overall Impact Score are estimated using a baseline value of 40.</description>
          <population>The ITT-RT comprised of all the subjects randomized at Visit 4.</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="23"/>
                <count group_id="O4" value="14"/>
                <count group_id="O5" value="11"/>
                <count group_id="O6" value="30"/>
                <count group_id="O7" value="79"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-28.13" lower_limit="-34.76" upper_limit="-21.50"/>
                    <measurement group_id="O2" value="-34.97" lower_limit="-44.69" upper_limit="-25.25"/>
                    <measurement group_id="O3" value="-21.71" lower_limit="-31.80" upper_limit="-11.62"/>
                    <measurement group_id="O4" value="-19.03" lower_limit="-32.06" upper_limit="-6.00"/>
                    <measurement group_id="O5" value="-23.84" lower_limit="-37.71" upper_limit="-9.96"/>
                    <measurement group_id="O6" value="-20.70" lower_limit="-29.45" upper_limit="-11.94"/>
                    <measurement group_id="O7" value="-25.32" lower_limit="-30.69" upper_limit="-19.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.5148</p_value>
            <p_value_desc>Threshold for significance at 0.05 level.</p_value_desc>
            <method>MMRM</method>
            <param_type>Mean Difference</param_type>
            <param_value>-2.81</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-11.31</ci_lower_limit>
            <ci_upper_limit>5.68</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0879</p_value>
            <p_value_desc>Threshold for significance at 0.05 level.</p_value_desc>
            <method>MMRM</method>
            <param_type>Mean Difference</param_type>
            <param_value>-9.65</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-20.75</ci_lower_limit>
            <ci_upper_limit>1.44</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.5335</p_value>
            <p_value_desc>Threshold for significance at 0.05 level.</p_value_desc>
            <method>MMRM</method>
            <param_type>Mean Difference</param_type>
            <param_value>3.61</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-7.79</ci_lower_limit>
            <ci_upper_limit>15.00</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.3787</p_value>
            <p_value_desc>Threshold for significance at 0.05 level.</p_value_desc>
            <method>MMRM</method>
            <param_type>Mean Difference</param_type>
            <param_value>6.29</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-7.76</ci_lower_limit>
            <ci_upper_limit>20.34</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.8448</p_value>
            <p_value_desc>Threshold for significance at 0.05 level.</p_value_desc>
            <method>MMRM</method>
            <param_type>Mean Difference</param_type>
            <param_value>1.48</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-13.41</ci_lower_limit>
            <ci_upper_limit>16.38</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O6</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.3751</p_value>
            <p_value_desc>Threshold for significance at 0.05 level.</p_value_desc>
            <method>MMRM</method>
            <param_type>Mean Difference</param_type>
            <param_value>4.62</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-5.63</ci_lower_limit>
            <ci_upper_limit>14.87</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Mean NI Diary Overall Impact Score at Week 12</title>
        <description>The NI Diary is a 12-item questionnaire with 11 core items (Q1-Q11) and an overall QoL impact question (Q12). For the overall impact question (Q12), response options range from 0 (not at all) to 4 (a great deal). The NI Diary Overall Impact Scores are standardized from 0 to 100 (lowest to highest impact).&#xD;
The score at each visit was calculated as the average over the three consecutive 24 hour periods just prior to the respective visit. Adjusted visit-specific mean changes from baseline in NI Diary Overall Impact Score are estimated using a baseline value of 40.</description>
        <time_frame>Baseline, Week 12</time_frame>
        <population>The ITT-RT comprised of all the subjects randomized at Visit 4.</population>
        <group_list>
          <group group_id="O1">
            <title>FE 201836 500 ug (Randomized Treatment Period)</title>
            <description>FE 201836 500 µg oral solution and placebo ODT, administered once daily</description>
          </group>
          <group group_id="O2">
            <title>FE 201836 350 ug (Randomized Treatment Period)</title>
            <description>FE 201836 350 µg oral solution and placebo ODT, administered once daily</description>
          </group>
          <group group_id="O3">
            <title>FE 201836 250 ug (Randomized Treatment Period)</title>
            <description>FE 201836 250 µg oral solution and placebo ODT, administered once daily</description>
          </group>
          <group group_id="O4">
            <title>FE 201836 150 ug (Randomized Treatment Period)</title>
            <description>FE 201836 150 µg oral solution and placebo ODT, administered once daily</description>
          </group>
          <group group_id="O5">
            <title>FE 201836 100 ug (Randomized Treatment Period)</title>
            <description>FE 201836 100 µg oral solution and placebo ODT, administered once daily</description>
          </group>
          <group group_id="O6">
            <title>FE 201836 50 ug (Randomized Treatment Period)</title>
            <description>FE 201836 50 µg oral solution and placebo ODT, administered once daily</description>
          </group>
          <group group_id="O7">
            <title>Placebo (Randomized Treatment Period)</title>
            <description>Placebo oral solution and placebo ODT, administered once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Mean NI Diary Overall Impact Score at Week 12</title>
          <description>The NI Diary is a 12-item questionnaire with 11 core items (Q1-Q11) and an overall QoL impact question (Q12). For the overall impact question (Q12), response options range from 0 (not at all) to 4 (a great deal). The NI Diary Overall Impact Scores are standardized from 0 to 100 (lowest to highest impact).&#xD;
The score at each visit was calculated as the average over the three consecutive 24 hour periods just prior to the respective visit. Adjusted visit-specific mean changes from baseline in NI Diary Overall Impact Score are estimated using a baseline value of 40.</description>
          <population>The ITT-RT comprised of all the subjects randomized at Visit 4.</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
                <count group_id="O2" value="22"/>
                <count group_id="O3" value="21"/>
                <count group_id="O4" value="14"/>
                <count group_id="O5" value="12"/>
                <count group_id="O6" value="31"/>
                <count group_id="O7" value="77"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-30.47" lower_limit="-37.49" upper_limit="-23.45"/>
                    <measurement group_id="O2" value="-36.76" lower_limit="-47.18" upper_limit="-26.34"/>
                    <measurement group_id="O3" value="-20.84" lower_limit="-31.65" upper_limit="-10.02"/>
                    <measurement group_id="O4" value="-15.32" lower_limit="-29.10" upper_limit="-1.54"/>
                    <measurement group_id="O5" value="-28.89" lower_limit="-43.40" upper_limit="-14.39"/>
                    <measurement group_id="O6" value="-27.13" lower_limit="-36.35" upper_limit="-17.91"/>
                    <measurement group_id="O7" value="-30.03" lower_limit="-35.74" upper_limit="-24.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.9245</p_value>
            <p_value_desc>Threshold for significance at 0.05 level.</p_value_desc>
            <method>MMRM</method>
            <param_type>Mean Difference</param_type>
            <param_value>-0.43</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-9.43</ci_lower_limit>
            <ci_upper_limit>8.57</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.2657</p_value>
            <p_value_desc>Threshold for significance at 0.05 level.</p_value_desc>
            <method>MMRM</method>
            <param_type>Mean Difference</param_type>
            <param_value>-6.72</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-18.59</ci_lower_limit>
            <ci_upper_limit>5.15</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.1383</p_value>
            <p_value_desc>Threshold for significance at 0.05 level.</p_value_desc>
            <method>MMRM</method>
            <param_type>Mean Difference</param_type>
            <param_value>9.20</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.99</ci_lower_limit>
            <ci_upper_limit>21.38</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0523</p_value>
            <p_value_desc>Threshold for significance at 0.05 level.</p_value_desc>
            <method>MMRM</method>
            <param_type>Mean Difference</param_type>
            <param_value>14.72</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.15</ci_lower_limit>
            <ci_upper_limit>29.59</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.8855</p_value>
            <p_value_desc>Threshold for significance at 0.05 level.</p_value_desc>
            <method>MMRM</method>
            <param_type>Mean Difference</param_type>
            <param_value>1.14</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-14.47</ci_lower_limit>
            <ci_upper_limit>16.75</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O6</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.5972</p_value>
            <p_value_desc>Threshold for significance at 0.05 level.</p_value_desc>
            <method>MMRM</method>
            <param_type>Mean Difference</param_type>
            <param_value>2.91</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-7.91</ci_lower_limit>
            <ci_upper_limit>13.72</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Aggregated Mean NI Diary Overall Impact Score During 12 Weeks of Treatment</title>
        <description>The NI Diary is a 12-item questionnaire with 11 core items (Q1-Q11) and an overall QoL impact question (Q12). For the overall impact question (Q12), response options range from 0 (not at all) to 4 (a great deal). The NI Diary Overall Impact Scores are standardized from 0 to 100 (lowest to highest impact).&#xD;
The score at each visit was calculated as the average over the three consecutive 24 hour periods just prior to the respective visit. The visit-specific means were aggregated into a mean of current and preceding visits.&#xD;
Level estimated for baseline value of mean NI Diary Overall Impact Score equal to 40 is presented in this endpoint.&#xD;
The 95% credibility interval (2.5 and 97.5 percentiles of the posterior distribution) instead of confidence interval is presented for this endpoint.</description>
        <time_frame>Baseline, during 12 weeks of treatment</time_frame>
        <population>The ITT-RT comprised of all the subjects randomized at Visit 4.</population>
        <group_list>
          <group group_id="O1">
            <title>FE 201836 500 ug (Randomized Treatment Period)</title>
            <description>FE 201836 500 µg oral solution and placebo ODT, administered once daily</description>
          </group>
          <group group_id="O2">
            <title>FE 201836 350 ug (Randomized Treatment Period)</title>
            <description>FE 201836 350 µg oral solution and placebo ODT, administered once daily</description>
          </group>
          <group group_id="O3">
            <title>FE 201836 250 ug (Randomized Treatment Period)</title>
            <description>FE 201836 250 µg oral solution and placebo ODT, administered once daily</description>
          </group>
          <group group_id="O4">
            <title>FE 201836 150 ug (Randomized Treatment Period)</title>
            <description>FE 201836 150 µg oral solution and placebo ODT, administered once daily</description>
          </group>
          <group group_id="O5">
            <title>FE 201836 100 ug (Randomized Treatment Period)</title>
            <description>FE 201836 100 µg oral solution and placebo ODT, administered once daily</description>
          </group>
          <group group_id="O6">
            <title>FE 201836 50 ug (Randomized Treatment Period)</title>
            <description>FE 201836 50 µg oral solution and placebo ODT, administered once daily</description>
          </group>
          <group group_id="O7">
            <title>Placebo (Randomized Treatment Period)</title>
            <description>Placebo oral solution and placebo ODT, administered once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Aggregated Mean NI Diary Overall Impact Score During 12 Weeks of Treatment</title>
          <description>The NI Diary is a 12-item questionnaire with 11 core items (Q1-Q11) and an overall QoL impact question (Q12). For the overall impact question (Q12), response options range from 0 (not at all) to 4 (a great deal). The NI Diary Overall Impact Scores are standardized from 0 to 100 (lowest to highest impact).&#xD;
The score at each visit was calculated as the average over the three consecutive 24 hour periods just prior to the respective visit. The visit-specific means were aggregated into a mean of current and preceding visits.&#xD;
Level estimated for baseline value of mean NI Diary Overall Impact Score equal to 40 is presented in this endpoint.&#xD;
The 95% credibility interval (2.5 and 97.5 percentiles of the posterior distribution) instead of confidence interval is presented for this endpoint.</description>
          <population>The ITT-RT comprised of all the subjects randomized at Visit 4.</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="60"/>
                <count group_id="O2" value="27"/>
                <count group_id="O3" value="24"/>
                <count group_id="O4" value="14"/>
                <count group_id="O5" value="13"/>
                <count group_id="O6" value="34"/>
                <count group_id="O7" value="87"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.50" lower_limit="-10.57" upper_limit="-2.85"/>
                    <measurement group_id="O2" value="-6.25" lower_limit="-9.78" upper_limit="-3.03"/>
                    <measurement group_id="O3" value="-6.11" lower_limit="-9.49" upper_limit="-2.90"/>
                    <measurement group_id="O4" value="-6.00" lower_limit="-9.28" upper_limit="-2.70"/>
                    <measurement group_id="O5" value="-5.98" lower_limit="-9.29" upper_limit="-2.58"/>
                    <measurement group_id="O6" value="-5.97" lower_limit="-9.32" upper_limit="-2.57"/>
                    <measurement group_id="O7" value="-5.96" lower_limit="-9.42" upper_limit="-2.49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <groups_desc>Based on a Bayesian analysis of a sigmoidal dose-response relationship.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Mean Difference</param_type>
            <param_value>-0.54</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-6.09</ci_lower_limit>
            <ci_upper_limit>2.28</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <groups_desc>Based on a Bayesian analysis of a sigmoidal dose-response relationship.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Mean Difference</param_type>
            <param_value>-0.28</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.30</ci_lower_limit>
            <ci_upper_limit>0.75</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <groups_desc>Based on a Bayesian analysis of a sigmoidal dose-response relationship.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Mean Difference</param_type>
            <param_value>-0.15</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.44</ci_lower_limit>
            <ci_upper_limit>0.33</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <groups_desc>Based on a Bayesian analysis of a sigmoidal dose-response relationship.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Mean Difference</param_type>
            <param_value>-0.04</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.92</ci_lower_limit>
            <ci_upper_limit>0.07</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <groups_desc>Based on a Bayesian analysis of a sigmoidal dose-response relationship.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Mean Difference</param_type>
            <param_value>-0.02</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.48</ci_lower_limit>
            <ci_upper_limit>0.02</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O6</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <groups_desc>Based on a Bayesian analysis of a sigmoidal dose-response relationship.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Mean Difference</param_type>
            <param_value>-0.00</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.15</ci_lower_limit>
            <ci_upper_limit>0.00</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Patient Global Impression of Improvement (PGI-I) Urinary Symptoms Scores at Week 1</title>
        <description>The PGI-I is a 1-item questionnaire designed to assess the patient's impression of changes in urinary symptoms. The PGI-I was scored from 1 (very much better) to 7 (very much worse).&#xD;
Visit-specific PGI-I in urinary symptoms is presented in this endpoint.</description>
        <time_frame>Week 1</time_frame>
        <population>The ITT-RT comprised of all the subjects randomized at Visit 4.</population>
        <group_list>
          <group group_id="O1">
            <title>FE 201836 500 ug (Randomized Treatment Period)</title>
            <description>FE 201836 500 µg oral solution and placebo ODT, administered once daily</description>
          </group>
          <group group_id="O2">
            <title>FE 201836 350 ug (Randomized Treatment Period)</title>
            <description>FE 201836 350 µg oral solution and placebo ODT, administered once daily</description>
          </group>
          <group group_id="O3">
            <title>FE 201836 250 ug (Randomized Treatment Period)</title>
            <description>FE 201836 250 µg oral solution and placebo ODT, administered once daily</description>
          </group>
          <group group_id="O4">
            <title>FE 201836 150 ug (Randomized Treatment Period)</title>
            <description>FE 201836 150 µg oral solution and placebo ODT, administered once daily</description>
          </group>
          <group group_id="O5">
            <title>FE 201836 100 ug (Randomized Treatment Period)</title>
            <description>FE 201836 100 µg oral solution and placebo ODT, administered once daily</description>
          </group>
          <group group_id="O6">
            <title>FE 201836 50 ug (Randomized Treatment Period)</title>
            <description>FE 201836 50 µg oral solution and placebo ODT, administered once dail</description>
          </group>
          <group group_id="O7">
            <title>Placebo (Randomized Treatment Period)</title>
            <description>Placebo oral solution and placebo ODT, administered once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Patient Global Impression of Improvement (PGI-I) Urinary Symptoms Scores at Week 1</title>
          <description>The PGI-I is a 1-item questionnaire designed to assess the patient's impression of changes in urinary symptoms. The PGI-I was scored from 1 (very much better) to 7 (very much worse).&#xD;
Visit-specific PGI-I in urinary symptoms is presented in this endpoint.</description>
          <population>The ITT-RT comprised of all the subjects randomized at Visit 4.</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="53"/>
                <count group_id="O2" value="23"/>
                <count group_id="O3" value="24"/>
                <count group_id="O4" value="14"/>
                <count group_id="O5" value="11"/>
                <count group_id="O6" value="33"/>
                <count group_id="O7" value="81"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.475" lower_limit="2.261" upper_limit="2.689"/>
                    <measurement group_id="O2" value="2.045" lower_limit="1.723" upper_limit="2.367"/>
                    <measurement group_id="O3" value="2.708" lower_limit="2.385" upper_limit="3.031"/>
                    <measurement group_id="O4" value="2.786" lower_limit="2.363" upper_limit="3.209"/>
                    <measurement group_id="O5" value="2.781" lower_limit="2.316" upper_limit="3.245"/>
                    <measurement group_id="O6" value="2.758" lower_limit="2.482" upper_limit="3.033"/>
                    <measurement group_id="O7" value="2.745" lower_limit="2.571" upper_limit="2.919"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0550</p_value>
            <p_value_desc>Threshold for significance at 0.05 level.</p_value_desc>
            <method>MMRM</method>
            <param_type>Mean Difference</param_type>
            <param_value>-0.270</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.545</ci_lower_limit>
            <ci_upper_limit>0.006</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0002</p_value>
            <p_value_desc>Threshold for significance at 0.05 level.</p_value_desc>
            <method>MMRM</method>
            <param_type>Mean Difference</param_type>
            <param_value>-0.700</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.066</ci_lower_limit>
            <ci_upper_limit>-0.335</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.8440</p_value>
            <p_value_desc>Threshold for significance at 0.05 level.</p_value_desc>
            <method>MMRM</method>
            <param_type>Mean Difference</param_type>
            <param_value>-0.037</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.404</ci_lower_limit>
            <ci_upper_limit>0.330</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.8610</p_value>
            <p_value_desc>Threshold for significance at 0.05 level.</p_value_desc>
            <method>MMRM</method>
            <param_type>Mean Difference</param_type>
            <param_value>0.041</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.417</ci_lower_limit>
            <ci_upper_limit>0.498</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.8871</p_value>
            <p_value_desc>Threshold for significance at 0.05 level.</p_value_desc>
            <method>MMRM</method>
            <param_type>Mean Difference</param_type>
            <param_value>0.036</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.460</ci_lower_limit>
            <ci_upper_limit>0.532</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O6</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.9396</p_value>
            <p_value_desc>Threshold for significance at 0.05 level.</p_value_desc>
            <method>MMRM</method>
            <param_type>Mean Difference</param_type>
            <param_value>0.013</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.313</ci_lower_limit>
            <ci_upper_limit>0.338</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Patient Global Impression of Improvement (PGI-I) Urinary Symptoms Scores at Week 4</title>
        <description>The PGI-I is a 1-item questionnaire designed to assess the patient's impression of changes in urinary symptoms. The PGI-I was scored from 1 (very much better) to 7 (very much worse).&#xD;
Visit-specific PGI-I in urinary symptoms is presented in this endpoint.</description>
        <time_frame>Week 4</time_frame>
        <population>The ITT-RT comprised of all the subjects randomized at Visit 4.</population>
        <group_list>
          <group group_id="O1">
            <title>FE 201836 500 ug (Randomized Treatment Period)</title>
            <description>FE 201836 500 µg oral solution and placebo ODT, administered once daily</description>
          </group>
          <group group_id="O2">
            <title>FE 201836 350 ug (Randomized Treatment Period)</title>
            <description>FE 201836 350 µg oral solution and placebo ODT, administered once daily</description>
          </group>
          <group group_id="O3">
            <title>FE 201836 250 ug (Randomized Treatment Period)</title>
            <description>FE 201836 250 µg oral solution and placebo ODT, administered once daily</description>
          </group>
          <group group_id="O4">
            <title>FE 201836 150 ug (Randomized Treatment Period)</title>
            <description>FE 201836 150 µg oral solution and placebo ODT, administered once daily</description>
          </group>
          <group group_id="O5">
            <title>FE 201836 100 ug (Randomized Treatment Period)</title>
            <description>FE 201836 100 µg oral solution and placebo ODT, administered once daily</description>
          </group>
          <group group_id="O6">
            <title>FE 201836 50 ug (Randomized Treatment Period)</title>
            <description>FE 201836 50 µg oral solution and placebo ODT, administered once daily</description>
          </group>
          <group group_id="O7">
            <title>Placebo (Randomized Treatment Period)</title>
            <description>Placebo oral solution and placebo ODT, administered once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Patient Global Impression of Improvement (PGI-I) Urinary Symptoms Scores at Week 4</title>
          <description>The PGI-I is a 1-item questionnaire designed to assess the patient's impression of changes in urinary symptoms. The PGI-I was scored from 1 (very much better) to 7 (very much worse).&#xD;
Visit-specific PGI-I in urinary symptoms is presented in this endpoint.</description>
          <population>The ITT-RT comprised of all the subjects randomized at Visit 4.</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="53"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="20"/>
                <count group_id="O4" value="12"/>
                <count group_id="O5" value="13"/>
                <count group_id="O6" value="30"/>
                <count group_id="O7" value="77"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.121" lower_limit="1.866" upper_limit="2.376"/>
                    <measurement group_id="O2" value="2.191" lower_limit="1.813" upper_limit="2.569"/>
                    <measurement group_id="O3" value="2.447" lower_limit="2.039" upper_limit="2.855"/>
                    <measurement group_id="O4" value="2.521" lower_limit="1.995" upper_limit="3.047"/>
                    <measurement group_id="O5" value="2.385" lower_limit="1.859" upper_limit="2.910"/>
                    <measurement group_id="O6" value="2.582" lower_limit="2.244" upper_limit="2.921"/>
                    <measurement group_id="O7" value="2.596" lower_limit="2.386" upper_limit="2.806"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0050</p_value>
            <p_value_desc>Threshold for significance at 0.05 level.</p_value_desc>
            <method>MMRM</method>
            <param_type>Mean Difference</param_type>
            <param_value>-0.475</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.806</ci_lower_limit>
            <ci_upper_limit>-0.145</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0665</p_value>
            <p_value_desc>Threshold for significance at 0.05 level.</p_value_desc>
            <method>MMRM</method>
            <param_type>Mean Difference</param_type>
            <param_value>-0.405</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.837</ci_lower_limit>
            <ci_upper_limit>0.028</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.5245</p_value>
            <p_value_desc>Threshold for significance at 0.05 level.</p_value_desc>
            <method>MMRM</method>
            <param_type>Mean Difference</param_type>
            <param_value>-0.149</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.608</ci_lower_limit>
            <ci_upper_limit>0.310</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.7947</p_value>
            <p_value_desc>Threshold for significance at 0.05 level.</p_value_desc>
            <method>MMRM</method>
            <param_type>Mean Difference</param_type>
            <param_value>-0.075</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.642</ci_lower_limit>
            <ci_upper_limit>0.492</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.4625</p_value>
            <p_value_desc>Threshold for significance at 0.05 level.</p_value_desc>
            <method>MMRM</method>
            <param_type>Mean Difference</param_type>
            <param_value>-0.211</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.777</ci_lower_limit>
            <ci_upper_limit>0.355</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O6</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.9465</p_value>
            <p_value_desc>Threshold for significance at 0.05 level.</p_value_desc>
            <method>MMRM</method>
            <param_type>Mean Difference</param_type>
            <param_value>-0.014</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.412</ci_lower_limit>
            <ci_upper_limit>0.385</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Patient Global Impression of Improvement (PGI-I) Urinary Symptoms Scores at Week 8</title>
        <description>The PGI-I is a 1-item questionnaire designed to assess the patient's impression of changes in urinary symptoms. The PGI-I was scored from 1 (very much better) to 7 (very much worse).&#xD;
Visit-specific PGI-I in urinary symptoms is presented in this endpoint.</description>
        <time_frame>Week 8</time_frame>
        <population>The ITT-RT comprised of all the subjects randomized at Visit 4.</population>
        <group_list>
          <group group_id="O1">
            <title>FE 201836 500 ug (Randomized Treatment Period)</title>
            <description>FE 201836 500 µg oral solution and placebo ODT, administered once daily</description>
          </group>
          <group group_id="O2">
            <title>FE 201836 350 ug (Randomized Treatment Period)</title>
            <description>FE 201836 500 µg oral solution and placebo ODT, administered once daily</description>
          </group>
          <group group_id="O3">
            <title>FE 201836 250 ug (Randomized Treatment Period)</title>
            <description>FE 201836 250 µg oral solution and placebo ODT, administered once daily</description>
          </group>
          <group group_id="O4">
            <title>FE 201836 150 ug (Randomized Treatment Period)</title>
            <description>FE 201836 150 µg oral solution and placebo ODT, administered once daily</description>
          </group>
          <group group_id="O5">
            <title>FE 201836 100 ug (Randomized Treatment Period)</title>
            <description>FE 201836 100 µg oral solution and placebo ODT, administered once daily</description>
          </group>
          <group group_id="O6">
            <title>FE 201836 50 ug (Randomized Treatment Period)</title>
            <description>FE 201836 50 µg oral solution and placebo ODT, administered once daily</description>
          </group>
          <group group_id="O7">
            <title>Placebo (Randomized Treatment Period)</title>
            <description>Placebo oral solution and placebo ODT, administered once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Patient Global Impression of Improvement (PGI-I) Urinary Symptoms Scores at Week 8</title>
          <description>The PGI-I is a 1-item questionnaire designed to assess the patient's impression of changes in urinary symptoms. The PGI-I was scored from 1 (very much better) to 7 (very much worse).&#xD;
Visit-specific PGI-I in urinary symptoms is presented in this endpoint.</description>
          <population>The ITT-RT comprised of all the subjects randomized at Visit 4.</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="49"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="21"/>
                <count group_id="O4" value="14"/>
                <count group_id="O5" value="11"/>
                <count group_id="O6" value="28"/>
                <count group_id="O7" value="78"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.843" lower_limit="1.572" upper_limit="2.113"/>
                    <measurement group_id="O2" value="1.887" lower_limit="1.493" upper_limit="2.281"/>
                    <measurement group_id="O3" value="2.528" lower_limit="2.109" upper_limit="2.947"/>
                    <measurement group_id="O4" value="2.286" lower_limit="1.761" upper_limit="2.811"/>
                    <measurement group_id="O5" value="2.155" lower_limit="1.587" upper_limit="2.723"/>
                    <measurement group_id="O6" value="2.273" lower_limit="1.917" upper_limit="2.629"/>
                    <measurement group_id="O7" value="2.573" lower_limit="2.355" upper_limit="2.791"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Threshold for significance at 0.05 level.</p_value_desc>
            <method>MMRM</method>
            <param_type>Mean Difference</param_type>
            <param_value>-0.730</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.078</ci_lower_limit>
            <ci_upper_limit>-0.383</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0030</p_value>
            <p_value_desc>Threshold for significance at 0.05 level.</p_value_desc>
            <method>MMRM</method>
            <param_type>Mean Difference</param_type>
            <param_value>-0.686</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.137</ci_lower_limit>
            <ci_upper_limit>-0.236</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.8520</p_value>
            <p_value_desc>Threshold for significance at 0.05 level.</p_value_desc>
            <method>MMRM</method>
            <param_type>Mean Difference</param_type>
            <param_value>-0.045</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.517</ci_lower_limit>
            <ci_upper_limit>0.427</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.3205</p_value>
            <p_value_desc>Threshold for significance at 0.05 level.</p_value_desc>
            <method>MMRM</method>
            <param_type>Mean Difference</param_type>
            <param_value>-0.287</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.856</ci_lower_limit>
            <ci_upper_limit>0.281</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.1769</p_value>
            <p_value_desc>Threshold for significance at 0.05 level.</p_value_desc>
            <method>MMRM</method>
            <param_type>Mean Difference</param_type>
            <param_value>-0.418</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.026</ci_lower_limit>
            <ci_upper_limit>0.190</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O6</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.1584</p_value>
            <p_value_desc>Threshold for significance at 0.05 level.</p_value_desc>
            <method>MMRM</method>
            <param_type>Mean Difference</param_type>
            <param_value>-0.300</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.717</ci_lower_limit>
            <ci_upper_limit>0.118</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Patient Global Impression of Improvement (PGI-I) Urinary Symptoms Scores at Week 12</title>
        <description>The PGI-I is a 1-item questionnaire designed to assess the patient's impression of changes in urinary symptoms. The PGI-I was scored from 1 (very much better) to 7 (very much worse).&#xD;
Visit-specific PGI-I in urinary symptoms is presented in this endpoint.</description>
        <time_frame>Week 12</time_frame>
        <population>The ITT-RT comprised of all the subjects randomized at Visit 4.</population>
        <group_list>
          <group group_id="O1">
            <title>FE 201836 500 ug (Randomized Treatment Period)</title>
            <description>FE 201836 500 µg oral solution and placebo ODT, administered once daily</description>
          </group>
          <group group_id="O2">
            <title>FE 201836 350 ug (Randomized Treatment Period)</title>
            <description>FE 201836 350 µg oral solution and placebo ODT, administered once daily</description>
          </group>
          <group group_id="O3">
            <title>FE 201836 250 ug (Randomized Treatment Period)</title>
            <description>FE 201836 250 µg oral solution and placebo ODT, administered once daily</description>
          </group>
          <group group_id="O4">
            <title>FE 201836 150 ug (Randomized Treatment Period)</title>
            <description>FE 201836 150 µg oral solution and placebo ODT, administered once daily</description>
          </group>
          <group group_id="O5">
            <title>FE 201836 100 ug (Randomized Treatment Period)</title>
            <description>FE 201836 100 µg oral solution and placebo ODT, administered once daily</description>
          </group>
          <group group_id="O6">
            <title>FE 201836 50 ug (Randomized Treatment Period)</title>
            <description>FE 201836 50 µg oral solution and placebo ODT, administered once daily</description>
          </group>
          <group group_id="O7">
            <title>Placebo (Randomized Treatment Period)</title>
            <description>Placebo oral solution and placebo ODT, administered once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Patient Global Impression of Improvement (PGI-I) Urinary Symptoms Scores at Week 12</title>
          <description>The PGI-I is a 1-item questionnaire designed to assess the patient's impression of changes in urinary symptoms. The PGI-I was scored from 1 (very much better) to 7 (very much worse).&#xD;
Visit-specific PGI-I in urinary symptoms is presented in this endpoint.</description>
          <population>The ITT-RT comprised of all the subjects randomized at Visit 4.</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="46"/>
                <count group_id="O2" value="23"/>
                <count group_id="O3" value="18"/>
                <count group_id="O4" value="13"/>
                <count group_id="O5" value="12"/>
                <count group_id="O6" value="31"/>
                <count group_id="O7" value="72"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.667" lower_limit="1.357" upper_limit="1.977"/>
                    <measurement group_id="O2" value="1.671" lower_limit="1.224" upper_limit="2.119"/>
                    <measurement group_id="O3" value="2.656" lower_limit="2.167" upper_limit="3.146"/>
                    <measurement group_id="O4" value="2.452" lower_limit="1.855" upper_limit="3.049"/>
                    <measurement group_id="O5" value="1.678" lower_limit="1.052" upper_limit="2.304"/>
                    <measurement group_id="O6" value="2.384" lower_limit="1.994" upper_limit="2.774"/>
                    <measurement group_id="O7" value="2.490" lower_limit="2.240" upper_limit="2.740"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Threshold for significance at 0.05 level.</p_value_desc>
            <method>MMRM</method>
            <param_type>Mean Difference</param_type>
            <param_value>-0.822</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.220</ci_lower_limit>
            <ci_upper_limit>-0.424</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0019</p_value>
            <p_value_desc>Threshold for significance at 0.05 level.</p_value_desc>
            <method>MMRM</method>
            <param_type>Mean Difference</param_type>
            <param_value>-0.818</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.331</ci_lower_limit>
            <ci_upper_limit>-0.306</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.5510</p_value>
            <p_value_desc>Threshold for significance at 0.05 level.</p_value_desc>
            <method>MMRM</method>
            <param_type>Mean Difference</param_type>
            <param_value>0.167</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.383</ci_lower_limit>
            <ci_upper_limit>0.716</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.9086</p_value>
            <p_value_desc>Threshold for significance at 0.05 level.</p_value_desc>
            <method>MMRM</method>
            <param_type>Mean Difference</param_type>
            <param_value>-0.038</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.685</ci_lower_limit>
            <ci_upper_limit>0.610</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0185</p_value>
            <p_value_desc>Threshold for significance at 0.05 level.</p_value_desc>
            <method>MMRM</method>
            <param_type>Mean Difference</param_type>
            <param_value>-0.812</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.486</ci_lower_limit>
            <ci_upper_limit>-0.138</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O6</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.6537</p_value>
            <p_value_desc>Threshold for significance at 0.05 level.</p_value_desc>
            <method>MMRM</method>
            <param_type>Mean Difference</param_type>
            <param_value>-0.106</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.569</ci_lower_limit>
            <ci_upper_limit>0.357</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Patient Global Impression of Severity (PGI-S) Scores at Week 1</title>
        <description>The PGI-S is a 1-item questionnaire designed to assess patient's impression of disease severity. The PGI-S was scored from 1 (none) to 4 (severe).&#xD;
Change from baseline in visit-specific PGI-S is presented in this endpoint.&#xD;
Level estimated for baseline value of PGI-S equal to 3 is presented in this endpoint.</description>
        <time_frame>Baseline, Week 1</time_frame>
        <population>The ITT-RT comprised of all the subjects randomized at Visit 4.</population>
        <group_list>
          <group group_id="O1">
            <title>FE 201836 500 ug (Randomized Treatment Period)</title>
            <description>FE 201836 500 μg oral solution and placebo ODT, administered once daily</description>
          </group>
          <group group_id="O2">
            <title>FE 201836 350 ug (Randomized Treatment Period)</title>
            <description>FE 201836 350 μg oral solution and placebo ODT, administered once daily</description>
          </group>
          <group group_id="O3">
            <title>FE 201836 250 ug (Randomized Treatment Period)</title>
            <description>FE 201836 250 μg oral solution and placebo ODT, administered once daily</description>
          </group>
          <group group_id="O4">
            <title>FE 201836 150 ug (Randomized Treatment Period)</title>
            <description>FE 201836 150 μg oral solution and placebo ODT, administered once daily</description>
          </group>
          <group group_id="O5">
            <title>FE 201836 100 ug (Randomized Treatment Period)</title>
            <description>FE 201836 100 μg oral solution and placebo ODT, administered once daily</description>
          </group>
          <group group_id="O6">
            <title>FE 201836 50 ug (Randomized Treatment Period)</title>
            <description>FE 201836 50 μg oral solution and placebo ODT, administered once daily</description>
          </group>
          <group group_id="O7">
            <title>Placebo (Randomized Treatment Period)</title>
            <description>Placebo oral solution and placebo ODT, administered once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Patient Global Impression of Severity (PGI-S) Scores at Week 1</title>
          <description>The PGI-S is a 1-item questionnaire designed to assess patient's impression of disease severity. The PGI-S was scored from 1 (none) to 4 (severe).&#xD;
Change from baseline in visit-specific PGI-S is presented in this endpoint.&#xD;
Level estimated for baseline value of PGI-S equal to 3 is presented in this endpoint.</description>
          <population>The ITT-RT comprised of all the subjects randomized at Visit 4.</population>
          <units>score on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="53"/>
                <count group_id="O2" value="23"/>
                <count group_id="O3" value="24"/>
                <count group_id="O4" value="14"/>
                <count group_id="O5" value="10"/>
                <count group_id="O6" value="28"/>
                <count group_id="O7" value="80"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.739" lower_limit="-0.927" upper_limit="-0.552"/>
                    <measurement group_id="O2" value="-0.970" lower_limit="-1.253" upper_limit="-0.688"/>
                    <measurement group_id="O3" value="-0.811" lower_limit="-1.094" upper_limit="-0.529"/>
                    <measurement group_id="O4" value="-0.643" lower_limit="-1.012" upper_limit="-0.273"/>
                    <measurement group_id="O5" value="-0.417" lower_limit="-0.840" upper_limit="0.007"/>
                    <measurement group_id="O6" value="-0.719" lower_limit="-0.984" upper_limit="-0.454"/>
                    <measurement group_id="O7" value="-0.593" lower_limit="-0.746" upper_limit="-0.440"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.2350</p_value>
            <p_value_desc>Threshold for significance at 0.05 level.</p_value_desc>
            <method>MMRM</method>
            <param_type>Least Square Mean Difference</param_type>
            <param_value>-0.146</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.388</ci_lower_limit>
            <ci_upper_limit>0.096</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0215</p_value>
            <p_value_desc>Threshold for significance at 0.05 level.</p_value_desc>
            <method>MMRM</method>
            <param_type>Least Square Mean Difference</param_type>
            <param_value>-0.377</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.699</ci_lower_limit>
            <ci_upper_limit>-0.056</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.1818</p_value>
            <p_value_desc>Threshold for significance at 0.05 level.</p_value_desc>
            <method>MMRM</method>
            <param_type>Least Square Mean Difference</param_type>
            <param_value>-0.218</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.540</ci_lower_limit>
            <ci_upper_limit>0.103</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.8063</p_value>
            <p_value_desc>Threshold for significance at 0.05 level.</p_value_desc>
            <method>MMRM</method>
            <param_type>Least Square Mean Difference</param_type>
            <param_value>-0.050</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.450</ci_lower_limit>
            <ci_upper_limit>0.350</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.4414</p_value>
            <p_value_desc>Threshold for significance at 0.05 level.</p_value_desc>
            <method>MMRM</method>
            <param_type>Least Square Mean Difference</param_type>
            <param_value>0.176</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.274</ci_lower_limit>
            <ci_upper_limit>0.627</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O6</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.4179</p_value>
            <p_value_desc>Threshold for significance at 0.05 level.</p_value_desc>
            <method>MMRM</method>
            <param_type>Least Square Mean Difference</param_type>
            <param_value>-0.126</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.432</ci_lower_limit>
            <ci_upper_limit>0.180</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in PGI-S Scores at Week 4</title>
        <description>The PGI-S is a 1-item questionnaire designed to assess patient's impression of disease severity. The PGI-S was scored from 1 (none) to 4 (severe).&#xD;
Change from baseline in visit-specific PGI-S is presented in this endpoint.&#xD;
Level estimated for baseline value of PGI-S equal to 3 is presented in this endpoint.</description>
        <time_frame>Baseline, Week 4</time_frame>
        <population>The ITT-RT comprised of all the subjects randomized at Visit 4.</population>
        <group_list>
          <group group_id="O1">
            <title>FE 201836 500 ug (Randomized Treatment Period)</title>
            <description>FE 201836 500 μg oral solution and placebo ODT, administered once daily</description>
          </group>
          <group group_id="O2">
            <title>FE 201836 350 ug (Randomized Treatment Period)</title>
            <description>FE 201836 350 μg oral solution and placebo ODT, administered once daily</description>
          </group>
          <group group_id="O3">
            <title>FE 201836 250 ug (Randomized Treatment Period)</title>
            <description>FE 201836 250 μg oral solution and placebo ODT, administered once daily</description>
          </group>
          <group group_id="O4">
            <title>FE 201836 150 ug (Randomized Treatment Period)</title>
            <description>FE 201836 150 μg oral solution and placebo ODT, administered once daily</description>
          </group>
          <group group_id="O5">
            <title>FE 201836 100 ug (Randomized Treatment Period)</title>
            <description>FE 201836 100 μg oral solution and placebo ODT, administered once daily</description>
          </group>
          <group group_id="O6">
            <title>FE 201836 50 ug (Randomized Treatment Period)</title>
            <description>FE 201836 50 μg oral solution and placebo ODT, administered once daily</description>
          </group>
          <group group_id="O7">
            <title>Placebo (Randomized Treatment Period)</title>
            <description>Placebo oral solution and placebo ODT, administered once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in PGI-S Scores at Week 4</title>
          <description>The PGI-S is a 1-item questionnaire designed to assess patient's impression of disease severity. The PGI-S was scored from 1 (none) to 4 (severe).&#xD;
Change from baseline in visit-specific PGI-S is presented in this endpoint.&#xD;
Level estimated for baseline value of PGI-S equal to 3 is presented in this endpoint.</description>
          <population>The ITT-RT comprised of all the subjects randomized at Visit 4.</population>
          <units>score on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="52"/>
                <count group_id="O2" value="23"/>
                <count group_id="O3" value="20"/>
                <count group_id="O4" value="12"/>
                <count group_id="O5" value="12"/>
                <count group_id="O6" value="27"/>
                <count group_id="O7" value="75"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.837" lower_limit="-1.015" upper_limit="-0.659"/>
                    <measurement group_id="O2" value="-1.025" lower_limit="-1.292" upper_limit="-0.758"/>
                    <measurement group_id="O3" value="-0.798" lower_limit="-1.081" upper_limit="-0.516"/>
                    <measurement group_id="O4" value="-0.749" lower_limit="-1.115" upper_limit="-0.383"/>
                    <measurement group_id="O5" value="-0.656" lower_limit="-1.033" upper_limit="-0.278"/>
                    <measurement group_id="O6" value="-0.936" lower_limit="-1.189" upper_limit="-0.684"/>
                    <measurement group_id="O7" value="-0.898" lower_limit="-1.045" upper_limit="-0.750"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.6042</p_value>
            <p_value_desc>Threshold for significance at 0.05 level.</p_value_desc>
            <method>MMRM</method>
            <param_type>Least Square Mean Difference</param_type>
            <param_value>0.061</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.170</ci_lower_limit>
            <ci_upper_limit>0.292</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.4114</p_value>
            <p_value_desc>Threshold for significance at 0.05 level.</p_value_desc>
            <method>MMRM</method>
            <param_type>Least Square Mean Difference</param_type>
            <param_value>-0.127</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.432</ci_lower_limit>
            <ci_upper_limit>0.177</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.5394</p_value>
            <p_value_desc>Threshold for significance at 0.05 level.</p_value_desc>
            <method>MMRM</method>
            <param_type>Least Square Mean Difference</param_type>
            <param_value>0.099</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.219</ci_lower_limit>
            <ci_upper_limit>0.418</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.4590</p_value>
            <p_value_desc>Threshold for significance at 0.05 level.</p_value_desc>
            <method>MMRM</method>
            <param_type>Least Square Mean Difference</param_type>
            <param_value>0.149</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.246</ci_lower_limit>
            <ci_upper_limit>0.544</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.2397</p_value>
            <p_value_desc>Threshold for significance at 0.05 level.</p_value_desc>
            <method>MMRM</method>
            <param_type>Least Square Mean Difference</param_type>
            <param_value>0.242</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.163</ci_lower_limit>
            <ci_upper_limit>0.647</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O6</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.7954</p_value>
            <p_value_desc>Threshold for significance at 0.05 level.</p_value_desc>
            <method>MMRM</method>
            <param_type>Least Square Mean Difference</param_type>
            <param_value>-0.039</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.332</ci_lower_limit>
            <ci_upper_limit>0.254</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in PGI-S Scores at Week 8</title>
        <description>The PGI-S is a 1-item questionnaire designed to assess patient's impression of disease severity. The PGI-S was scored from 1 (none) to 4 (severe).&#xD;
Change from baseline in visit-specific PGI-S is presented in this endpoint.&#xD;
Level estimated for baseline value of PGI-S equal to 3 is presented in this endpoint.</description>
        <time_frame>Baseline, Week 8</time_frame>
        <population>The ITT-RT comprised of all the subjects randomized at Visit 4.</population>
        <group_list>
          <group group_id="O1">
            <title>FE 201836 500 ug (Randomized Treatment Period)</title>
            <description>FE 201836 500 µg oral solution for daily intake</description>
          </group>
          <group group_id="O2">
            <title>FE 201836 350 ug (Randomized Treatment Period)</title>
            <description>FE 201836 350 µg oral solution for daily intake</description>
          </group>
          <group group_id="O3">
            <title>FE 201836 250 ug (Randomized Treatment Period)</title>
            <description>FE 201836 250 µg oral solution for daily intake</description>
          </group>
          <group group_id="O4">
            <title>FE 201836 150 ug (Randomized Treatment Period)</title>
            <description>FE 201836 150 µg oral solution for daily intake</description>
          </group>
          <group group_id="O5">
            <title>FE 201836 100 ug (Randomized Treatment Period)</title>
            <description>FE 201836 100 µg oral solution for daily intake</description>
          </group>
          <group group_id="O6">
            <title>FE 201836 50 ug (Randomized Treatment Period)</title>
            <description>FE 201836 50 µg oral solution for daily intake</description>
          </group>
          <group group_id="O7">
            <title>Placebo (Randomized Treatment Period)</title>
            <description>Placebo ODT, mimics active comparator drug</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in PGI-S Scores at Week 8</title>
          <description>The PGI-S is a 1-item questionnaire designed to assess patient's impression of disease severity. The PGI-S was scored from 1 (none) to 4 (severe).&#xD;
Change from baseline in visit-specific PGI-S is presented in this endpoint.&#xD;
Level estimated for baseline value of PGI-S equal to 3 is presented in this endpoint.</description>
          <population>The ITT-RT comprised of all the subjects randomized at Visit 4.</population>
          <units>score on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="48"/>
                <count group_id="O2" value="23"/>
                <count group_id="O3" value="21"/>
                <count group_id="O4" value="14"/>
                <count group_id="O5" value="11"/>
                <count group_id="O6" value="25"/>
                <count group_id="O7" value="76"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.132" lower_limit="-1.322" upper_limit="-0.942"/>
                    <measurement group_id="O2" value="-1.410" lower_limit="-1.688" upper_limit="-1.132"/>
                    <measurement group_id="O3" value="-0.825" lower_limit="-1.114" upper_limit="-0.536"/>
                    <measurement group_id="O4" value="-0.643" lower_limit="-1.004" upper_limit="-0.281"/>
                    <measurement group_id="O5" value="-0.816" lower_limit="-1.215" upper_limit="-0.418"/>
                    <measurement group_id="O6" value="-1.013" lower_limit="-1.279" upper_limit="-0.747"/>
                    <measurement group_id="O7" value="-0.800" lower_limit="-0.953" upper_limit="-0.647"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0077</p_value>
            <p_value_desc>Threshold for significance at 0.05 level.</p_value_desc>
            <method>MMRM</method>
            <param_type>Least Square Mean Difference</param_type>
            <param_value>-0.332</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.576</ci_lower_limit>
            <ci_upper_limit>-0.089</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0002</p_value>
            <p_value_desc>Threshold for significance at 0.05 level.</p_value_desc>
            <method>MMRM</method>
            <param_type>Least Square Mean Difference</param_type>
            <param_value>-0.610</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.927</ci_lower_limit>
            <ci_upper_limit>-0.293</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.8778</p_value>
            <p_value_desc>Threshold for significance at 0.05 level.</p_value_desc>
            <method>MMRM</method>
            <param_type>Least Square Mean Difference</param_type>
            <param_value>-0.026</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.352</ci_lower_limit>
            <ci_upper_limit>0.301</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.4309</p_value>
            <p_value_desc>Threshold for significance at 0.05 level.</p_value_desc>
            <method>MMRM</method>
            <param_type>Least Square Mean Difference</param_type>
            <param_value>0.157</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.235</ci_lower_limit>
            <ci_upper_limit>0.549</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.9392</p_value>
            <p_value_desc>Threshold for significance at 0.05 level.</p_value_desc>
            <method>MMRM</method>
            <param_type>Least Square Mean Difference</param_type>
            <param_value>-0.017</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.444</ci_lower_limit>
            <ci_upper_limit>0.411</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O6</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.1734</p_value>
            <p_value_desc>Threshold for significance at 0.05 level.</p_value_desc>
            <method>MMRM</method>
            <param_type>Least Square Mean Difference</param_type>
            <param_value>-0.213</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.521</ci_lower_limit>
            <ci_upper_limit>0.094</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in PGI-S Scores at Week 12</title>
        <description>The PGI-S is a 1-item questionnaire designed to assess patient's impression of disease severity. The PGI-S was scored from 1 (none) to 4 (severe).&#xD;
Change from baseline in visit-specific PGI-S is presented in this endpoint.&#xD;
Level estimated for baseline value of PGI-S equal to 3 is presented in this endpoint.</description>
        <time_frame>Baseline, Week 12</time_frame>
        <population>The ITT-RT comprised of all the subjects randomized at Visit 4.</population>
        <group_list>
          <group group_id="O1">
            <title>FE 201836 500 ug (Randomized Treatment Period)</title>
            <description>FE 201836 500 µg oral solution and placebo ODT, administered once daily</description>
          </group>
          <group group_id="O2">
            <title>FE 201836 350 ug (Randomized Treatment Period)</title>
            <description>FE 201836 350 µg oral solution and placebo ODT, administered once daily</description>
          </group>
          <group group_id="O3">
            <title>FE 201836 250 ug (Randomized Treatment Period)</title>
            <description>FE 201836 250 µg oral solution and placebo ODT, administered once daily</description>
          </group>
          <group group_id="O4">
            <title>FE 201836 150 ug (Randomized Treatment Period)</title>
            <description>FE 201836 150 µg oral solution and placebo ODT, administered once daily</description>
          </group>
          <group group_id="O5">
            <title>FE 201836 100 ug (Randomized Treatment Period)</title>
            <description>FE 201836 100 µg oral solution and placebo ODT, administered once daily</description>
          </group>
          <group group_id="O6">
            <title>FE 201836 50 ug (Randomized Treatment Period)</title>
            <description>FE 201836 50 µg oral solution and placebo ODT, administered once daily</description>
          </group>
          <group group_id="O7">
            <title>Placebo (Randomized Treatment Period)</title>
            <description>Placebo oral solution and placebo ODT, administered once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in PGI-S Scores at Week 12</title>
          <description>The PGI-S is a 1-item questionnaire designed to assess patient's impression of disease severity. The PGI-S was scored from 1 (none) to 4 (severe).&#xD;
Change from baseline in visit-specific PGI-S is presented in this endpoint.&#xD;
Level estimated for baseline value of PGI-S equal to 3 is presented in this endpoint.</description>
          <population>The ITT-RT comprised of all the subjects randomized at Visit 4.</population>
          <units>score on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="45"/>
                <count group_id="O2" value="22"/>
                <count group_id="O3" value="18"/>
                <count group_id="O4" value="13"/>
                <count group_id="O5" value="12"/>
                <count group_id="O6" value="27"/>
                <count group_id="O7" value="70"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.181" lower_limit="-1.383" upper_limit="-0.979"/>
                    <measurement group_id="O2" value="-1.338" lower_limit="-1.630" upper_limit="-1.045"/>
                    <measurement group_id="O3" value="-0.894" lower_limit="-1.208" upper_limit="-0.579"/>
                    <measurement group_id="O4" value="-0.638" lower_limit="-1.020" upper_limit="-0.257"/>
                    <measurement group_id="O5" value="-1.168" lower_limit="-1.571" upper_limit="-0.764"/>
                    <measurement group_id="O6" value="-1.041" lower_limit="-1.312" upper_limit="-0.770"/>
                    <measurement group_id="O7" value="-0.853" lower_limit="-1.016" upper_limit="-0.690"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0133</p_value>
            <p_value_desc>Threshold for significance at 0.05 level.</p_value_desc>
            <method>MMRM</method>
            <param_type>Least Square Mean Difference</param_type>
            <param_value>-0.328</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.587</ci_lower_limit>
            <ci_upper_limit>-0.069</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0048</p_value>
            <p_value_desc>Threshold for significance at 0.05 level.</p_value_desc>
            <method>MMRM</method>
            <param_type>Least Square Mean Difference</param_type>
            <param_value>-0.484</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.819</ci_lower_limit>
            <ci_upper_limit>-0.150</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.8223</p_value>
            <p_value_desc>Threshold for significance at 0.05 level.</p_value_desc>
            <method>MMRM</method>
            <param_type>Least Square Mean Difference</param_type>
            <param_value>-0.040</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.395</ci_lower_limit>
            <ci_upper_limit>0.314</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.3083</p_value>
            <p_value_desc>Threshold for significance at 0.05 level.</p_value_desc>
            <method>MMRM</method>
            <param_type>Least Square Mean Difference</param_type>
            <param_value>0.215</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.200</ci_lower_limit>
            <ci_upper_limit>0.630</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.1556</p_value>
            <p_value_desc>Threshold for significance at 0.05 level.</p_value_desc>
            <method>MMRM</method>
            <param_type>Least Square Mean Difference</param_type>
            <param_value>-0.315</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.750</ci_lower_limit>
            <ci_upper_limit>0.121</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O6</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.2423</p_value>
            <p_value_desc>Threshold for significance at 0.05 level.</p_value_desc>
            <method>MMRM</method>
            <param_type>Least Square Mean Difference</param_type>
            <param_value>-0.188</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.504</ci_lower_limit>
            <ci_upper_limit>0.128</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Hsu 5-point Likert Bother Scale at Week 1</title>
        <description>The Hsu 5-point Likert Bother scale is a questionnaire designed to assess the subjective bothersomeness and functional disruptiveness of nocturia. The Hsu 5 point Likert Bother Scale was scored from 0 (not at all) to 4 (extremely).&#xD;
Change from baseline in visit-specific Hsu Bother is presented in this endpoint.&#xD;
Level estimated for baseline value of Hsu Bother equal to 3 is presented in this endpoint.</description>
        <time_frame>Baseline, Week 1</time_frame>
        <population>The ITT-RT comprised of all the subjects randomized at Visit 4.</population>
        <group_list>
          <group group_id="O1">
            <title>FE 201836 500 ug (Randomized Treatment Period)</title>
            <description>FE 201836 500 µg oral solution and placebo ODT, administered once daily</description>
          </group>
          <group group_id="O2">
            <title>FE 201836 350 ug (Randomized Treatment Period)</title>
            <description>FE 201836 350 µg oral solution and placebo ODT, administered once daily</description>
          </group>
          <group group_id="O3">
            <title>FE 201836 250 ug (Randomized Treatment Period)</title>
            <description>FE 201836 250 µg oral solution and placebo ODT, administered once daily</description>
          </group>
          <group group_id="O4">
            <title>FE 201836 150 ug (Randomized Treatment Period)</title>
            <description>FE 201836 150 µg oral solution and placebo ODT, administered once daily</description>
          </group>
          <group group_id="O5">
            <title>FE 201836 100 ug (Randomized Treatment Period)</title>
            <description>FE 201836 100 µg oral solution and placebo ODT, administered once daily</description>
          </group>
          <group group_id="O6">
            <title>FE 201836 50 ug (Randomized Treatment Period)</title>
            <description>FE 201836 50 µg oral solution and placebo ODT, administered once daily</description>
          </group>
          <group group_id="O7">
            <title>Placebo (Randomized Treatment Period)</title>
            <description>Placebo oral solution and placebo ODT, administered once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Hsu 5-point Likert Bother Scale at Week 1</title>
          <description>The Hsu 5-point Likert Bother scale is a questionnaire designed to assess the subjective bothersomeness and functional disruptiveness of nocturia. The Hsu 5 point Likert Bother Scale was scored from 0 (not at all) to 4 (extremely).&#xD;
Change from baseline in visit-specific Hsu Bother is presented in this endpoint.&#xD;
Level estimated for baseline value of Hsu Bother equal to 3 is presented in this endpoint.</description>
          <population>The ITT-RT comprised of all the subjects randomized at Visit 4.</population>
          <units>score on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
                <count group_id="O2" value="23"/>
                <count group_id="O3" value="24"/>
                <count group_id="O4" value="14"/>
                <count group_id="O5" value="9"/>
                <count group_id="O6" value="30"/>
                <count group_id="O7" value="70"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.649" lower_limit="-0.922" upper_limit="-0.376"/>
                    <measurement group_id="O2" value="-1.072" lower_limit="-1.441" upper_limit="-0.703"/>
                    <measurement group_id="O3" value="-0.748" lower_limit="-1.125" upper_limit="-0.370"/>
                    <measurement group_id="O4" value="-0.458" lower_limit="-0.942" upper_limit="0.026"/>
                    <measurement group_id="O5" value="-0.346" lower_limit="-0.955" upper_limit="0.262"/>
                    <measurement group_id="O6" value="-0.376" lower_limit="-0.714" upper_limit="-0.039"/>
                    <measurement group_id="O7" value="-0.570" lower_limit="-0.799" upper_limit="-0.341"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.6381</p_value>
            <p_value_desc>Threshold for significance at 0.05 level.</p_value_desc>
            <method>MMRM</method>
            <param_type>Least Square Mean Difference</param_type>
            <param_value>-0.079</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.409</ci_lower_limit>
            <ci_upper_limit>0.251</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0221</p_value>
            <p_value_desc>Threshold for significance at 0.05 level.</p_value_desc>
            <method>MMRM</method>
            <param_type>Least Square Mean Difference</param_type>
            <param_value>-0.502</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.931</ci_lower_limit>
            <ci_upper_limit>-0.073</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.4112</p_value>
            <p_value_desc>Threshold for significance at 0.05 level.</p_value_desc>
            <method>MMRM</method>
            <param_type>Least Square Mean Difference</param_type>
            <param_value>-0.177</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.602</ci_lower_limit>
            <ci_upper_limit>0.247</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.6761</p_value>
            <p_value_desc>Threshold for significance at 0.05 level.</p_value_desc>
            <method>MMRM</method>
            <param_type>Least Square Mean Difference</param_type>
            <param_value>0.112</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.416</ci_lower_limit>
            <ci_upper_limit>0.640</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.4898</p_value>
            <p_value_desc>Threshold for significance at 0.05 level.</p_value_desc>
            <method>MMRM</method>
            <param_type>Least Square Mean Difference</param_type>
            <param_value>0.224</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.414</ci_lower_limit>
            <ci_upper_limit>0.861</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O6</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.3311</p_value>
            <p_value_desc>Threshold for significance at 0.05 level.</p_value_desc>
            <method>MMRM</method>
            <param_type>Least Square Mean Difference</param_type>
            <param_value>0.194</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.198</ci_lower_limit>
            <ci_upper_limit>0.585</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Hsu 5-point Likert Bother Scale at Week 4</title>
        <description>The Hsu 5-point Likert Bother scale is a questionnaire designed to assess the subjective bothersomeness and functional disruptiveness of nocturia. The Hsu 5 point Likert Bother Scale was scored from 0 (not at all) to 4 (extremely).&#xD;
Change from baseline in visit-specific Hsu Bother is presented in this endpoint.&#xD;
Level estimated for baseline value of Hsu Bother equal to 3 is presented in this endpoint.</description>
        <time_frame>Baseline, Week 4</time_frame>
        <population>The ITT-RT comprised of all the subjects randomized at Visit 4.</population>
        <group_list>
          <group group_id="O1">
            <title>FE 201836 500 ug (Randomized Treatment Period)</title>
            <description>FE 201836 500 µg oral solution and placebo ODT, administered once daily</description>
          </group>
          <group group_id="O2">
            <title>FE 201836 350 ug (Randomized Treatment Period)</title>
            <description>FE 201836 350 µg oral solution and placebo ODT, administered once daily</description>
          </group>
          <group group_id="O3">
            <title>FE 201836 250 ug (Randomized Treatment Period)</title>
            <description>FE 201836 250 µg oral solution and placebo ODT, administered once daily</description>
          </group>
          <group group_id="O4">
            <title>FE 201836 150 ug (Randomized Treatment Period)</title>
            <description>FE 201836 150 µg oral solution and placebo ODT, administered once daily</description>
          </group>
          <group group_id="O5">
            <title>FE 201836 100 ug (Randomized Treatment Period)</title>
            <description>FE 201836 100 µg oral solution and placebo ODT, administered once daily</description>
          </group>
          <group group_id="O6">
            <title>FE 201836 50 ug (Randomized Treatment Period)</title>
            <description>FE 201836 50 µg oral solution and placebo ODT, administered once daily</description>
          </group>
          <group group_id="O7">
            <title>Placebo (Randomized Treatment Period)</title>
            <description>Placebo oral solution and placebo ODT, administered once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Hsu 5-point Likert Bother Scale at Week 4</title>
          <description>The Hsu 5-point Likert Bother scale is a questionnaire designed to assess the subjective bothersomeness and functional disruptiveness of nocturia. The Hsu 5 point Likert Bother Scale was scored from 0 (not at all) to 4 (extremely).&#xD;
Change from baseline in visit-specific Hsu Bother is presented in this endpoint.&#xD;
Level estimated for baseline value of Hsu Bother equal to 3 is presented in this endpoint.</description>
          <population>The ITT-RT comprised of all the subjects randomized at Visit 4.</population>
          <units>score on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="47"/>
                <count group_id="O2" value="23"/>
                <count group_id="O3" value="22"/>
                <count group_id="O4" value="13"/>
                <count group_id="O5" value="8"/>
                <count group_id="O6" value="27"/>
                <count group_id="O7" value="68"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.896" lower_limit="-1.161" upper_limit="-0.630"/>
                    <measurement group_id="O2" value="-0.940" lower_limit="-1.294" upper_limit="-0.586"/>
                    <measurement group_id="O3" value="-0.712" lower_limit="-1.083" upper_limit="-0.340"/>
                    <measurement group_id="O4" value="-0.606" lower_limit="-1.079" upper_limit="-0.132"/>
                    <measurement group_id="O5" value="-1.096" lower_limit="-1.698" upper_limit="-0.493"/>
                    <measurement group_id="O6" value="-0.861" lower_limit="-1.193" upper_limit="-0.530"/>
                    <measurement group_id="O7" value="-0.665" lower_limit="-0.885" upper_limit="-0.445"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.1583</p_value>
            <p_value_desc>Threshold for significance at 0.05 level.</p_value_desc>
            <method>MMRM</method>
            <param_type>Least Square Mean Difference</param_type>
            <param_value>-0.230</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.551</ci_lower_limit>
            <ci_upper_limit>0.090</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.1884</p_value>
            <p_value_desc>Threshold for significance at 0.05 level.</p_value_desc>
            <method>MMRM</method>
            <param_type>Least Square Mean Difference</param_type>
            <param_value>-0.275</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.685</ci_lower_limit>
            <ci_upper_limit>0.136</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.8256</p_value>
            <p_value_desc>Threshold for significance at 0.05 level.</p_value_desc>
            <method>MMRM</method>
            <param_type>Least Square Mean Difference</param_type>
            <param_value>-0.047</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.463</ci_lower_limit>
            <ci_upper_limit>0.369</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.8198</p_value>
            <p_value_desc>Threshold for significance at 0.05 level.</p_value_desc>
            <method>MMRM</method>
            <param_type>Least Square Mean Difference</param_type>
            <param_value>0.059</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.455</ci_lower_limit>
            <ci_upper_limit>0.574</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.1793</p_value>
            <p_value_desc>Threshold for significance at 0.05 level.</p_value_desc>
            <method>MMRM</method>
            <param_type>Least Square Mean Difference</param_type>
            <param_value>-0.431</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.061</ci_lower_limit>
            <ci_upper_limit>0.199</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O6</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.3155</p_value>
            <p_value_desc>Threshold for significance at 0.05 level.</p_value_desc>
            <method>MMRM</method>
            <param_type>Least Square Mean Difference</param_type>
            <param_value>-0.196</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.581</ci_lower_limit>
            <ci_upper_limit>0.189</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Hsu 5-point Likert Bother Scale at Week 8</title>
        <description>The Hsu 5-point Likert Bother scale is a questionnaire designed to assess the subjective bothersomeness and functional disruptiveness of nocturia. The Hsu 5 point Likert Bother Scale was scored from 0 (not at all) to 4 (extremely).&#xD;
Change from baseline in visit-specific Hsu Bother is presented in this endpoint.&#xD;
Level estimated for baseline value of Hsu Bother equal to 3 is presented in this endpoint.</description>
        <time_frame>Baseline, Week 8</time_frame>
        <population>The ITT-RT comprised of all the subjects randomized at Visit 4.</population>
        <group_list>
          <group group_id="O1">
            <title>FE 201836 500 ug (Randomized Treatment Period)</title>
            <description>FE 201836 500 µg oral solution and placebo ODT, administered once daily</description>
          </group>
          <group group_id="O2">
            <title>FE 201836 350 ug (Randomized Treatment Period)</title>
            <description>FE 201836 350 µg oral solution and placebo ODT, administered once daily</description>
          </group>
          <group group_id="O3">
            <title>FE 201836 250 ug (Randomized Treatment Period)</title>
            <description>FE 201836 250 µg oral solution and placebo ODT, administered once daily</description>
          </group>
          <group group_id="O4">
            <title>FE 201836 150 ug (Randomized Treatment Period)</title>
            <description>FE 201836 150 µg oral solution and placebo ODT, administered once daily</description>
          </group>
          <group group_id="O5">
            <title>FE 201836 100 ug (Randomized Treatment Period)</title>
            <description>FE 201836 100 µg oral solution and placebo ODT, administered once daily</description>
          </group>
          <group group_id="O6">
            <title>FE 201836 50 ug (Randomized Treatment Period)</title>
            <description>FE 201836 50 µg oral solution and placebo ODT, administered once daily</description>
          </group>
          <group group_id="O7">
            <title>Placebo (Randomized Treatment Period)</title>
            <description>Placebo oral solution and placebo ODT, administered once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Hsu 5-point Likert Bother Scale at Week 8</title>
          <description>The Hsu 5-point Likert Bother scale is a questionnaire designed to assess the subjective bothersomeness and functional disruptiveness of nocturia. The Hsu 5 point Likert Bother Scale was scored from 0 (not at all) to 4 (extremely).&#xD;
Change from baseline in visit-specific Hsu Bother is presented in this endpoint.&#xD;
Level estimated for baseline value of Hsu Bother equal to 3 is presented in this endpoint.</description>
          <population>The ITT-RT comprised of all the subjects randomized at Visit 4.</population>
          <units>score on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="23"/>
                <count group_id="O4" value="14"/>
                <count group_id="O5" value="7"/>
                <count group_id="O6" value="27"/>
                <count group_id="O7" value="71"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.972" lower_limit="-1.273" upper_limit="-0.672"/>
                    <measurement group_id="O2" value="-1.044" lower_limit="-1.423" upper_limit="-0.664"/>
                    <measurement group_id="O3" value="-0.991" lower_limit="-1.389" upper_limit="-0.594"/>
                    <measurement group_id="O4" value="-0.499" lower_limit="-1.001" upper_limit="0.004"/>
                    <measurement group_id="O5" value="-1.012" lower_limit="-1.691" upper_limit="-0.333"/>
                    <measurement group_id="O6" value="-0.881" lower_limit="-1.240" upper_limit="-0.522"/>
                    <measurement group_id="O7" value="-0.731" lower_limit="-0.968" upper_limit="-0.495"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.1830</p_value>
            <p_value_desc>Threshold for significance at 0.05 level.</p_value_desc>
            <method>MMRM</method>
            <param_type>Least Square Mean Difference</param_type>
            <param_value>-0.241</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.596</ci_lower_limit>
            <ci_upper_limit>0.114</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.1618</p_value>
            <p_value_desc>Threshold for significance at 0.05 level.</p_value_desc>
            <method>MMRM</method>
            <param_type>Least Square Mean Difference</param_type>
            <param_value>-0.313</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.751</ci_lower_limit>
            <ci_upper_limit>0.126</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.2519</p_value>
            <p_value_desc>Threshold for significance at 0.05 level.</p_value_desc>
            <method>MMRM</method>
            <param_type>Least Square Mean Difference</param_type>
            <param_value>-0.260</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.706</ci_lower_limit>
            <ci_upper_limit>0.186</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.4044</p_value>
            <p_value_desc>Threshold for significance at 0.05 level.</p_value_desc>
            <method>MMRM</method>
            <param_type>Least Square Mean Difference</param_type>
            <param_value>0.232</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.316</ci_lower_limit>
            <ci_upper_limit>0.781</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.4348</p_value>
            <p_value_desc>Threshold for significance at 0.05 level.</p_value_desc>
            <method>MMRM</method>
            <param_type>Least Square Mean Difference</param_type>
            <param_value>-0.280</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.986</ci_lower_limit>
            <ci_upper_limit>0.426</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O6</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.4786</p_value>
            <p_value_desc>Threshold for significance at 0.05 level.</p_value_desc>
            <method>MMRM</method>
            <param_type>Least Square Mean Difference</param_type>
            <param_value>-0.150</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.565</ci_lower_limit>
            <ci_upper_limit>0.266</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Hsu 5-point Likert Bother Scale at Week 12</title>
        <description>The Hsu 5-point Likert Bother scale is a questionnaire designed to assess the subjective bothersomeness and functional disruptiveness of nocturia. The Hsu 5 point Likert Bother Scale was scored from 0 (not at all) to 4 (extremely).&#xD;
Change from baseline in visit-specific Hsu Bother is presented in this endpoint.&#xD;
Level estimated for baseline value of Hsu Bother equal to 3 is presented in this endpoint.</description>
        <time_frame>Baseline, Week 12</time_frame>
        <population>The ITT-RT comprised of all the subjects randomized at Visit 4.</population>
        <group_list>
          <group group_id="O1">
            <title>FE 201836 500 ug (Randomized Treatment Period)</title>
            <description>FE 201836 500 µg oral solution and placebo ODT, administered once daily</description>
          </group>
          <group group_id="O2">
            <title>FE 201836 350 ug (Randomized Treatment Period)</title>
            <description>FE 201836 350 µg oral solution and placebo ODT, administered once daily</description>
          </group>
          <group group_id="O3">
            <title>FE 201836 250 ug (Randomized Treatment Period)</title>
            <description>FE 201836 250 µg oral solution and placebo ODT, administered once daily</description>
          </group>
          <group group_id="O4">
            <title>FE 201836 150 ug (Randomized Treatment Period)</title>
            <description>FE 201836 150 µg oral solution and placebo ODT, administered once daily</description>
          </group>
          <group group_id="O5">
            <title>FE 201836 100 ug (Randomized Treatment Period)</title>
            <description>FE 201836 100 µg oral solution and placebo ODT, administered once daily</description>
          </group>
          <group group_id="O6">
            <title>FE 201836 50 ug (Randomized Treatment Period)</title>
            <description>FE 201836 50 µg oral solution and placebo ODT, administered once daily</description>
          </group>
          <group group_id="O7">
            <title>Placebo (Randomized Treatment Period)</title>
            <description>Placebo oral solution and placebo ODT, administered once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Hsu 5-point Likert Bother Scale at Week 12</title>
          <description>The Hsu 5-point Likert Bother scale is a questionnaire designed to assess the subjective bothersomeness and functional disruptiveness of nocturia. The Hsu 5 point Likert Bother Scale was scored from 0 (not at all) to 4 (extremely).&#xD;
Change from baseline in visit-specific Hsu Bother is presented in this endpoint.&#xD;
Level estimated for baseline value of Hsu Bother equal to 3 is presented in this endpoint.</description>
          <population>The ITT-RT comprised of all the subjects randomized at Visit 4.</population>
          <units>score on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="45"/>
                <count group_id="O2" value="22"/>
                <count group_id="O3" value="21"/>
                <count group_id="O4" value="14"/>
                <count group_id="O5" value="8"/>
                <count group_id="O6" value="28"/>
                <count group_id="O7" value="67"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.992" lower_limit="-1.306" upper_limit="-0.679"/>
                    <measurement group_id="O2" value="-1.249" lower_limit="-1.663" upper_limit="-0.834"/>
                    <measurement group_id="O3" value="-0.700" lower_limit="-1.132" upper_limit="-0.267"/>
                    <measurement group_id="O4" value="-0.880" lower_limit="-1.416" upper_limit="-0.343"/>
                    <measurement group_id="O5" value="-0.974" lower_limit="-1.676" upper_limit="-0.272"/>
                    <measurement group_id="O6" value="-0.921" lower_limit="-1.303" upper_limit="-0.540"/>
                    <measurement group_id="O7" value="-0.769" lower_limit="-1.027" upper_limit="-0.511"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.2412</p_value>
            <p_value_desc>Threshold for significance at 0.05 level.</p_value_desc>
            <method>MMRM</method>
            <param_type>Least Square Mean Difference</param_type>
            <param_value>-0.223</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.598</ci_lower_limit>
            <ci_upper_limit>0.151</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0501</p_value>
            <p_value_desc>Threshold for significance at 0.05 level.</p_value_desc>
            <method>MMRM</method>
            <param_type>Least Square Mean Difference</param_type>
            <param_value>-0.480</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.959</ci_lower_limit>
            <ci_upper_limit>0.000</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.7788</p_value>
            <p_value_desc>Threshold for significance at 0.05 level.</p_value_desc>
            <method>MMRM</method>
            <param_type>Least Square Mean Difference</param_type>
            <param_value>0.069</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.417</ci_lower_limit>
            <ci_upper_limit>0.556</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.7111</p_value>
            <p_value_desc>Threshold for significance at 0.05 level.</p_value_desc>
            <method>MMRM</method>
            <param_type>Least Square Mean Difference</param_type>
            <param_value>-0.111</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.698</ci_lower_limit>
            <ci_upper_limit>0.477</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.5816</p_value>
            <p_value_desc>Threshold for significance at 0.05 level.</p_value_desc>
            <method>MMRM</method>
            <param_type>Least Square Mean Difference</param_type>
            <param_value>-0.205</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.937</ci_lower_limit>
            <ci_upper_limit>0.527</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O6</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.4981</p_value>
            <p_value_desc>Threshold for significance at 0.05 level.</p_value_desc>
            <method>MMRM</method>
            <param_type>Least Square Mean Difference</param_type>
            <param_value>-0.152</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.595</ci_lower_limit>
            <ci_upper_limit>0.290</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in ISI at Week 4</title>
        <description>The ISI is a 7-item questionnaire which comprises of four 'sleep-related' items and three 'wake-related' items. Each item is rated on a 0-4 scale and the total score ranges from 0 to 28 (higher score suggests more severe insomnia).&#xD;
Change from baseline in visit-specific ISI is presented in this endpoint.&#xD;
Level estimated for baseline value of ISI equal to 15 is presented in this endpoint.</description>
        <time_frame>Baseline, Week 4</time_frame>
        <population>The ITT-RT comprised of all the subjects randomized at Visit 4.</population>
        <group_list>
          <group group_id="O1">
            <title>FE 201836 500 ug (Randomized Treatment Period)</title>
            <description>FE 201836 500 µg oral solution and placebo ODT, administered once daily</description>
          </group>
          <group group_id="O2">
            <title>FE 201836 350 ug (Randomized Treatment Period)</title>
            <description>FE 201836 350 µg oral solution and placebo ODT, administered once daily</description>
          </group>
          <group group_id="O3">
            <title>FE 201836 250 ug (Randomized Treatment Period)</title>
            <description>FE 201836 250 µg oral solution and placebo ODT, administered once daily</description>
          </group>
          <group group_id="O4">
            <title>FE 201836 150 ug (Randomized Treatment Period)</title>
            <description>FE 201836 150 µg oral solution and placebo ODT, administered once daily</description>
          </group>
          <group group_id="O5">
            <title>FE 201836 100 ug (Randomized Treatment Period)</title>
            <description>FE 201836 100 µg oral solution and placebo ODT, administered once daily</description>
          </group>
          <group group_id="O6">
            <title>FE 201836 50 ug (Randomized Treatment Period)</title>
            <description>FE 201836 50 µg oral solution and placebo ODT, administered once daily</description>
          </group>
          <group group_id="O7">
            <title>Placebo (Randomized Treatment Period)</title>
            <description>Placebo oral solution and placebo ODT, administered once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in ISI at Week 4</title>
          <description>The ISI is a 7-item questionnaire which comprises of four 'sleep-related' items and three 'wake-related' items. Each item is rated on a 0-4 scale and the total score ranges from 0 to 28 (higher score suggests more severe insomnia).&#xD;
Change from baseline in visit-specific ISI is presented in this endpoint.&#xD;
Level estimated for baseline value of ISI equal to 15 is presented in this endpoint.</description>
          <population>The ITT-RT comprised of all the subjects randomized at Visit 4.</population>
          <units>score on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="47"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="22"/>
                <count group_id="O4" value="13"/>
                <count group_id="O5" value="8"/>
                <count group_id="O6" value="27"/>
                <count group_id="O7" value="68"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.589" lower_limit="-8.046" upper_limit="-5.133"/>
                    <measurement group_id="O2" value="-6.652" lower_limit="-8.689" upper_limit="-4.616"/>
                    <measurement group_id="O3" value="-5.630" lower_limit="-7.772" upper_limit="-3.487"/>
                    <measurement group_id="O4" value="-5.428" lower_limit="-8.200" upper_limit="-2.656"/>
                    <measurement group_id="O5" value="-4.510" lower_limit="-7.996" upper_limit="-1.023"/>
                    <measurement group_id="O6" value="-6.372" lower_limit="-8.291" upper_limit="-4.452"/>
                    <measurement group_id="O7" value="-5.277" lower_limit="-6.493" upper_limit="-4.061"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.1733</p_value>
            <p_value_desc>Threshold for significance at 0.05 level.</p_value_desc>
            <method>MMRM</method>
            <param_type>Least Square Mean Difference</param_type>
            <param_value>-1.313</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.207</ci_lower_limit>
            <ci_upper_limit>0.582</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.2538</p_value>
            <p_value_desc>Threshold for significance at 0.05 level.</p_value_desc>
            <method>MMRM</method>
            <param_type>Least Square Mean Difference</param_type>
            <param_value>-1.375</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.745</ci_lower_limit>
            <ci_upper_limit>0.994</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.7782</p_value>
            <p_value_desc>Threshold for significance at 0.05 level.</p_value_desc>
            <method>MMRM</method>
            <param_type>Least Square Mean Difference</param_type>
            <param_value>-0.353</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.818</ci_lower_limit>
            <ci_upper_limit>2.113</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.9218</p_value>
            <p_value_desc>Threshold for significance at 0.05 level.</p_value_desc>
            <method>MMRM</method>
            <param_type>Least Square Mean Difference</param_type>
            <param_value>-0.151</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.182</ci_lower_limit>
            <ci_upper_limit>2.880</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.6823</p_value>
            <p_value_desc>Threshold for significance at 0.05 level.</p_value_desc>
            <method>MMRM</method>
            <param_type>Least Square Mean Difference</param_type>
            <param_value>0.767</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.923</ci_lower_limit>
            <ci_upper_limit>4.457</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O6</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.3436</p_value>
            <p_value_desc>Threshold for significance at 0.05 level.</p_value_desc>
            <method>MMRM</method>
            <param_type>Least Square Mean Difference</param_type>
            <param_value>-1.095</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.369</ci_lower_limit>
            <ci_upper_limit>1.179</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in ISI at Week 8</title>
        <description>The ISI is a 7-item questionnaire which comprises of four 'sleep-related' items and three 'wake-related' items. Each item is rated on a 0-4 scale and the total score ranges from 0 to 28 (higher score suggests more severe insomnia).&#xD;
Change from baseline in visit-specific ISI is presented in this endpoint.&#xD;
Level estimated for baseline value of ISI equal to 15 is presented in this endpoint.</description>
        <time_frame>Baseline, Week 8</time_frame>
        <population>The ITT-RT comprised of all the subjects randomized at Visit 4.</population>
        <group_list>
          <group group_id="O1">
            <title>FE 201836 500 ug (Randomized Treatment Period)</title>
            <description>FE 201836 500 µg oral solution and placebo ODT, administered once daily</description>
          </group>
          <group group_id="O2">
            <title>FE 201836 350 ug (Randomized Treatment Period)</title>
            <description>FE 201836 350 µg oral solution and placebo ODT, administered once daily</description>
          </group>
          <group group_id="O3">
            <title>FE 201836 250 ug (Randomized Treatment Period)</title>
            <description>FE 201836 250 µg oral solution and placebo ODT, administered once daily</description>
          </group>
          <group group_id="O4">
            <title>FE 201836 150 ug (Randomized Treatment Period)</title>
            <description>FE 201836 150 µg oral solution and placebo ODT, administered once daily</description>
          </group>
          <group group_id="O5">
            <title>FE 201836 100 ug (Randomized Treatment Period)</title>
            <description>FE 201836 100 µg oral solution and placebo ODT, administered once daily</description>
          </group>
          <group group_id="O6">
            <title>FE 201836 50 ug (Randomized Treatment Period)</title>
            <description>FE 201836 50 µg oral solution and placebo ODT, administered once daily</description>
          </group>
          <group group_id="O7">
            <title>Placebo (Randomized Treatment Period)</title>
            <description>Placebo oral solution and placebo ODT, administered once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in ISI at Week 8</title>
          <description>The ISI is a 7-item questionnaire which comprises of four 'sleep-related' items and three 'wake-related' items. Each item is rated on a 0-4 scale and the total score ranges from 0 to 28 (higher score suggests more severe insomnia).&#xD;
Change from baseline in visit-specific ISI is presented in this endpoint.&#xD;
Level estimated for baseline value of ISI equal to 15 is presented in this endpoint.</description>
          <population>The ITT-RT comprised of all the subjects randomized at Visit 4.</population>
          <units>score on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="23"/>
                <count group_id="O4" value="14"/>
                <count group_id="O5" value="7"/>
                <count group_id="O6" value="28"/>
                <count group_id="O7" value="71"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.643" lower_limit="-9.140" upper_limit="-6.147"/>
                    <measurement group_id="O2" value="-8.091" lower_limit="-10.116" upper_limit="-6.067"/>
                    <measurement group_id="O3" value="-6.693" lower_limit="-8.799" upper_limit="-4.588"/>
                    <measurement group_id="O4" value="-6.959" lower_limit="-9.668" upper_limit="-4.250"/>
                    <measurement group_id="O5" value="-5.707" lower_limit="-9.283" upper_limit="-2.131"/>
                    <measurement group_id="O6" value="-7.167" lower_limit="-9.055" upper_limit="-5.280"/>
                    <measurement group_id="O7" value="-6.408" lower_limit="-7.603" upper_limit="-5.213"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.2042</p_value>
            <p_value_desc>Threshold for significance at 0.05 level.</p_value_desc>
            <method>MMRM</method>
            <param_type>Least Square Mean Difference</param_type>
            <param_value>-1.235</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.146</ci_lower_limit>
            <ci_upper_limit>0.676</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.1591</p_value>
            <p_value_desc>Threshold for significance at 0.05 level.</p_value_desc>
            <method>MMRM</method>
            <param_type>Least Square Mean Difference</param_type>
            <param_value>-1.683</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.031</ci_lower_limit>
            <ci_upper_limit>0.665</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.8168</p_value>
            <p_value_desc>Threshold for significance at 0.05 level.</p_value_desc>
            <method>MMRM</method>
            <param_type>Least Square Mean Difference</param_type>
            <param_value>-0.285</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.708</ci_lower_limit>
            <ci_upper_limit>2.138</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.7148</p_value>
            <p_value_desc>Threshold for significance at 0.05 level.</p_value_desc>
            <method>MMRM</method>
            <param_type>Least Square Mean Difference</param_type>
            <param_value>-0.551</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.517</ci_lower_limit>
            <ci_upper_limit>2.416</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.7141</p_value>
            <p_value_desc>Threshold for significance at 0.05 level.</p_value_desc>
            <method>MMRM</method>
            <param_type>Least Square Mean Difference</param_type>
            <param_value>0.701</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.066</ci_lower_limit>
            <ci_upper_limit>4.468</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O6</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.5041</p_value>
            <p_value_desc>Threshold for significance at 0.05 level.</p_value_desc>
            <method>MMRM</method>
            <param_type>Least Square Mean Difference</param_type>
            <param_value>-0.759</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.995</ci_lower_limit>
            <ci_upper_limit>1.477</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in ISI at Week 12</title>
        <description>The ISI is a 7-item questionnaire which comprises of four 'sleep-related' items and three 'wake-related' items. Each item is rated on a 0-4 scale and the total score ranges from 0 to 28 (higher score suggests more severe insomnia).&#xD;
Change from baseline in visit-specific ISI is presented in this endpoint.&#xD;
Level estimated for baseline value of ISI equal to 15 is presented in this endpoint.</description>
        <time_frame>Baseline, Week 12</time_frame>
        <population>The ITT-RT comprised of all the subjects randomized at Visit 4.</population>
        <group_list>
          <group group_id="O1">
            <title>FE 201836 500 ug (Randomized Treatment Period)</title>
            <description>FE 201836 500 µg oral solution and placebo ODT, administered once daily</description>
          </group>
          <group group_id="O2">
            <title>FE 201836 350 ug (Randomized Treatment Period)</title>
            <description>FE 201836 350 µg oral solution and placebo ODT, administered once daily</description>
          </group>
          <group group_id="O3">
            <title>FE 201836 250 ug (Randomized Treatment Period)</title>
            <description>FE 201836 250 µg oral solution and placebo ODT, administered once daily</description>
          </group>
          <group group_id="O4">
            <title>FE 201836 150 ug (Randomized Treatment Period)</title>
            <description>FE 201836 150 µg oral solution and placebo ODT, administered once daily</description>
          </group>
          <group group_id="O5">
            <title>FE 201836 100 ug (Randomized Treatment Period)</title>
            <description>FE 201836 100 µg oral solution and placebo ODT, administered once daily</description>
          </group>
          <group group_id="O6">
            <title>FE 201836 50 ug (Randomized Treatment Period)</title>
            <description>FE 201836 50 µg oral solution and placebo ODT, administered once daily</description>
          </group>
          <group group_id="O7">
            <title>Placebo (Randomized Treatment Period)</title>
            <description>Placebo oral solution and placebo ODT, administered once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in ISI at Week 12</title>
          <description>The ISI is a 7-item questionnaire which comprises of four 'sleep-related' items and three 'wake-related' items. Each item is rated on a 0-4 scale and the total score ranges from 0 to 28 (higher score suggests more severe insomnia).&#xD;
Change from baseline in visit-specific ISI is presented in this endpoint.&#xD;
Level estimated for baseline value of ISI equal to 15 is presented in this endpoint.</description>
          <population>The ITT-RT comprised of all the subjects randomized at Visit 4.</population>
          <units>score on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="45"/>
                <count group_id="O2" value="22"/>
                <count group_id="O3" value="21"/>
                <count group_id="O4" value="14"/>
                <count group_id="O5" value="8"/>
                <count group_id="O6" value="27"/>
                <count group_id="O7" value="67"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.807" lower_limit="-9.427" upper_limit="-6.188"/>
                    <measurement group_id="O2" value="-9.329" lower_limit="-11.619" upper_limit="-7.040"/>
                    <measurement group_id="O3" value="-6.355" lower_limit="-8.733" upper_limit="-3.977"/>
                    <measurement group_id="O4" value="-6.193" lower_limit="-9.195" upper_limit="-3.191"/>
                    <measurement group_id="O5" value="-5.002" lower_limit="-8.865" upper_limit="-1.138"/>
                    <measurement group_id="O6" value="-7.908" lower_limit="-10.016" upper_limit="-5.800"/>
                    <measurement group_id="O7" value="-6.678" lower_limit="-8.018" upper_limit="-5.338"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.2896</p_value>
            <p_value_desc>Threshold for significance at 0.05 level.</p_value_desc>
            <method>MMRM</method>
            <param_type>Least Square Mean Difference</param_type>
            <param_value>-1.129</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.226</ci_lower_limit>
            <ci_upper_limit>0.967</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0498</p_value>
            <p_value_desc>Threshold for significance at 0.05 level.</p_value_desc>
            <method>MMRM</method>
            <param_type>Least Square Mean Difference</param_type>
            <param_value>-2.652</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-5.301</ci_lower_limit>
            <ci_upper_limit>-0.003</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.8159</p_value>
            <p_value_desc>Threshold for significance at 0.05 level.</p_value_desc>
            <method>MMRM</method>
            <param_type>Least Square Mean Difference</param_type>
            <param_value>0.323</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.409</ci_lower_limit>
            <ci_upper_limit>3.055</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.7719</p_value>
            <p_value_desc>Threshold for significance at 0.05 level.</p_value_desc>
            <method>MMRM</method>
            <param_type>Least Square Mean Difference</param_type>
            <param_value>0.485</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.809</ci_lower_limit>
            <ci_upper_limit>3.779</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.4193</p_value>
            <p_value_desc>Threshold for significance at 0.05 level.</p_value_desc>
            <method>MMRM</method>
            <param_type>Least Square Mean Difference</param_type>
            <param_value>1.676</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.407</ci_lower_limit>
            <ci_upper_limit>5.760</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O6</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.3333</p_value>
            <p_value_desc>Threshold for significance at 0.05 level.</p_value_desc>
            <method>MMRM</method>
            <param_type>Least Square Mean Difference</param_type>
            <param_value>-1.230</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.730</ci_lower_limit>
            <ci_upper_limit>1.270</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Mean Duration of First Undisturbed Sleep Period (FUSP) at Week 1</title>
        <description>The FUSP is defined as the time in minutes from the time of going to bed to the time of first nocturnal void, or time of awakening if no void occured.&#xD;
The duration of FUSP at each visit was calculated as the average over the 3 consecutive 24-hour periods just prior to the respective visit. Adjusted visit-specific mean changes from baseline in FUSP are estimated using a baseline value of 180 (min).</description>
        <time_frame>Baseline, Week 1</time_frame>
        <population>The ITT-RT comprised of all the subjects randomized at Visit 4.</population>
        <group_list>
          <group group_id="O1">
            <title>FE 201836 500 ug (Randomized Treatment Period)</title>
            <description>FE 201836 500 µg oral solution and placebo ODT, administered once daily</description>
          </group>
          <group group_id="O2">
            <title>FE 201836 350 ug (Randomized Treatment Period)</title>
            <description>FE 201836 350 µg oral solution and placebo ODT, administered once daily</description>
          </group>
          <group group_id="O3">
            <title>FE 201836 250 ug (Randomized Treatment Period)</title>
            <description>FE 201836 250 µg oral solution and placebo ODT, administered once daily</description>
          </group>
          <group group_id="O4">
            <title>FE 201836 150 ug (Randomized Treatment Period)</title>
            <description>FE 201836 150 µg oral solution and placebo ODT, administered once daily</description>
          </group>
          <group group_id="O5">
            <title>FE 201836 100 ug (Randomized Treatment Period)</title>
            <description>FE 201836 100 µg oral solution and placebo ODT, administered once daily</description>
          </group>
          <group group_id="O6">
            <title>FE 201836 50 ug (Randomized Treatment Period)</title>
            <description>FE 201836 50 µg oral solution and placebo ODT, administered once daily</description>
          </group>
          <group group_id="O7">
            <title>Placebo (Randomized Treatment Period)</title>
            <description>Placebo oral solution and placebo ODT, administered once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Mean Duration of First Undisturbed Sleep Period (FUSP) at Week 1</title>
          <description>The FUSP is defined as the time in minutes from the time of going to bed to the time of first nocturnal void, or time of awakening if no void occured.&#xD;
The duration of FUSP at each visit was calculated as the average over the 3 consecutive 24-hour periods just prior to the respective visit. Adjusted visit-specific mean changes from baseline in FUSP are estimated using a baseline value of 180 (min).</description>
          <population>The ITT-RT comprised of all the subjects randomized at Visit 4.</population>
          <units>minutes</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="54"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="24"/>
                <count group_id="O4" value="14"/>
                <count group_id="O5" value="11"/>
                <count group_id="O6" value="33"/>
                <count group_id="O7" value="80"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="122.9" lower_limit="86.2" upper_limit="159.7"/>
                    <measurement group_id="O2" value="187.0" lower_limit="132.3" upper_limit="241.7"/>
                    <measurement group_id="O3" value="106.0" lower_limit="49.6" upper_limit="162.4"/>
                    <measurement group_id="O4" value="91.7" lower_limit="18.7" upper_limit="164.8"/>
                    <measurement group_id="O5" value="82.9" lower_limit="2.5" upper_limit="163.4"/>
                    <measurement group_id="O6" value="51.3" lower_limit="3.9" upper_limit="98.7"/>
                    <measurement group_id="O7" value="81.1" lower_limit="50.8" upper_limit="111.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0853</p_value>
            <p_value_desc>Threshold for significance at 0.05 level.</p_value_desc>
            <method>MMRM</method>
            <param_type>Mean Difference</param_type>
            <param_value>41.8</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-5.9</ci_lower_limit>
            <ci_upper_limit>89.6</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0010</p_value>
            <p_value_desc>Threshold for significance at 0.05 level.</p_value_desc>
            <method>MMRM</method>
            <param_type>Mean Difference</param_type>
            <param_value>105.9</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>43.4</ci_lower_limit>
            <ci_upper_limit>168.4</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.4418</p_value>
            <p_value_desc>Threshold for significance at 0.05 level.</p_value_desc>
            <method>MMRM</method>
            <param_type>Mean Difference</param_type>
            <param_value>24.9</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-38.8</ci_lower_limit>
            <ci_upper_limit>88.6</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.7902</p_value>
            <p_value_desc>Threshold for significance at 0.05 level.</p_value_desc>
            <method>MMRM</method>
            <param_type>Mean Difference</param_type>
            <param_value>10.7</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-68.2</ci_lower_limit>
            <ci_upper_limit>89.6</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.9664</p_value>
            <p_value_desc>Threshold for significance at 0.05 level.</p_value_desc>
            <method>MMRM</method>
            <param_type>Mean Difference</param_type>
            <param_value>1.8</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-84.2</ci_lower_limit>
            <ci_upper_limit>87.9</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O6</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.2977</p_value>
            <p_value_desc>Threshold for significance at 0.05 level.</p_value_desc>
            <method>MMRM</method>
            <param_type>Mean Difference</param_type>
            <param_value>-29.8</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-85.9</ci_lower_limit>
            <ci_upper_limit>26.4</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Mean Duration of FUSP at Week 4</title>
        <description>The FUSP is defined as the time in minutes from the time of going to bed to the time of first nocturnal void, or time of awakening if no void occurred.&#xD;
The duration of FUSP at each visit was calculated as the average over the 3 consecutive 24-hour periods just prior to the respective visit. Adjusted visit-specific mean changes from baseline in FUSP are estimated using a baseline value of 180 (min).</description>
        <time_frame>Baseline, Week 4</time_frame>
        <population>The ITT-RT comprised of all the subjects randomized at Visit 4.</population>
        <group_list>
          <group group_id="O1">
            <title>FE 201836 500 ug (Randomized Treatment Period)</title>
            <description>FE 201836 500 µg oral solution and placebo ODT, administered once daily</description>
          </group>
          <group group_id="O2">
            <title>FE 201836 350 ug (Randomized Treatment Period)</title>
            <description>FE 201836 350 µg oral solution and placebo ODT, administered once daily</description>
          </group>
          <group group_id="O3">
            <title>FE 201836 250 ug (Randomized Treatment Period)</title>
            <description>FE 201836 250 µg oral solution and placebo ODT, administered once daily</description>
          </group>
          <group group_id="O4">
            <title>FE 201836 150 ug (Randomized Treatment Period)</title>
            <description>FE 201836 150 µg oral solution and placebo ODT, administered once daily</description>
          </group>
          <group group_id="O5">
            <title>FE 201836 100 ug (Randomized Treatment Period)</title>
            <description>FE 201836 100 µg oral solution and placebo ODT, administered once daily</description>
          </group>
          <group group_id="O6">
            <title>FE 201836 50 ug (Randomized Treatment Period)</title>
            <description>FE 201836 50 µg oral solution and placebo ODT, administered once daily</description>
          </group>
          <group group_id="O7">
            <title>Placebo (Randomized Treatment Period)</title>
            <description>Placebo oral solution and placebo ODT, administered once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Mean Duration of FUSP at Week 4</title>
          <description>The FUSP is defined as the time in minutes from the time of going to bed to the time of first nocturnal void, or time of awakening if no void occurred.&#xD;
The duration of FUSP at each visit was calculated as the average over the 3 consecutive 24-hour periods just prior to the respective visit. Adjusted visit-specific mean changes from baseline in FUSP are estimated using a baseline value of 180 (min).</description>
          <population>The ITT-RT comprised of all the subjects randomized at Visit 4.</population>
          <units>minutes</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
                <count group_id="O2" value="22"/>
                <count group_id="O3" value="21"/>
                <count group_id="O4" value="12"/>
                <count group_id="O5" value="12"/>
                <count group_id="O6" value="31"/>
                <count group_id="O7" value="76"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="164.5" lower_limit="127.9" upper_limit="201.0"/>
                    <measurement group_id="O2" value="211.0" lower_limit="156.3" upper_limit="265.7"/>
                    <measurement group_id="O3" value="132.3" lower_limit="75.2" upper_limit="189.4"/>
                    <measurement group_id="O4" value="89.5" lower_limit="15.1" upper_limit="163.9"/>
                    <measurement group_id="O5" value="122.0" lower_limit="46.8" upper_limit="197.3"/>
                    <measurement group_id="O6" value="95.5" lower_limit="48.6" upper_limit="142.5"/>
                    <measurement group_id="O7" value="150.2" lower_limit="120.4" upper_limit="180.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.5523</p_value>
            <p_value_desc>Threshold for significance at 0.05 level.</p_value_desc>
            <method>MMRM</method>
            <param_type>Mean Difference</param_type>
            <param_value>14.3</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-33.0</ci_lower_limit>
            <ci_upper_limit>61.5</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0556</p_value>
            <p_value_desc>Threshold for significance at 0.05 level.</p_value_desc>
            <method>MMRM</method>
            <param_type>Mean Difference</param_type>
            <param_value>60.8</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.5</ci_lower_limit>
            <ci_upper_limit>123.0</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.5837</p_value>
            <p_value_desc>Threshold for significance at 0.05 level.</p_value_desc>
            <method>MMRM</method>
            <param_type>Mean Difference</param_type>
            <param_value>-17.9</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-82.0</ci_lower_limit>
            <ci_upper_limit>46.3</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.1363</p_value>
            <p_value_desc>Threshold for significance at 0.05 level.</p_value_desc>
            <method>MMRM</method>
            <param_type>Mean Difference</param_type>
            <param_value>-60.7</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-140.7</ci_lower_limit>
            <ci_upper_limit>19.3</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.4938</p_value>
            <p_value_desc>Threshold for significance at 0.05 level.</p_value_desc>
            <method>MMRM</method>
            <param_type>Mean Difference</param_type>
            <param_value>-28.2</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-109.1</ci_lower_limit>
            <ci_upper_limit>52.8</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O6</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0535</p_value>
            <p_value_desc>Threshold for significance at 0.05 level.</p_value_desc>
            <method>MMRM</method>
            <param_type>Mean Difference</param_type>
            <param_value>-54.7</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-110.2</ci_lower_limit>
            <ci_upper_limit>0.8</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Mean Duration of FUSP at Week 8</title>
        <description>The FUSP is defined as the time in minutes from the time of going to bed to the time of first nocturnal void, or time of awakening if no void occurred.&#xD;
The duration of FUSP at each visit was calculated as the average over the 3 consecutive 24-hour periods just prior to the respective visit. Adjusted visit-specific mean changes from baseline in FUSP are estimated using a baseline value of 180 (min).</description>
        <time_frame>Baseline, Week 8</time_frame>
        <population>The ITT-RT comprised of all the subjects randomized at Visit 4.</population>
        <group_list>
          <group group_id="O1">
            <title>FE 201836 500 ug (Randomized Treatment Period)</title>
            <description>FE 201836 500 µg oral solution and placebo ODT, administered once daily</description>
          </group>
          <group group_id="O2">
            <title>FE 201836 350 ug (Randomized Treatment Period)</title>
            <description>FE 201836 350 µg oral solution and placebo ODT, administered once daily</description>
          </group>
          <group group_id="O3">
            <title>FE 201836 250 ug (Randomized Treatment Period)</title>
            <description>FE 201836 250 µg oral solution and placebo ODT, administered once daily</description>
          </group>
          <group group_id="O4">
            <title>FE 201836 150 ug (Randomized Treatment Period)</title>
            <description>FE 201836 150 µg oral solution and placebo ODT, administered once daily</description>
          </group>
          <group group_id="O5">
            <title>FE 201836 100 ug (Randomized Treatment Period)</title>
            <description>FE 201836 100 µg oral solution and placebo ODT, administered once daily</description>
          </group>
          <group group_id="O6">
            <title>FE 201836 50 ug (Randomized Treatment Period)</title>
            <description>FE 201836 50 µg oral solution and placebo ODT, administered once daily</description>
          </group>
          <group group_id="O7">
            <title>Placebo (Randomized Treatment Period)</title>
            <description>Placebo oral solution and placebo ODT, administered once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Mean Duration of FUSP at Week 8</title>
          <description>The FUSP is defined as the time in minutes from the time of going to bed to the time of first nocturnal void, or time of awakening if no void occurred.&#xD;
The duration of FUSP at each visit was calculated as the average over the 3 consecutive 24-hour periods just prior to the respective visit. Adjusted visit-specific mean changes from baseline in FUSP are estimated using a baseline value of 180 (min).</description>
          <population>The ITT-RT comprised of all the subjects randomized at Visit 4.</population>
          <units>minutes</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="44"/>
                <count group_id="O2" value="23"/>
                <count group_id="O3" value="21"/>
                <count group_id="O4" value="14"/>
                <count group_id="O5" value="12"/>
                <count group_id="O6" value="30"/>
                <count group_id="O7" value="70"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="160.4" lower_limit="112.4" upper_limit="208.3"/>
                    <measurement group_id="O2" value="225.4" lower_limit="157.9" upper_limit="293.0"/>
                    <measurement group_id="O3" value="190.2" lower_limit="118.9" upper_limit="261.6"/>
                    <measurement group_id="O4" value="136.8" lower_limit="48.3" upper_limit="225.4"/>
                    <measurement group_id="O5" value="163.2" lower_limit="68.7" upper_limit="257.8"/>
                    <measurement group_id="O6" value="164.3" lower_limit="104.9" upper_limit="223.7"/>
                    <measurement group_id="O7" value="161.0" lower_limit="122.6" upper_limit="199.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.9829</p_value>
            <p_value_desc>Threshold for significance at 0.05 level.</p_value_desc>
            <method>MMRM</method>
            <param_type>Mean Difference</param_type>
            <param_value>-0.7</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-62.2</ci_lower_limit>
            <ci_upper_limit>60.9</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.1038</p_value>
            <p_value_desc>Threshold for significance at 0.05 level.</p_value_desc>
            <method>MMRM</method>
            <param_type>Mean Difference</param_type>
            <param_value>64.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-13.3</ci_lower_limit>
            <ci_upper_limit>142.1</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.4764</p_value>
            <p_value_desc>Threshold for significance at 0.05 level.</p_value_desc>
            <method>MMRM</method>
            <param_type>Mean Difference</param_type>
            <param_value>29.2</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-51.4</ci_lower_limit>
            <ci_upper_limit>109.8</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.6204</p_value>
            <p_value_desc>Threshold for significance at 0.05 level.</p_value_desc>
            <method>MMRM</method>
            <param_type>Mean Difference</param_type>
            <param_value>-24.2</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-120.5</ci_lower_limit>
            <ci_upper_limit>72.0</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.9660</p_value>
            <p_value_desc>Threshold for significance at 0.05 level.</p_value_desc>
            <method>MMRM</method>
            <param_type>Mean Difference</param_type>
            <param_value>2.2</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-100.1</ci_lower_limit>
            <ci_upper_limit>104.6</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O6</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.9275</p_value>
            <p_value_desc>Threshold for significance at 0.05 level.</p_value_desc>
            <method>MMRM</method>
            <param_type>Mean Difference</param_type>
            <param_value>3.3</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-67.4</ci_lower_limit>
            <ci_upper_limit>73.9</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Mean Duration of FUSP at Week 12</title>
        <description>The FUSP is defined as the time in minutes from the time of going to bed to the time of first nocturnal void, or time of awakening if no void occurred.&#xD;
The duration of FUSP at each visit was calculated as the average over the 3 consecutive 24-hour periods just prior to the respective visit. Adjusted visit-specific mean changes from baseline in FUSP are estimated using a baseline value of 180 (min).</description>
        <time_frame>Baseline, Week 12</time_frame>
        <population>The ITT-RT comprised of all the subjects randomized at Visit 4.</population>
        <group_list>
          <group group_id="O1">
            <title>FE 201836 500 ug (Randomized Treatment Period)</title>
            <description>FE 201836 500 µg oral solution and placebo ODT, administered once daily</description>
          </group>
          <group group_id="O2">
            <title>FE 201836 350 ug (Randomized Treatment Period)</title>
            <description>FE 201836 350 µg oral solution and placebo ODT, administered once daily</description>
          </group>
          <group group_id="O3">
            <title>FE 201836 250 ug (Randomized Treatment Period)</title>
            <description>FE 201836 250 µg oral solution and placebo ODT, administered once daily</description>
          </group>
          <group group_id="O4">
            <title>FE 201836 150 ug (Randomized Treatment Period)</title>
            <description>FE 201836 150 µg oral solution and placebo ODT, administered once daily</description>
          </group>
          <group group_id="O5">
            <title>FE 201836 100 ug (Randomized Treatment Period)</title>
            <description>FE 201836 100 µg oral solution and placebo ODT, administered once daily</description>
          </group>
          <group group_id="O6">
            <title>FE 201836 50 ug (Randomized Treatment Period)</title>
            <description>FE 201836 50 µg oral solution and placebo ODT, administered once daily</description>
          </group>
          <group group_id="O7">
            <title>Placebo (Randomized Treatment Period)</title>
            <description>Placebo oral solution and placebo ODT, administered once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Mean Duration of FUSP at Week 12</title>
          <description>The FUSP is defined as the time in minutes from the time of going to bed to the time of first nocturnal void, or time of awakening if no void occurred.&#xD;
The duration of FUSP at each visit was calculated as the average over the 3 consecutive 24-hour periods just prior to the respective visit. Adjusted visit-specific mean changes from baseline in FUSP are estimated using a baseline value of 180 (min).</description>
          <population>The ITT-RT comprised of all the subjects randomized at Visit 4.</population>
          <units>minutes</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="19"/>
                <count group_id="O3" value="19"/>
                <count group_id="O4" value="14"/>
                <count group_id="O5" value="11"/>
                <count group_id="O6" value="29"/>
                <count group_id="O7" value="69"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="178.5" lower_limit="132.5" upper_limit="224.5"/>
                    <measurement group_id="O2" value="160.0" lower_limit="93.3" upper_limit="226.6"/>
                    <measurement group_id="O3" value="180.7" lower_limit="112.2" upper_limit="249.2"/>
                    <measurement group_id="O4" value="111.5" lower_limit="29.7" upper_limit="193.2"/>
                    <measurement group_id="O5" value="141.1" lower_limit="51.3" upper_limit="230.9"/>
                    <measurement group_id="O6" value="166.2" lower_limit="110.5" upper_limit="221.8"/>
                    <measurement group_id="O7" value="162.8" lower_limit="126.9" upper_limit="198.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.5964</p_value>
            <p_value_desc>Threshold for significance at 0.05 level.</p_value_desc>
            <method>MMRM</method>
            <param_type>Mean Difference</param_type>
            <param_value>15.7</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-42.7</ci_lower_limit>
            <ci_upper_limit>74.2</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.9418</p_value>
            <p_value_desc>Threshold for significance at 0.05 level.</p_value_desc>
            <method>MMRM</method>
            <param_type>Mean Difference</param_type>
            <param_value>-2.8</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-78.5</ci_lower_limit>
            <ci_upper_limit>72.9</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.6452</p_value>
            <p_value_desc>Threshold for significance at 0.05 level.</p_value_desc>
            <method>MMRM</method>
            <param_type>Mean Difference</param_type>
            <param_value>18.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-58.8</ci_lower_limit>
            <ci_upper_limit>94.7</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.2565</p_value>
            <p_value_desc>Threshold for significance at 0.05 level.</p_value_desc>
            <method>MMRM</method>
            <param_type>Mean Difference</param_type>
            <param_value>-51.3</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-140.2</ci_lower_limit>
            <ci_upper_limit>37.6</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.6605</p_value>
            <p_value_desc>Threshold for significance at 0.05 level.</p_value_desc>
            <method>MMRM</method>
            <param_type>Mean Difference</param_type>
            <param_value>-21.6</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-118.6</ci_lower_limit>
            <ci_upper_limit>75.4</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O6</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.9191</p_value>
            <p_value_desc>Threshold for significance at 0.05 level.</p_value_desc>
            <method>MMRM</method>
            <param_type>Mean Difference</param_type>
            <param_value>3.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-62.6</ci_lower_limit>
            <ci_upper_limit>69.4</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Aggregated Mean Duration of FUSP During 12 Weeks of Treatment</title>
        <description>The FUSP is defined as the time in minutes from the time of going to bed to the time of first nocturnal void, or time of awakening if no void occurred.&#xD;
The visit-specific means were aggregated into a mean of current and preceding visits.&#xD;
Level estimated for baseline value of mean duration of FUSP (minutes) equal to 180 is presented in this endpoint.&#xD;
The 95% credibility interval (2.5 and 97.5 percentiles of the posterior distribution) instead of confidence interval is presented for this endpoint.</description>
        <time_frame>Baseline, During 12 Weeks of Treatment</time_frame>
        <population>The ITT-RT comprised of all the subjects randomized at Visit 4.</population>
        <group_list>
          <group group_id="O1">
            <title>FE 201836 500 ug (Randomized Treatment Period)</title>
            <description>FE 201836 500 µg oral solution and placebo ODT, administered once daily</description>
          </group>
          <group group_id="O2">
            <title>FE 201836 350 ug (Randomized Treatment Period)</title>
            <description>FE 201836 350 µg oral solution and placebo ODT, administered once daily</description>
          </group>
          <group group_id="O3">
            <title>FE 201836 250 ug (Randomized Treatment Period)</title>
            <description>FE 201836 250 µg oral solution and placebo ODT, administered once daily</description>
          </group>
          <group group_id="O4">
            <title>FE 201836 150 ug (Randomized Treatment Period)</title>
            <description>FE 201836 150 µg oral solution and placebo ODT, administered once daily</description>
          </group>
          <group group_id="O5">
            <title>FE 201836 100 ug (Randomized Treatment Period)</title>
            <description>FE 201836 100 µg oral solution and placebo ODT, administered once daily</description>
          </group>
          <group group_id="O6">
            <title>FE 201836 50 ug (Randomized Treatment Period)</title>
            <description>FE 201836 50 µg oral solution and placebo ODT, administered once daily</description>
          </group>
          <group group_id="O7">
            <title>Placebo (Randomized Treatment Period)</title>
            <description>Placebo oral solution and placebo ODT, administered once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Aggregated Mean Duration of FUSP During 12 Weeks of Treatment</title>
          <description>The FUSP is defined as the time in minutes from the time of going to bed to the time of first nocturnal void, or time of awakening if no void occurred.&#xD;
The visit-specific means were aggregated into a mean of current and preceding visits.&#xD;
Level estimated for baseline value of mean duration of FUSP (minutes) equal to 180 is presented in this endpoint.&#xD;
The 95% credibility interval (2.5 and 97.5 percentiles of the posterior distribution) instead of confidence interval is presented for this endpoint.</description>
          <population>The ITT-RT comprised of all the subjects randomized at Visit 4.</population>
          <units>minutes</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="60"/>
                <count group_id="O2" value="27"/>
                <count group_id="O3" value="24"/>
                <count group_id="O4" value="14"/>
                <count group_id="O5" value="13"/>
                <count group_id="O6" value="34"/>
                <count group_id="O7" value="87"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="154.98" lower_limit="130.41" upper_limit="189.10"/>
                    <measurement group_id="O2" value="150.23" lower_limit="130.20" upper_limit="181.15"/>
                    <measurement group_id="O3" value="145.95" lower_limit="128.21" upper_limit="170.90"/>
                    <measurement group_id="O4" value="140.74" lower_limit="120.51" upper_limit="160.16"/>
                    <measurement group_id="O5" value="139.19" lower_limit="117.86" upper_limit="157.42"/>
                    <measurement group_id="O6" value="138.13" lower_limit="115.62" upper_limit="157.24"/>
                    <measurement group_id="O7" value="137.45" lower_limit="114.12" upper_limit="157.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <groups_desc>Based on a Bayesian analysis of a sigmoidal dose-response relationship.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Mean Difference</param_type>
            <param_value>17.52</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-6.19</ci_lower_limit>
            <ci_upper_limit>62.09</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <groups_desc>Based on a Bayesian analysis of a sigmoidal dose-response relationship.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Mean Difference</param_type>
            <param_value>12.78</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.73</ci_lower_limit>
            <ci_upper_limit>55.89</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <groups_desc>Based on a Bayesian analysis of a sigmoidal dose-response relationship.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Mean Difference</param_type>
            <param_value>8.50</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.14</ci_lower_limit>
            <ci_upper_limit>47.28</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <groups_desc>Based on a Bayesian analysis of a sigmoidal dose-response relationship.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Mean Difference</param_type>
            <param_value>3.29</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.01</ci_lower_limit>
            <ci_upper_limit>28.07</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <groups_desc>Based on a Bayesian analysis of a sigmoidal dose-response relationship.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Mean Difference</param_type>
            <param_value>1.74</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.00</ci_lower_limit>
            <ci_upper_limit>17.90</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O6</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <groups_desc>Based on a Bayesian analysis of a sigmoidal dose-response relationship.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Mean Difference</param_type>
            <param_value>0.68</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.00</ci_lower_limit>
            <ci_upper_limit>7.55</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Nocturnal Diuresis Rate Profiles at Week 1</title>
        <description>The nocturnal diuresis rate (mL/min) is calculated as the mean of the nocturnal diuresis for each of the three nights, with the single-night nocturnal diuresis calculated as the ratio of NUV to total time in bed.&#xD;
Change from baseline in visit-specific mean nocturnal diuresis (mL/min) is presented.&#xD;
Level estimated for baseline value of mean nocturnal diuresis (mL/min) equal to 1.3 is presented in this endpoint.</description>
        <time_frame>Baseline, Week 1</time_frame>
        <population>The ITT-RT comprised of all the subjects randomized at Visit 4.</population>
        <group_list>
          <group group_id="O1">
            <title>FE 201836 500 ug (Randomized Treatment Period)</title>
            <description>FE 201836 500 µg oral solution and placebo ODT, administered once daily</description>
          </group>
          <group group_id="O2">
            <title>FE 201836 350 ug (Randomized Treatment Period)</title>
            <description>FE 201836 350 µg oral solution and placebo ODT, administered once daily</description>
          </group>
          <group group_id="O3">
            <title>FE 201836 250 ug (Randomized Treatment Period)</title>
            <description>FE 201836 250 µg oral solution and placebo ODT, administered once daily</description>
          </group>
          <group group_id="O4">
            <title>FE 201836 150 ug (Randomized Treatment Period)</title>
            <description>FE 201836 150 µg oral solution and placebo ODT, administered once daily</description>
          </group>
          <group group_id="O5">
            <title>FE 201836 100 ug (Randomized Treatment Period)</title>
            <description>FE 201836 100 µg oral solution and placebo ODT, administered once daily</description>
          </group>
          <group group_id="O6">
            <title>FE 201836 50 ug (Randomized Treatment Period)</title>
            <description>FE 201836 50 µg oral solution and placebo ODT, administered once daily</description>
          </group>
          <group group_id="O7">
            <title>Placebo (Randomized Treatment Period)</title>
            <description>Placebo oral solution and placebo ODT, administered once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Nocturnal Diuresis Rate Profiles at Week 1</title>
          <description>The nocturnal diuresis rate (mL/min) is calculated as the mean of the nocturnal diuresis for each of the three nights, with the single-night nocturnal diuresis calculated as the ratio of NUV to total time in bed.&#xD;
Change from baseline in visit-specific mean nocturnal diuresis (mL/min) is presented.&#xD;
Level estimated for baseline value of mean nocturnal diuresis (mL/min) equal to 1.3 is presented in this endpoint.</description>
          <population>The ITT-RT comprised of all the subjects randomized at Visit 4.</population>
          <units>mL/min</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="53"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="24"/>
                <count group_id="O4" value="14"/>
                <count group_id="O5" value="11"/>
                <count group_id="O6" value="32"/>
                <count group_id="O7" value="78"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.575" lower_limit="-0.687" upper_limit="-0.463"/>
                    <measurement group_id="O2" value="-0.635" lower_limit="-0.801" upper_limit="-0.468"/>
                    <measurement group_id="O3" value="-0.610" lower_limit="-0.779" upper_limit="-0.440"/>
                    <measurement group_id="O4" value="-0.459" lower_limit="-0.678" upper_limit="-0.239"/>
                    <measurement group_id="O5" value="-0.523" lower_limit="-0.766" upper_limit="-0.280"/>
                    <measurement group_id="O6" value="-0.328" lower_limit="-0.474" upper_limit="-0.182"/>
                    <measurement group_id="O7" value="-0.402" lower_limit="-0.494" upper_limit="-0.310"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0196</p_value>
            <p_value_desc>Threshold for significance at 0.05 level.</p_value_desc>
            <method>MMRM</method>
            <param_type>Mean Difference</param_type>
            <param_value>-0.173</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.318</ci_lower_limit>
            <ci_upper_limit>-0.028</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0167</p_value>
            <p_value_desc>Threshold for significance at 0.05 level.</p_value_desc>
            <method>MMRM</method>
            <param_type>Mean Difference</param_type>
            <param_value>-0.233</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.423</ci_lower_limit>
            <ci_upper_limit>-0.043</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0352</p_value>
            <p_value_desc>Threshold for significance at 0.05 level.</p_value_desc>
            <method>MMRM</method>
            <param_type>Mean Difference</param_type>
            <param_value>-0.208</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.401</ci_lower_limit>
            <ci_upper_limit>-0.015</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.6402</p_value>
            <p_value_desc>Threshold for significance at 0.05 level.</p_value_desc>
            <method>MMRM</method>
            <param_type>Mean Difference</param_type>
            <param_value>-0.057</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.295</ci_lower_limit>
            <ci_upper_limit>0.182</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.3602</p_value>
            <p_value_desc>Threshold for significance at 0.05 level.</p_value_desc>
            <method>MMRM</method>
            <param_type>Mean Difference</param_type>
            <param_value>-0.121</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.381</ci_lower_limit>
            <ci_upper_limit>0.139</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O6</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.4018</p_value>
            <p_value_desc>Threshold for significance at 0.05 level.</p_value_desc>
            <method>MMRM</method>
            <param_type>Mean Difference</param_type>
            <param_value>0.074</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.099</ci_lower_limit>
            <ci_upper_limit>0.247</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Nocturnal Diuresis Rate Profiles at Week 12</title>
        <description>The nocturnal diuresis rate (mL/min) is calculated as the mean of the nocturnal diuresis for each of the three nights, with the single-night nocturnal diuresis calculated as the ratio of NUV to total time in bed.&#xD;
Change from baseline in visit-specific mean nocturnal diuresis (mL/min) is presented.&#xD;
Level estimated for baseline value of mean nocturnal diuresis (mL/min) equal to 1.3 is presented in this endpoint.</description>
        <time_frame>Baseline, Week 12</time_frame>
        <population>The ITT-RT comprised of all the subjects randomized at Visit 4.</population>
        <group_list>
          <group group_id="O1">
            <title>FE 201836 500 ug (Randomized Treatment Period)</title>
            <description>FE 201836 500 µg oral solution and placebo ODT, administered once daily</description>
          </group>
          <group group_id="O2">
            <title>FE 201836 350 ug (Randomized Treatment Period)</title>
            <description>FE 201836 350 µg oral solution and placebo ODT, administered once daily</description>
          </group>
          <group group_id="O3">
            <title>FE 201836 250 ug (Randomized Treatment Period)</title>
            <description>FE 201836 250 µg oral solution and placebo ODT, administered once daily</description>
          </group>
          <group group_id="O4">
            <title>FE 201836 150 ug (Randomized Treatment Period)</title>
            <description>FE 201836 150 µg oral solution and placebo ODT, administered once daily</description>
          </group>
          <group group_id="O5">
            <title>FE 201836 100 ug (Randomized Treatment Period)</title>
            <description>FE 201836 100 µg oral solution and placebo ODT, administered once daily</description>
          </group>
          <group group_id="O6">
            <title>FE 201836 50 ug (Randomized Treatment Period)</title>
            <description>FE 201836 50 µg oral solution and placebo ODT, administered once daily</description>
          </group>
          <group group_id="O7">
            <title>Placebo (Randomized Treatment Period)</title>
            <description>Placebo oral solution and placebo ODT, administered once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Nocturnal Diuresis Rate Profiles at Week 12</title>
          <description>The nocturnal diuresis rate (mL/min) is calculated as the mean of the nocturnal diuresis for each of the three nights, with the single-night nocturnal diuresis calculated as the ratio of NUV to total time in bed.&#xD;
Change from baseline in visit-specific mean nocturnal diuresis (mL/min) is presented.&#xD;
Level estimated for baseline value of mean nocturnal diuresis (mL/min) equal to 1.3 is presented in this endpoint.</description>
          <population>The ITT-RT comprised of all the subjects randomized at Visit 4.</population>
          <units>mL/min</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="35"/>
                <count group_id="O2" value="18"/>
                <count group_id="O3" value="18"/>
                <count group_id="O4" value="14"/>
                <count group_id="O5" value="11"/>
                <count group_id="O6" value="29"/>
                <count group_id="O7" value="68"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.648" lower_limit="-0.789" upper_limit="-0.508"/>
                    <measurement group_id="O2" value="-0.606" lower_limit="-0.805" upper_limit="-0.408"/>
                    <measurement group_id="O3" value="-0.735" lower_limit="-0.937" upper_limit="-0.533"/>
                    <measurement group_id="O4" value="-0.458" lower_limit="-0.693" upper_limit="-0.223"/>
                    <measurement group_id="O5" value="-0.685" lower_limit="-0.945" upper_limit="-0.425"/>
                    <measurement group_id="O6" value="-0.651" lower_limit="-0.812" upper_limit="-0.490"/>
                    <measurement group_id="O7" value="-0.515" lower_limit="-0.619" upper_limit="-0.412"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.1354</p_value>
            <p_value_desc>Threshold for significance at 0.05 level.</p_value_desc>
            <method>MMRM</method>
            <param_type>Mean Difference</param_type>
            <param_value>-0.133</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.308</ci_lower_limit>
            <ci_upper_limit>0.042</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.4238</p_value>
            <p_value_desc>Threshold for significance at 0.05 level.</p_value_desc>
            <method>MMRM</method>
            <param_type>Mean Difference</param_type>
            <param_value>-0.091</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.315</ci_lower_limit>
            <ci_upper_limit>0.133</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0574</p_value>
            <p_value_desc>Threshold for significance at 0.05 level.</p_value_desc>
            <method>MMRM</method>
            <param_type>Mean Difference</param_type>
            <param_value>-0.220</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.446</ci_lower_limit>
            <ci_upper_limit>0.007</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.6579</p_value>
            <p_value_desc>Threshold for significance at 0.05 level.</p_value_desc>
            <method>MMRM</method>
            <param_type>Mean Difference</param_type>
            <param_value>0.058</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.199</ci_lower_limit>
            <ci_upper_limit>0.315</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.2337</p_value>
            <p_value_desc>Threshold for significance at 0.05 level.</p_value_desc>
            <method>MMRM</method>
            <param_type>Mean Difference</param_type>
            <param_value>-0.170</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.450</ci_lower_limit>
            <ci_upper_limit>0.110</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O6</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.1639</p_value>
            <p_value_desc>Threshold for significance at 0.05 level.</p_value_desc>
            <method>MMRM</method>
            <param_type>Mean Difference</param_type>
            <param_value>-0.136</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.328</ci_lower_limit>
            <ci_upper_limit>0.056</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Mean NUV in Week 1</title>
        <description>The NUV is defined as the total urine volume from 5 minutes after bedtime with the intention to sleep including the first void within 30 minutes of rising in the morning.&#xD;
The NUV at each visit was calculated as the average over the 3 consecutive 24-hour periods just prior to the respective visit. Adjusted visit-specific mean changes from baseline in NUV are estimated using a baseline value of 750 (mL).</description>
        <time_frame>Baseline, Week 1</time_frame>
        <population>The ITT-RT comprised of all the subjects randomized at Visit 4.</population>
        <group_list>
          <group group_id="O1">
            <title>FE 201836 500 ug (Randomized Treatment Period)</title>
            <description>FE 201836 500 µg oral solution and placebo ODT, administered once daily</description>
          </group>
          <group group_id="O2">
            <title>FE 201836 350 ug (Randomized Treatment Period)</title>
            <description>FE 201836 350 µg oral solution and placebo ODT, administered once daily</description>
          </group>
          <group group_id="O3">
            <title>FE 201836 250 ug (Randomized Treatment Period)</title>
            <description>FE 201836 250 µg oral solution and placebo ODT, administered once daily</description>
          </group>
          <group group_id="O4">
            <title>FE 201836 150 ug (Randomized Treatment Period)</title>
            <description>FE 201836 150 µg oral solution and placebo ODT, administered once daily</description>
          </group>
          <group group_id="O5">
            <title>FE 201836 100 ug (Randomized Treatment Period)</title>
            <description>FE 201836 100 µg oral solution and placebo ODT, administered once daily</description>
          </group>
          <group group_id="O6">
            <title>FE 201836 50 ug (Randomized Treatment Period)</title>
            <description>FE 201836 50 µg oral solution and placebo ODT, administered once daily</description>
          </group>
          <group group_id="O7">
            <title>Placebo (Randomized Treatment Period)</title>
            <description>Placebo oral solution and placebo ODT, administered once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Mean NUV in Week 1</title>
          <description>The NUV is defined as the total urine volume from 5 minutes after bedtime with the intention to sleep including the first void within 30 minutes of rising in the morning.&#xD;
The NUV at each visit was calculated as the average over the 3 consecutive 24-hour periods just prior to the respective visit. Adjusted visit-specific mean changes from baseline in NUV are estimated using a baseline value of 750 (mL).</description>
          <population>The ITT-RT comprised of all the subjects randomized at Visit 4.</population>
          <units>mL</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="53"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="24"/>
                <count group_id="O4" value="14"/>
                <count group_id="O5" value="11"/>
                <count group_id="O6" value="32"/>
                <count group_id="O7" value="78"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-328.8" lower_limit="-395.3" upper_limit="-262.3"/>
                    <measurement group_id="O2" value="-371.8" lower_limit="-470.4" upper_limit="-273.3"/>
                    <measurement group_id="O3" value="-352.4" lower_limit="-452.8" upper_limit="-252.1"/>
                    <measurement group_id="O4" value="-265.5" lower_limit="-395.5" upper_limit="-135.6"/>
                    <measurement group_id="O5" value="-312.6" lower_limit="-455.9" upper_limit="-169.3"/>
                    <measurement group_id="O6" value="-218.2" lower_limit="-304.9" upper_limit="-131.6"/>
                    <measurement group_id="O7" value="-241.6" lower_limit="-296.3" upper_limit="-186.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0470</p_value>
            <method>MMRM</method>
            <param_type>Mean Difference</param_type>
            <param_value>-87.2</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-173.2</ci_lower_limit>
            <ci_upper_limit>-1.2</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0237</p_value>
            <method>MMRM</method>
            <param_type>Mean Difference</param_type>
            <param_value>-130.2</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-242.9</ci_lower_limit>
            <ci_upper_limit>-17.6</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0569</p_value>
            <method>MMRM</method>
            <param_type>Mean Difference</param_type>
            <param_value>-110.8</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-224.9</ci_lower_limit>
            <ci_upper_limit>3.3</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.7383</p_value>
            <method>MMRM</method>
            <param_type>Mean Difference</param_type>
            <param_value>-23.9</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-164.8</ci_lower_limit>
            <ci_upper_limit>117.0</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.3626</p_value>
            <method>MMRM</method>
            <param_type>Mean Difference</param_type>
            <param_value>-71.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-224.3</ci_lower_limit>
            <ci_upper_limit>82.3</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O6</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.6524</p_value>
            <method>MMRM</method>
            <param_type>Mean Difference</param_type>
            <param_value>23.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-78.9</ci_lower_limit>
            <ci_upper_limit>125.7</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Mean NUV at Week 12</title>
        <description>The NUV is defined as the total urine volume from 5 minutes after bedtime with the intention to sleep including the first void within 30 minutes of rising in the morning.&#xD;
The NUV at each visit was calculated as the average over the 3 consecutive 24-hour periods just prior to the respective visit. Adjusted visit-specific mean changes from baseline in NUV are estimated using a baseline value of 750 (mL).</description>
        <time_frame>Baseline, Week 12</time_frame>
        <population>The ITT-RT comprised of all the subjects randomized at Visit 4.</population>
        <group_list>
          <group group_id="O1">
            <title>FE 201836 500 ug (Randomized Treatment Period)</title>
            <description>FE 201836 500 µg oral solution and placebo ODT, administered once daily</description>
          </group>
          <group group_id="O2">
            <title>FE 201836 350 ug (Randomized Treatment Period)</title>
            <description>FE 201836 350 µg oral solution and placebo ODT, administered once daily</description>
          </group>
          <group group_id="O3">
            <title>FE 201836 250 ug (Randomized Treatment Period)</title>
            <description>FE 201836 250 µg oral solution and placebo ODT, administered once daily</description>
          </group>
          <group group_id="O4">
            <title>FE 201836 150 ug (Randomized Treatment Period)</title>
            <description>FE 201836 150 µg oral solution and placebo ODT, administered once daily</description>
          </group>
          <group group_id="O5">
            <title>FE 201836 100 ug (Randomized Treatment Period)</title>
            <description>FE 201836 100 µg oral solution and placebo ODT, administered once daily</description>
          </group>
          <group group_id="O6">
            <title>FE 201836 50 ug (Randomized Treatment Period)</title>
            <description>FE 201836 50 µg oral solution and placebo ODT, administered once daily</description>
          </group>
          <group group_id="O7">
            <title>Placebo (Randomized Treatment Period)</title>
            <description>Placebo oral solution and placebo ODT, administered once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Mean NUV at Week 12</title>
          <description>The NUV is defined as the total urine volume from 5 minutes after bedtime with the intention to sleep including the first void within 30 minutes of rising in the morning.&#xD;
The NUV at each visit was calculated as the average over the 3 consecutive 24-hour periods just prior to the respective visit. Adjusted visit-specific mean changes from baseline in NUV are estimated using a baseline value of 750 (mL).</description>
          <population>The ITT-RT comprised of all the subjects randomized at Visit 4.</population>
          <units>mL</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="35"/>
                <count group_id="O2" value="18"/>
                <count group_id="O3" value="18"/>
                <count group_id="O4" value="14"/>
                <count group_id="O5" value="11"/>
                <count group_id="O6" value="29"/>
                <count group_id="O7" value="68"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-367.3" lower_limit="-447.1" upper_limit="-287.5"/>
                    <measurement group_id="O2" value="-392.4" lower_limit="-505.2" upper_limit="-279.5"/>
                    <measurement group_id="O3" value="-411.3" lower_limit="-526.0" upper_limit="-296.7"/>
                    <measurement group_id="O4" value="-284.2" lower_limit="-418.4" upper_limit="-149.9"/>
                    <measurement group_id="O5" value="-393.5" lower_limit="-541.9" upper_limit="-245.1"/>
                    <measurement group_id="O6" value="-403.2" lower_limit="-495.5" upper_limit="-310.9"/>
                    <measurement group_id="O7" value="-317.8" lower_limit="-377.1" upper_limit="-258.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.3273</p_value>
            <p_value_desc>Threshold for significance at 0.05 level.</p_value_desc>
            <method>MMRM</method>
            <param_type>Mean Difference</param_type>
            <param_value>-49.5</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-148.9</ci_lower_limit>
            <ci_upper_limit>49.9</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.2500</p_value>
            <p_value_desc>Threshold for significance at 0.05 level.</p_value_desc>
            <method>MMRM</method>
            <param_type>Mean Difference</param_type>
            <param_value>-74.6</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-202.0</ci_lower_limit>
            <ci_upper_limit>52.9</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.1537</p_value>
            <p_value_desc>Threshold for significance at 0.05 level.</p_value_desc>
            <method>MMRM</method>
            <param_type>Mean Difference</param_type>
            <param_value>-93.5</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-222.3</ci_lower_limit>
            <ci_upper_limit>35.2</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.6515</p_value>
            <p_value_desc>Threshold for significance at 0.05 level.</p_value_desc>
            <method>MMRM</method>
            <param_type>Mean Difference</param_type>
            <param_value>33.6</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-113.1</ci_lower_limit>
            <ci_upper_limit>180.3</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.3506</p_value>
            <p_value_desc>Threshold for significance at 0.05 level.</p_value_desc>
            <method>MMRM</method>
            <param_type>Mean Difference</param_type>
            <param_value>-75.7</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-235.3</ci_lower_limit>
            <ci_upper_limit>83.9</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O6</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.1255</p_value>
            <p_value_desc>Threshold for significance at 0.05 level.</p_value_desc>
            <method>MMRM</method>
            <param_type>Mean Difference</param_type>
            <param_value>-85.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-194.8</ci_lower_limit>
            <ci_upper_limit>24.1</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Enrichment period: Treatment-emergent adverse events (AEs) occurring in the time interval from V2 (active run-in) to V4 (randomization), including AEs with missing start date. Randomized treatment period: Treatment-emergent AEs occurring in the time interval from V4 to end-of-trial.</time_frame>
      <desc>The Safety Analysis Set for the enrichment period comprised subjects who received investigational medicinal product (IMP) at V2 and did not return all IMP unused at/before V4. The Safety Analysis Set for the randomized treatment period comprised subjects who received IMP at V4 and did not return all IMP unused, and who had at least 1 safety assessment after V4.</desc>
      <group_list>
        <group group_id="E1">
          <title>FE 201836 500 µg (Enrichment Period)</title>
          <description>FE 201836 500 µg oral solution and placebo ODT, administered once daily</description>
        </group>
        <group group_id="E2">
          <title>FE 201836 500 µg (Randomized Treatment Period)</title>
          <description>FE 201836 500 µg oral solution and placebo ODT, administered once daily</description>
        </group>
        <group group_id="E3">
          <title>FE 201836 350 µg (Randomized Treatment Period)</title>
          <description>FE 201836 350 µg oral solution and placebo ODT, administered once daily</description>
        </group>
        <group group_id="E4">
          <title>FE 201836 250 µg (Randomized Treatment Period)</title>
          <description>FE 201836 250 µg oral solution and placebo ODT, administered once daily</description>
        </group>
        <group group_id="E5">
          <title>FE 201836 150 µg (Randomized Treatment Period)</title>
          <description>FE 201836 150 µg oral solution and placebo ODT, administered once daily</description>
        </group>
        <group group_id="E6">
          <title>FE 201836 100 µg (Randomized Treatment Period)</title>
          <description>FE 201836 100 µg oral solution and placebo ODT, administered once daily</description>
        </group>
        <group group_id="E7">
          <title>FE 201836 50 µg (Randomized Treatment Period)</title>
          <description>FE 201836 50 µg oral solution and placebo ODT, administered once daily</description>
        </group>
        <group group_id="E8">
          <title>Placebo (Randomized Treatment Period)</title>
          <description>Placebo oral solution and placebo ODT, administered once daily</description>
        </group>
        <group group_id="E9">
          <title>Desmopressin 25 µg (Randomized Treatment Period)</title>
          <description>Desmopressin 25 µg ODT and placebo oral solution, administered once daily (female subjects)</description>
        </group>
        <group group_id="E10">
          <title>Desmopressin 50 µg (Randomized Treatment Period)</title>
          <description>Desmopressin 50 µg ODT and placebo oral solution, administered once daily (male subjects)</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (20.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="531"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="531"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="60"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="27"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="87"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="531"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Colitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="531"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="87"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Serum sickness-like reaction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="531"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="60"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="531"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="87"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Staphylococcal infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="531"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="531"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Facial bones fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="531"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Subdural haematoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="531"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hyponatraemia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="531"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Prostate cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="531"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Transitional cell carcinoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="531"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="531"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Acute respiratory failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="531"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="531"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="87"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Urticaria</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="531"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E8" events="2" subjects_affected="1" subjects_at_risk="87"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (20.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="531"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="60"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="27"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="24"/>
                <counts group_id="E5" subjects_affected="8" subjects_at_risk="14"/>
                <counts group_id="E6" subjects_affected="5" subjects_at_risk="13"/>
                <counts group_id="E7" subjects_affected="7" subjects_at_risk="34"/>
                <counts group_id="E8" subjects_affected="16" subjects_at_risk="87"/>
                <counts group_id="E9" subjects_affected="8" subjects_at_risk="26"/>
                <counts group_id="E10" subjects_affected="9" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="531"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="60"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="87"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="531"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E10" events="3" subjects_affected="1" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="531"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="60"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="24"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E8" events="4" subjects_affected="3" subjects_at_risk="87"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="531"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="60"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="87"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="531"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="531"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="14"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="87"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="531"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="531"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="60"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="531"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="87"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="531"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Accidental overdose</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="531"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E8" events="4" subjects_affected="3" subjects_at_risk="87"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E10" events="6" subjects_affected="4" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Hand fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="531"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Laceration</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="531"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Road traffic accident</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="531"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Weight increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="531"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="60"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="87"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Gamma-glutamyltransferase increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="531"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="60"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="14"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Blood creatine phosphokinase increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="531"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="87"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Blood sodium decreased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="531"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="60"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E10" events="2" subjects_affected="1" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Hepatic enzyme increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="531"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E9" events="3" subjects_affected="3" subjects_at_risk="26"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="531"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="14"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="531"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="14"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Blood alkaline phosphatase</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="531"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hyponatraemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="531"/>
                <counts group_id="E2" events="5" subjects_affected="3" subjects_at_risk="60"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="27"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Hypoglycaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="531"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="87"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Muscle spasms</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="531"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="60"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Joint swelling</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="531"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="531"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="531"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="60"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E8" events="2" subjects_affected="2" subjects_at_risk="87"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="531"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="87"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Dysuria</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="531"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="87"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Renal impairment</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="531"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="87"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="531"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E8" events="2" subjects_affected="2" subjects_at_risk="87"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="531"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="60"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E8" events="2" subjects_affected="1" subjects_at_risk="87"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Global Clinical Compliance</name_or_title>
      <organization>Ferring Pharmaceuticals</organization>
      <email>DK0-Disclosure@ferring.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

